#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=The SyBil-AA real-time fMRI neurofeedback study: protocol of a single-blind randomized controlled trial in alcohol use disorder
#Text=Background
#Text=Alcohol Use Disorder is a highly prevalent mental disorder which puts a severe burden on individuals, families, and society.
1-1	0-3	The	_
1-2	4-12	SyBil-AA	_
1-3	13-22	real-time	_
1-4	23-27	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-5	28-41	neurofeedback	_
1-6	42-47	study	_
1-7	47-48	:	_
1-8	49-57	protocol	_
1-9	58-60	of	_
1-10	61-62	a	_
1-11	63-75	single-blind	_
1-12	76-86	randomized	_
1-13	87-97	controlled	_
1-14	98-103	trial	_
1-15	104-106	in	_
1-16	107-114	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]
1-17	115-118	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]
1-18	119-127	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]
1-19	128-138	Background	_
1-20	139-146	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-21	147-150	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-22	151-159	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-23	160-162	is	_
1-24	163-164	a	_
1-25	165-171	highly	_
1-26	172-181	prevalent	_
1-27	182-188	mental	_
1-28	189-197	disorder	_
1-29	198-203	which	_
1-30	204-208	puts	_
1-31	209-210	a	_
1-32	211-217	severe	_
1-33	218-224	burden	_
1-34	225-227	on	_
1-35	228-239	individuals	_
1-36	239-240	,	_
1-37	241-249	families	_
1-38	249-250	,	_
1-39	251-254	and	_
1-40	255-262	society	_
1-41	262-263	.	_

#Text=The treatment of Alcohol Use Disorder is challenging and novel and innovative treatment approaches are needed to expand treatment options.
2-1	264-267	The	_
2-2	268-277	treatment	_
2-3	278-280	of	_
2-4	281-288	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]
2-5	289-292	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]
2-6	293-301	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]
2-7	302-304	is	_
2-8	305-316	challenging	_
2-9	317-320	and	_
2-10	321-326	novel	_
2-11	327-330	and	_
2-12	331-341	innovative	_
2-13	342-351	treatment	_
2-14	352-362	approaches	_
2-15	363-366	are	_
2-16	367-373	needed	_
2-17	374-376	to	_
2-18	377-383	expand	_
2-19	384-393	treatment	_
2-20	394-401	options	_
2-21	401-402	.	_

#Text=A promising neuroscience-based intervention method that allows targeting cortical as well as subcortical brain processes is real-time functional magnetic resonance imaging neurofeedback.
3-1	403-404	A	_
3-2	405-414	promising	_
3-3	415-433	neuroscience-based	_
3-4	434-446	intervention	_
3-5	447-453	method	_
3-6	454-458	that	_
3-7	459-465	allows	_
3-8	466-475	targeting	_
3-9	476-484	cortical	_
3-10	485-487	as	_
3-11	488-492	well	_
3-12	493-495	as	_
3-13	496-507	subcortical	_
3-14	508-513	brain	_
3-15	514-523	processes	_
3-16	524-526	is	_
3-17	527-536	real-time	_
3-18	537-547	functional	_
3-19	548-556	magnetic	_
3-20	557-566	resonance	_
3-21	567-574	imaging	_
3-22	575-588	neurofeedback	_
3-23	588-589	.	_

#Text=However, the efficacy of this technique as an add-on treatment of Alcohol Use Disorder in a clinical setting is hitherto unclear and will be assessed in the Systems Biology of Alcohol Addiction (SyBil-AA) neurofeedback study.
4-1	590-597	However	_
4-2	597-598	,	_
4-3	599-602	the	_
4-4	603-611	efficacy	_
4-5	612-614	of	_
4-6	615-619	this	_
4-7	620-629	technique	_
4-8	630-632	as	_
4-9	633-635	an	_
4-10	636-642	add-on	_
4-11	643-652	treatment	_
4-12	653-655	of	_
4-13	656-663	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[4]
4-14	664-667	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[4]
4-15	668-676	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[4]
4-16	677-679	in	_
4-17	680-681	a	_
4-18	682-690	clinical	_
4-19	691-698	setting	_
4-20	699-701	is	_
4-21	702-710	hitherto	_
4-22	711-718	unclear	_
4-23	719-722	and	_
4-24	723-727	will	_
4-25	728-730	be	_
4-26	731-739	assessed	_
4-27	740-742	in	_
4-28	743-746	the	_
4-29	747-754	Systems	_
4-30	755-762	Biology	_
4-31	763-765	of	_
4-32	766-773	Alcohol	_
4-33	774-783	Addiction	_
4-34	784-785	(	_
4-35	785-793	SyBil-AA	_
4-36	793-794	)	_
4-37	795-808	neurofeedback	_
4-38	809-814	study	_
4-39	814-815	.	_

#Text=Methods
#Text=N = 100 patients with Alcohol Use Disorder will be randomized to 5 parallel groups in a single-blind fashion and receive real-time functional magnetic resonance imaging neurofeedback while they are presented pictures of alcoholic beverages.
5-1	816-823	Methods	_
5-2	824-825	N	_
5-3	826-827	=	_
5-4	828-831	100	_
5-5	832-840	patients	_
5-6	841-845	with	_
5-7	846-853	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]
5-8	854-857	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]
5-9	858-866	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[5]
5-10	867-871	will	_
5-11	872-874	be	_
5-12	875-885	randomized	_
5-13	886-888	to	_
5-14	889-890	5	_
5-15	891-899	parallel	_
5-16	900-906	groups	_
5-17	907-909	in	_
5-18	910-911	a	_
5-19	912-924	single-blind	_
5-20	925-932	fashion	_
5-21	933-936	and	_
5-22	937-944	receive	_
5-23	945-954	real-time	_
5-24	955-965	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]
5-25	966-974	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]
5-26	975-984	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]
5-27	985-992	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]
5-28	993-1006	neurofeedback	_
5-29	1007-1012	while	_
5-30	1013-1017	they	_
5-31	1018-1021	are	_
5-32	1022-1031	presented	_
5-33	1032-1040	pictures	_
5-34	1041-1043	of	_
5-35	1044-1053	alcoholic	_
5-36	1054-1063	beverages	_
5-37	1063-1064	.	_

#Text=The groups will either downregulate the ventral striatum, upregulate the right inferior frontal gyrus, negatively modulate the connectivity between these regions, upregulate, or downregulate the auditory cortex as a control region.
6-1	1065-1068	The	_
6-2	1069-1075	groups	_
6-3	1076-1080	will	_
6-4	1081-1087	either	_
6-5	1088-1100	downregulate	_
6-6	1101-1104	the	_
6-7	1105-1112	ventral	_
6-8	1113-1121	striatum	_
6-9	1121-1122	,	_
6-10	1123-1133	upregulate	_
6-11	1134-1137	the	_
6-12	1138-1143	right	_
6-13	1144-1152	inferior	_
6-14	1153-1160	frontal	_
6-15	1161-1166	gyrus	_
6-16	1166-1167	,	_
6-17	1168-1178	negatively	_
6-18	1179-1187	modulate	_
6-19	1188-1191	the	_
6-20	1192-1204	connectivity	_
6-21	1205-1212	between	_
6-22	1213-1218	these	_
6-23	1219-1226	regions	_
6-24	1226-1227	,	_
6-25	1228-1238	upregulate	_
6-26	1238-1239	,	_
6-27	1240-1242	or	_
6-28	1243-1255	downregulate	_
6-29	1256-1259	the	_
6-30	1260-1268	auditory	_
6-31	1269-1275	cortex	_
6-32	1276-1278	as	_
6-33	1279-1280	a	_
6-34	1281-1288	control	_
6-35	1289-1295	region	_
6-36	1295-1296	.	_

#Text=After receiving 3 sessions of neurofeedback training within a maximum of 2 weeks, participants will be followed up monthly for a period of 3 months and relapse rates will be assessed as the primary outcome measure.
7-1	1297-1302	After	_
7-2	1303-1312	receiving	_
7-3	1313-1314	3	_
7-4	1315-1323	sessions	_
7-5	1324-1326	of	_
7-6	1327-1340	neurofeedback	_
7-7	1341-1349	training	_
7-8	1350-1356	within	_
7-9	1357-1358	a	_
7-10	1359-1366	maximum	_
7-11	1367-1369	of	_
7-12	1370-1371	2	_
7-13	1371-1372	 	_
7-14	1372-1377	weeks	_
7-15	1377-1378	,	_
7-16	1379-1391	participants	_
7-17	1392-1396	will	_
7-18	1397-1399	be	_
7-19	1400-1408	followed	_
7-20	1409-1411	up	_
7-21	1412-1419	monthly	_
7-22	1420-1423	for	_
7-23	1424-1425	a	_
7-24	1426-1432	period	_
7-25	1433-1435	of	_
7-26	1436-1437	3	_
7-27	1437-1438	 	_
7-28	1438-1444	months	_
7-29	1445-1448	and	_
7-30	1449-1456	relapse	_
7-31	1457-1462	rates	_
7-32	1463-1467	will	_
7-33	1468-1470	be	_
7-34	1471-1479	assessed	_
7-35	1480-1482	as	_
7-36	1483-1486	the	_
7-37	1487-1494	primary	_
7-38	1495-1502	outcome	_
7-39	1503-1510	measure	_
7-40	1510-1511	.	_

#Text=Discussion
#Text=The results of this study will provide insights into the efficacy of real-time functional magnetic resonance imaging neurofeedback training in the treatment of Alcohol Use Disorder as well as in the involved brain systems.
8-1	1512-1522	Discussion	_
8-2	1523-1526	The	_
8-3	1527-1534	results	_
8-4	1535-1537	of	_
8-5	1538-1542	this	_
8-6	1543-1548	study	_
8-7	1549-1553	will	_
8-8	1554-1561	provide	_
8-9	1562-1570	insights	_
8-10	1571-1575	into	_
8-11	1576-1579	the	_
8-12	1580-1588	efficacy	_
8-13	1589-1591	of	_
8-14	1592-1601	real-time	_
8-15	1602-1612	functional	_
8-16	1613-1621	magnetic	_
8-17	1622-1631	resonance	_
8-18	1632-1639	imaging	_
8-19	1640-1653	neurofeedback	_
8-20	1654-1662	training	_
8-21	1663-1665	in	_
8-22	1666-1669	the	_
8-23	1670-1679	treatment	_
8-24	1680-1682	of	_
8-25	1683-1690	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
8-26	1691-1694	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
8-27	1695-1703	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]
8-28	1704-1706	as	_
8-29	1707-1711	well	_
8-30	1712-1714	as	_
8-31	1715-1717	in	_
8-32	1718-1721	the	_
8-33	1722-1730	involved	_
8-34	1731-1736	brain	_
8-35	1737-1744	systems	_
8-36	1744-1745	.	_

#Text=This might help to identify predictors of successful neurofeedback treatment which could potentially be useful in developing personalized treatment approaches.
9-1	1746-1750	This	_
9-2	1751-1756	might	_
9-3	1757-1761	help	_
9-4	1762-1764	to	_
9-5	1765-1773	identify	_
9-6	1774-1784	predictors	_
9-7	1785-1787	of	_
9-8	1788-1798	successful	_
9-9	1799-1812	neurofeedback	_
9-10	1813-1822	treatment	_
9-11	1823-1828	which	_
9-12	1829-1834	could	_
9-13	1835-1846	potentially	_
9-14	1847-1849	be	_
9-15	1850-1856	useful	_
9-16	1857-1859	in	_
9-17	1860-1870	developing	_
9-18	1871-1883	personalized	_
9-19	1884-1893	treatment	_
9-20	1894-1904	approaches	_
9-21	1904-1905	.	_

#Text=Trial registration
#Text=The study was retrospectively registered in the German Clinical Trials Register (trial identifier: DRKS00010253; WHO Universal Trial Number (UTN): U1111–1181-4218) on May 10th, 2016.
10-1	1906-1911	Trial	_
10-2	1912-1924	registration	_
10-3	1925-1928	The	_
10-4	1929-1934	study	_
10-5	1935-1938	was	_
10-6	1939-1954	retrospectively	_
10-7	1955-1965	registered	_
10-8	1966-1968	in	_
10-9	1969-1972	the	_
10-10	1973-1979	German	_
10-11	1980-1988	Clinical	_
10-12	1989-1995	Trials	_
10-13	1996-2004	Register	_
10-14	2005-2006	(	_
10-15	2006-2011	trial	_
10-16	2012-2022	identifier	_
10-17	2022-2023	:	_
10-18	2024-2036	DRKS00010253	_
10-19	2036-2037	;	_
10-20	2038-2041	WHO	_
10-21	2042-2051	Universal	_
10-22	2052-2057	Trial	_
10-23	2058-2064	Number	_
10-24	2065-2066	(	_
10-25	2066-2069	UTN	_
10-26	2069-2070	)	_
10-27	2070-2071	:	_
10-28	2072-2077	U1111	_
10-29	2077-2078	–	_
10-30	2078-2082	1181	_
10-31	2082-2083	-	_
10-32	2083-2087	4218	_
10-33	2087-2088	)	_
10-34	2089-2091	on	_
10-35	2092-2095	May	_
10-36	2096-2100	10th	_
10-37	2100-2101	,	_
10-38	2102-2106	2016	_
10-39	2106-2107	.	_

#Text=Background
#Text=Alcohol use disorder (AUD) is characterized by drinking of alcohol despite negative or harmful consequences, a loss of control over drinking behavior, the development of craving for alcohol, and the occurrence of withdrawal symptoms.
11-1	2108-2118	Background	_
11-2	2119-2126	Alcohol	_
11-3	2127-2130	use	_
11-4	2131-2139	disorder	_
11-5	2140-2141	(	_
11-6	2141-2144	AUD	_
11-7	2144-2145	)	_
11-8	2146-2148	is	_
11-9	2149-2162	characterized	_
11-10	2163-2165	by	_
11-11	2166-2174	drinking	_
11-12	2175-2177	of	_
11-13	2178-2185	alcohol	_
11-14	2186-2193	despite	_
11-15	2194-2202	negative	_
11-16	2203-2205	or	_
11-17	2206-2213	harmful	_
11-18	2214-2226	consequences	_
11-19	2226-2227	,	_
11-20	2228-2229	a	_
11-21	2230-2234	loss	_
11-22	2235-2237	of	_
11-23	2238-2245	control	_
11-24	2246-2250	over	_
11-25	2251-2259	drinking	_
11-26	2260-2268	behavior	_
11-27	2268-2269	,	_
11-28	2270-2273	the	_
11-29	2274-2285	development	_
11-30	2286-2288	of	_
11-31	2289-2296	craving	_
11-32	2297-2300	for	_
11-33	2301-2308	alcohol	_
11-34	2308-2309	,	_
11-35	2310-2313	and	_
11-36	2314-2317	the	_
11-37	2318-2328	occurrence	_
11-38	2329-2331	of	_
11-39	2332-2342	withdrawal	_
11-40	2343-2351	symptoms	_
11-41	2351-2352	.	_

#Text=AUD puts a severe burden on individuals, families, and societies and is highly prevalent in western countries with a twelve-month prevalence of 13.9% in the United States and around 7% in Europe, where prevalence differs over a wide range between countries.
12-1	2353-2356	AUD	_
12-2	2357-2361	puts	_
12-3	2362-2363	a	_
12-4	2364-2370	severe	_
12-5	2371-2377	burden	_
12-6	2378-2380	on	_
12-7	2381-2392	individuals	_
12-8	2392-2393	,	_
12-9	2394-2402	families	_
12-10	2402-2403	,	_
12-11	2404-2407	and	_
12-12	2408-2417	societies	_
12-13	2418-2421	and	_
12-14	2422-2424	is	_
12-15	2425-2431	highly	_
12-16	2432-2441	prevalent	_
12-17	2442-2444	in	_
12-18	2445-2452	western	_
12-19	2453-2462	countries	_
12-20	2463-2467	with	_
12-21	2468-2469	a	_
12-22	2470-2482	twelve-month	_
12-23	2483-2493	prevalence	_
12-24	2494-2496	of	_
12-25	2497-2502	13.9%	_
12-26	2503-2505	in	_
12-27	2506-2509	the	_
12-28	2510-2516	United	_
12-29	2517-2523	States	_
12-30	2524-2527	and	_
12-31	2528-2534	around	_
12-32	2535-2537	7%	_
12-33	2538-2540	in	_
12-34	2541-2547	Europe	_
12-35	2547-2548	,	_
12-36	2549-2554	where	_
12-37	2555-2565	prevalence	_
12-38	2566-2573	differs	_
12-39	2574-2578	over	_
12-40	2579-2580	a	_
12-41	2581-2585	wide	_
12-42	2586-2591	range	_
12-43	2592-2599	between	_
12-44	2600-2609	countries	_
12-45	2609-2610	.	_

#Text=More than 80% of people suffering from AUD do not receive formal treatment, and of those who do, only 25–43% remain abstinent.
13-1	2611-2615	More	_
13-2	2616-2620	than	_
13-3	2621-2624	80%	_
13-4	2625-2627	of	_
13-5	2628-2634	people	_
13-6	2635-2644	suffering	_
13-7	2645-2649	from	_
13-8	2650-2653	AUD	_
13-9	2654-2656	do	_
13-10	2657-2660	not	_
13-11	2661-2668	receive	_
13-12	2669-2675	formal	_
13-13	2676-2685	treatment	_
13-14	2685-2686	,	_
13-15	2687-2690	and	_
13-16	2691-2693	of	_
13-17	2694-2699	those	_
13-18	2700-2703	who	_
13-19	2704-2706	do	_
13-20	2706-2707	,	_
13-21	2708-2712	only	_
13-22	2713-2715	25	_
13-23	2715-2716	–	_
13-24	2716-2719	43%	_
13-25	2720-2726	remain	_
13-26	2727-2736	abstinent	_
13-27	2736-2737	.	_

#Text=To increase the efficacy of AUD treatment, novel treatment approaches are needed which would optimally be designed as modules that can flexibly be administered in personalized multimodal treatment programs.
14-1	2738-2740	To	_
14-2	2741-2749	increase	_
14-3	2750-2753	the	_
14-4	2754-2762	efficacy	_
14-5	2763-2765	of	_
14-6	2766-2769	AUD	_
14-7	2770-2779	treatment	_
14-8	2779-2780	,	_
14-9	2781-2786	novel	_
14-10	2787-2796	treatment	_
14-11	2797-2807	approaches	_
14-12	2808-2811	are	_
14-13	2812-2818	needed	_
14-14	2819-2824	which	_
14-15	2825-2830	would	_
14-16	2831-2840	optimally	_
14-17	2841-2843	be	_
14-18	2844-2852	designed	_
14-19	2853-2855	as	_
14-20	2856-2863	modules	_
14-21	2864-2868	that	_
14-22	2869-2872	can	_
14-23	2873-2881	flexibly	_
14-24	2882-2884	be	_
14-25	2885-2897	administered	_
14-26	2898-2900	in	_
14-27	2901-2913	personalized	_
14-28	2914-2924	multimodal	_
14-29	2925-2934	treatment	_
14-30	2935-2943	programs	_
14-31	2943-2944	.	_

#Text=The progress of basic neuroscientific knowledge about alcohol addiction and advances in methodology now make neuroscience-based treatment approaches like transcranial magnetic stimulation (TMS), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), and real-time functional magnetic resonance neurofeedback (rtfMRI NFB) available, which are able to target disease-related brain regions and brain processes with more or less precision.
15-1	2945-2948	The	_
15-2	2949-2957	progress	_
15-3	2958-2960	of	_
15-4	2961-2966	basic	_
15-5	2967-2982	neuroscientific	_
15-6	2983-2992	knowledge	_
15-7	2993-2998	about	_
15-8	2999-3006	alcohol	_
15-9	3007-3016	addiction	_
15-10	3017-3020	and	_
15-11	3021-3029	advances	_
15-12	3030-3032	in	_
15-13	3033-3044	methodology	_
15-14	3045-3048	now	_
15-15	3049-3053	make	_
15-16	3054-3072	neuroscience-based	_
15-17	3073-3082	treatment	_
15-18	3083-3093	approaches	_
15-19	3094-3098	like	_
15-20	3099-3111	transcranial	_
15-21	3112-3120	magnetic	_
15-22	3121-3132	stimulation	_
15-23	3133-3134	(	_
15-24	3134-3137	TMS	_
15-25	3137-3138	)	_
15-26	3138-3139	,	_
15-27	3140-3152	transcranial	_
15-28	3153-3159	direct	_
15-29	3160-3167	current	_
15-30	3168-3179	stimulation	_
15-31	3180-3181	(	_
15-32	3181-3185	tDCS	_
15-33	3185-3186	)	_
15-34	3186-3187	,	_
15-35	3188-3192	deep	_
15-36	3193-3198	brain	_
15-37	3199-3210	stimulation	_
15-38	3211-3212	(	_
15-39	3212-3215	DBS	_
15-40	3215-3216	)	_
15-41	3216-3217	,	_
15-42	3218-3221	and	_
15-43	3222-3231	real-time	_
15-44	3232-3242	functional	_
15-45	3243-3251	magnetic	_
15-46	3252-3261	resonance	_
15-47	3262-3275	neurofeedback	_
15-48	3276-3277	(	_
15-49	3277-3283	rtfMRI	_
15-50	3284-3287	NFB	_
15-51	3287-3288	)	_
15-52	3289-3298	available	_
15-53	3298-3299	,	_
15-54	3300-3305	which	_
15-55	3306-3309	are	_
15-56	3310-3314	able	_
15-57	3315-3317	to	_
15-58	3318-3324	target	_
15-59	3325-3340	disease-related	_
15-60	3341-3346	brain	_
15-61	3347-3354	regions	_
15-62	3355-3358	and	_
15-63	3359-3364	brain	_
15-64	3365-3374	processes	_
15-65	3375-3379	with	_
15-66	3380-3384	more	_
15-67	3385-3387	or	_
15-68	3388-3392	less	_
15-69	3393-3402	precision	_
15-70	3402-3403	.	_

#Text=One process that has prominently been linked to AUD and is a promising aim for targeted neuroscience-based interventions is the cue-reactivity response, the reaction to the presentation of alcohol-related stimuli, e.g. pictures, odors, or taste of alcoholic beverages.
16-1	3404-3407	One	_
16-2	3408-3415	process	_
16-3	3416-3420	that	_
16-4	3421-3424	has	_
16-5	3425-3436	prominently	_
16-6	3437-3441	been	_
16-7	3442-3448	linked	_
16-8	3449-3451	to	_
16-9	3452-3455	AUD	_
16-10	3456-3459	and	_
16-11	3460-3462	is	_
16-12	3463-3464	a	_
16-13	3465-3474	promising	_
16-14	3475-3478	aim	_
16-15	3479-3482	for	_
16-16	3483-3491	targeted	_
16-17	3492-3510	neuroscience-based	_
16-18	3511-3524	interventions	_
16-19	3525-3527	is	_
16-20	3528-3531	the	_
16-21	3532-3546	cue-reactivity	_
16-22	3547-3555	response	_
16-23	3555-3556	,	_
16-24	3557-3560	the	_
16-25	3561-3569	reaction	_
16-26	3570-3572	to	_
16-27	3573-3576	the	_
16-28	3577-3589	presentation	_
16-29	3590-3592	of	_
16-30	3593-3608	alcohol-related	_
16-31	3609-3616	stimuli	_
16-32	3616-3617	,	_
16-33	3618-3621	e.g	_
16-34	3621-3622	.	_
16-35	3623-3631	pictures	_
16-36	3631-3632	,	_
16-37	3633-3638	odors	_
16-38	3638-3639	,	_
16-39	3640-3642	or	_
16-40	3643-3648	taste	_
16-41	3649-3651	of	_
16-42	3652-3661	alcoholic	_
16-43	3662-3671	beverages	_
16-44	3671-3672	.	_

#Text=In the brain, core regions associated with cue-reactivity are the ventral striatum (VS), the anterior cingulate cortex (ACC), and the ventromedial prefrontal cortex (vmPFC).
17-1	3673-3675	In	_
17-2	3676-3679	the	_
17-3	3680-3685	brain	_
17-4	3685-3686	,	_
17-5	3687-3691	core	_
17-6	3692-3699	regions	_
17-7	3700-3710	associated	_
17-8	3711-3715	with	_
17-9	3716-3730	cue-reactivity	_
17-10	3731-3734	are	_
17-11	3735-3738	the	_
17-12	3739-3746	ventral	_
17-13	3747-3755	striatum	_
17-14	3756-3757	(	_
17-15	3757-3759	VS	_
17-16	3759-3760	)	_
17-17	3760-3761	,	_
17-18	3762-3765	the	_
17-19	3766-3774	anterior	_
17-20	3775-3784	cingulate	_
17-21	3785-3791	cortex	_
17-22	3792-3793	(	_
17-23	3793-3796	ACC	_
17-24	3796-3797	)	_
17-25	3797-3798	,	_
17-26	3799-3802	and	_
17-27	3803-3806	the	_
17-28	3807-3819	ventromedial	_
17-29	3820-3830	prefrontal	_
17-30	3831-3837	cortex	_
17-31	3838-3839	(	_
17-32	3839-3844	vmPFC	_
17-33	3844-3845	)	_
17-34	3845-3846	.	_

#Text=Reviewing the cognitive neuroscience literature on behavioral change in AUD, Naqvi & Morgenstern concluded that enhanced reactivity of the ventral striatum to alcohol and alcohol-related cues together with impairments in prefrontal control regions are the major factors responsible for maintaining AUD.
18-1	3847-3856	Reviewing	_
18-2	3857-3860	the	_
18-3	3861-3870	cognitive	_
18-4	3871-3883	neuroscience	_
18-5	3884-3894	literature	_
18-6	3895-3897	on	_
18-7	3898-3908	behavioral	_
18-8	3909-3915	change	_
18-9	3916-3918	in	_
18-10	3919-3922	AUD	_
18-11	3922-3923	,	_
18-12	3924-3929	Naqvi	_
18-13	3930-3931	&	_
18-14	3932-3943	Morgenstern	_
18-15	3944-3953	concluded	_
18-16	3954-3958	that	_
18-17	3959-3967	enhanced	_
18-18	3968-3978	reactivity	_
18-19	3979-3981	of	_
18-20	3982-3985	the	_
18-21	3986-3993	ventral	_
18-22	3994-4002	striatum	_
18-23	4003-4005	to	_
18-24	4006-4013	alcohol	_
18-25	4014-4017	and	_
18-26	4018-4033	alcohol-related	_
18-27	4034-4038	cues	_
18-28	4039-4047	together	_
18-29	4048-4052	with	_
18-30	4053-4064	impairments	_
18-31	4065-4067	in	_
18-32	4068-4078	prefrontal	_
18-33	4079-4086	control	_
18-34	4087-4094	regions	_
18-35	4095-4098	are	_
18-36	4099-4102	the	_
18-37	4103-4108	major	_
18-38	4109-4116	factors	_
18-39	4117-4128	responsible	_
18-40	4129-4132	for	_
18-41	4133-4144	maintaining	_
18-42	4145-4148	AUD	_
18-43	4148-4149	.	_

#Text=Along these lines, Becker et al. have recently demonstrated enhanced striatal reward sensitivity and impairments in prefrontal-striatal connectivity in patients with AUD in a monetary reward task, hinting at a more generalized impairment in reward processing in AUD, which has also been found being predictive for neural changes during psychotherapeutic treatment.
19-1	4150-4155	Along	_
19-2	4156-4161	these	_
19-3	4162-4167	lines	_
19-4	4167-4168	,	_
19-5	4169-4175	Becker	_
19-6	4176-4178	et	_
19-7	4179-4181	al	_
19-8	4181-4182	.	_
19-9	4183-4187	have	_
19-10	4188-4196	recently	_
19-11	4197-4209	demonstrated	_
19-12	4210-4218	enhanced	_
19-13	4219-4227	striatal	_
19-14	4228-4234	reward	_
19-15	4235-4246	sensitivity	_
19-16	4247-4250	and	_
19-17	4251-4262	impairments	_
19-18	4263-4265	in	_
19-19	4266-4285	prefrontal-striatal	_
19-20	4286-4298	connectivity	_
19-21	4299-4301	in	_
19-22	4302-4310	patients	_
19-23	4311-4315	with	_
19-24	4316-4319	AUD	_
19-25	4320-4322	in	_
19-26	4323-4324	a	_
19-27	4325-4333	monetary	_
19-28	4334-4340	reward	_
19-29	4341-4345	task	_
19-30	4345-4346	,	_
19-31	4347-4354	hinting	_
19-32	4355-4357	at	_
19-33	4358-4359	a	_
19-34	4360-4364	more	_
19-35	4365-4376	generalized	_
19-36	4377-4387	impairment	_
19-37	4388-4390	in	_
19-38	4391-4397	reward	_
19-39	4398-4408	processing	_
19-40	4409-4411	in	_
19-41	4412-4415	AUD	_
19-42	4415-4416	,	_
19-43	4417-4422	which	_
19-44	4423-4426	has	_
19-45	4427-4431	also	_
19-46	4432-4436	been	_
19-47	4437-4442	found	_
19-48	4443-4448	being	_
19-49	4449-4459	predictive	_
19-50	4460-4463	for	_
19-51	4464-4470	neural	_
19-52	4471-4478	changes	_
19-53	4479-4485	during	_
19-54	4486-4503	psychotherapeutic	_
19-55	4504-4513	treatment	_
19-56	4513-4514	.	_

#Text=To target the cortical and subcortical processes involved in cue-reactivity and cognitive control, real-time fMRI Neurofeedback is a promising approach.
20-1	4515-4517	To	_
20-2	4518-4524	target	_
20-3	4525-4528	the	_
20-4	4529-4537	cortical	_
20-5	4538-4541	and	_
20-6	4542-4553	subcortical	_
20-7	4554-4563	processes	_
20-8	4564-4572	involved	_
20-9	4573-4575	in	_
20-10	4576-4590	cue-reactivity	_
20-11	4591-4594	and	_
20-12	4595-4604	cognitive	_
20-13	4605-4612	control	_
20-14	4612-4613	,	_
20-15	4614-4623	real-time	_
20-16	4624-4628	fMRI	_
20-17	4629-4642	Neurofeedback	_
20-18	4643-4645	is	_
20-19	4646-4647	a	_
20-20	4648-4657	promising	_
20-21	4658-4666	approach	_
20-22	4666-4667	.	_

#Text=In rtfMRI NFB participants are shown a near real-time feedback signal indicating a specific brain process while they are lying in an MR scanner and are instructed to influence this feedback signal in a desired direction (see Fig. 2 for an illustration).
21-1	4668-4670	In	_
21-2	4671-4677	rtfMRI	_
21-3	4678-4681	NFB	_
21-4	4682-4694	participants	_
21-5	4695-4698	are	_
21-6	4699-4704	shown	_
21-7	4705-4706	a	_
21-8	4707-4711	near	_
21-9	4712-4721	real-time	_
21-10	4722-4730	feedback	_
21-11	4731-4737	signal	_
21-12	4738-4748	indicating	_
21-13	4749-4750	a	_
21-14	4751-4759	specific	_
21-15	4760-4765	brain	_
21-16	4766-4773	process	_
21-17	4774-4779	while	_
21-18	4780-4784	they	_
21-19	4785-4788	are	_
21-20	4789-4794	lying	_
21-21	4795-4797	in	_
21-22	4798-4800	an	_
21-23	4801-4803	MR	_
21-24	4804-4811	scanner	_
21-25	4812-4815	and	_
21-26	4816-4819	are	_
21-27	4820-4830	instructed	_
21-28	4831-4833	to	_
21-29	4834-4843	influence	_
21-30	4844-4848	this	_
21-31	4849-4857	feedback	_
21-32	4858-4864	signal	_
21-33	4865-4867	in	_
21-34	4868-4869	a	_
21-35	4870-4877	desired	_
21-36	4878-4887	direction	_
21-37	4888-4889	(	_
21-38	4889-4892	see	_
21-39	4893-4896	Fig	_
21-40	4896-4897	.	_
21-41	4897-4898	 	_
21-42	4898-4899	2	_
21-43	4900-4903	for	_
21-44	4904-4906	an	_
21-45	4907-4919	illustration	_
21-46	4919-4920	)	_
21-47	4920-4921	.	_

#Text=In contrast to other treatment approaches like pharmacological interventions, TMS, or DBS, in rtfRMI NFB patients are actively engaging to influence a brain process, which might have additional psychological therapeutic benefits by promoting self-efficacy and self-regulation.
22-1	4922-4924	In	_
22-2	4925-4933	contrast	_
22-3	4934-4936	to	_
22-4	4937-4942	other	_
22-5	4943-4952	treatment	_
22-6	4953-4963	approaches	_
22-7	4964-4968	like	_
22-8	4969-4984	pharmacological	_
22-9	4985-4998	interventions	_
22-10	4998-4999	,	_
22-11	5000-5003	TMS	_
22-12	5003-5004	,	_
22-13	5005-5007	or	_
22-14	5008-5011	DBS	_
22-15	5011-5012	,	_
22-16	5013-5015	in	_
22-17	5016-5022	rtfRMI	_
22-18	5023-5026	NFB	_
22-19	5027-5035	patients	_
22-20	5036-5039	are	_
22-21	5040-5048	actively	_
22-22	5049-5057	engaging	_
22-23	5058-5060	to	_
22-24	5061-5070	influence	_
22-25	5071-5072	a	_
22-26	5073-5078	brain	_
22-27	5079-5086	process	_
22-28	5086-5087	,	_
22-29	5088-5093	which	_
22-30	5094-5099	might	_
22-31	5100-5104	have	_
22-32	5105-5115	additional	_
22-33	5116-5129	psychological	_
22-34	5130-5141	therapeutic	_
22-35	5142-5150	benefits	_
22-36	5151-5153	by	_
22-37	5154-5163	promoting	_
22-38	5164-5177	self-efficacy	_
22-39	5178-5181	and	_
22-40	5182-5197	self-regulation	_
22-41	5197-5198	.	_

#Text=Furthermore, in comparison, rtfMRI NFB offers a relatively high spatial acuity, especially in subcortical brain regions.
23-1	5199-5210	Furthermore	_
23-2	5210-5211	,	_
23-3	5212-5214	in	_
23-4	5215-5225	comparison	_
23-5	5225-5226	,	_
23-6	5227-5233	rtfMRI	_
23-7	5234-5237	NFB	_
23-8	5238-5244	offers	_
23-9	5245-5246	a	_
23-10	5247-5257	relatively	_
23-11	5258-5262	high	_
23-12	5263-5270	spatial	_
23-13	5271-5277	acuity	_
23-14	5277-5278	,	_
23-15	5279-5289	especially	_
23-16	5290-5292	in	_
23-17	5293-5304	subcortical	_
23-18	5305-5310	brain	_
23-19	5311-5318	regions	_
23-20	5318-5319	.	_

#Text=While rtfRMI NFB treatment is a relatively new tool in psychiatry, first results are promising.
24-1	5320-5325	While	_
24-2	5326-5332	rtfRMI	_
24-3	5333-5336	NFB	_
24-4	5337-5346	treatment	_
24-5	5347-5349	is	_
24-6	5350-5351	a	_
24-7	5352-5362	relatively	_
24-8	5363-5366	new	_
24-9	5367-5371	tool	_
24-10	5372-5374	in	_
24-11	5375-5385	psychiatry	_
24-12	5385-5386	,	_
24-13	5387-5392	first	_
24-14	5393-5400	results	_
24-15	5401-5404	are	_
24-16	5405-5414	promising	_
24-17	5414-5415	.	_

#Text=Initial evidence has been presented that rtfRMI NFB has effects for example in major depressive disorder, schizophrenia, attention deficit hyperactivity disorder, phobia, autism, posttraumatic stress disorder, and Borderline personality disorder.
25-1	5416-5423	Initial	_
25-2	5424-5432	evidence	_
25-3	5433-5436	has	_
25-4	5437-5441	been	_
25-5	5442-5451	presented	_
25-6	5452-5456	that	_
25-7	5457-5463	rtfRMI	_
25-8	5464-5467	NFB	_
25-9	5468-5471	has	_
25-10	5472-5479	effects	_
25-11	5480-5483	for	_
25-12	5484-5491	example	_
25-13	5492-5494	in	_
25-14	5495-5500	major	_
25-15	5501-5511	depressive	_
25-16	5512-5520	disorder	_
25-17	5520-5521	,	_
25-18	5522-5535	schizophrenia	_
25-19	5535-5536	,	_
25-20	5537-5546	attention	_
25-21	5547-5554	deficit	_
25-22	5555-5568	hyperactivity	_
25-23	5569-5577	disorder	_
25-24	5577-5578	,	_
25-25	5579-5585	phobia	_
25-26	5585-5586	,	_
25-27	5587-5593	autism	_
25-28	5593-5594	,	_
25-29	5595-5608	posttraumatic	_
25-30	5609-5615	stress	_
25-31	5616-5624	disorder	_
25-32	5624-5625	,	_
25-33	5626-5629	and	_
25-34	5630-5640	Borderline	_
25-35	5641-5652	personality	_
25-36	5653-5661	disorder	_
25-37	5661-5662	.	_

#Text=With regard to substance use disorders, rtfMRI NFB has been mainly explored in the treatment of nicotine addiction.
26-1	5663-5667	With	_
26-2	5668-5674	regard	_
26-3	5675-5677	to	_
26-4	5678-5687	substance	_
26-5	5688-5691	use	_
26-6	5692-5701	disorders	_
26-7	5701-5702	,	_
26-8	5703-5709	rtfMRI	_
26-9	5710-5713	NFB	_
26-10	5714-5717	has	_
26-11	5718-5722	been	_
26-12	5723-5729	mainly	_
26-13	5730-5738	explored	_
26-14	5739-5741	in	_
26-15	5742-5745	the	_
26-16	5746-5755	treatment	_
26-17	5756-5758	of	_
26-18	5759-5767	nicotine	_
26-19	5768-5777	addiction	_
26-20	5777-5778	.	_

#Text=Several studies have demonstrated a reduction of nicotine craving through NFB.
27-1	5779-5786	Several	_
27-2	5787-5794	studies	_
27-3	5795-5799	have	_
27-4	5800-5812	demonstrated	_
27-5	5813-5814	a	_
27-6	5815-5824	reduction	_
27-7	5825-5827	of	_
27-8	5828-5836	nicotine	_
27-9	5837-5844	craving	_
27-10	5845-5852	through	_
27-11	5853-5856	NFB	_
27-12	5856-5857	.	_

#Text=Interestingly, a recent study has found that including functional connectivity information in the feedback signal leads to a higher reduction of nicotine craving.
28-1	5858-5871	Interestingly	_
28-2	5871-5872	,	_
28-3	5873-5874	a	_
28-4	5875-5881	recent	_
28-5	5882-5887	study	_
28-6	5888-5891	has	_
28-7	5892-5897	found	_
28-8	5898-5902	that	_
28-9	5903-5912	including	_
28-10	5913-5923	functional	_
28-11	5924-5936	connectivity	_
28-12	5937-5948	information	_
28-13	5949-5951	in	_
28-14	5952-5955	the	_
28-15	5956-5964	feedback	_
28-16	5965-5971	signal	_
28-17	5972-5977	leads	_
28-18	5978-5980	to	_
28-19	5981-5982	a	_
28-20	5983-5989	higher	_
28-21	5990-5999	reduction	_
28-22	6000-6002	of	_
28-23	6003-6011	nicotine	_
28-24	6012-6019	craving	_
28-25	6019-6020	.	_

#Text=So far, only few studies have been conducted to assess the use of rtfRMI NFB as an interventional tool in AUD.
29-1	6021-6023	So	_
29-2	6024-6027	far	_
29-3	6027-6028	,	_
29-4	6029-6033	only	_
29-5	6034-6037	few	_
29-6	6038-6045	studies	_
29-7	6046-6050	have	_
29-8	6051-6055	been	_
29-9	6056-6065	conducted	_
29-10	6066-6068	to	_
29-11	6069-6075	assess	_
29-12	6076-6079	the	_
29-13	6080-6083	use	_
29-14	6084-6086	of	_
29-15	6087-6093	rtfRMI	_
29-16	6094-6097	NFB	_
29-17	6098-6100	as	_
29-18	6101-6103	an	_
29-19	6104-6118	interventional	_
29-20	6119-6123	tool	_
29-21	6124-6126	in	_
29-22	6127-6130	AUD	_
29-23	6130-6131	.	_

#Text=Showing that neurofeedback training with feedback from individually chosen cortical regions was able to reduce craving in patients with AUD directly after neurofeedback training, Karch et al. demonstrated the feasibility of neurofeedback interventions in AUD.
30-1	6132-6139	Showing	_
30-2	6140-6144	that	_
30-3	6145-6158	neurofeedback	_
30-4	6159-6167	training	_
30-5	6168-6172	with	_
30-6	6173-6181	feedback	_
30-7	6182-6186	from	_
30-8	6187-6199	individually	_
30-9	6200-6206	chosen	_
30-10	6207-6215	cortical	_
30-11	6216-6223	regions	_
30-12	6224-6227	was	_
30-13	6228-6232	able	_
30-14	6233-6235	to	_
30-15	6236-6242	reduce	_
30-16	6243-6250	craving	_
30-17	6251-6253	in	_
30-18	6254-6262	patients	_
30-19	6263-6267	with	_
30-20	6268-6271	AUD	_
30-21	6272-6280	directly	_
30-22	6281-6286	after	_
30-23	6287-6300	neurofeedback	_
30-24	6301-6309	training	_
30-25	6309-6310	,	_
30-26	6311-6316	Karch	_
30-27	6317-6319	et	_
30-28	6320-6322	al	_
30-29	6322-6323	.	_
30-30	6324-6336	demonstrated	_
30-31	6337-6340	the	_
30-32	6341-6352	feasibility	_
30-33	6353-6355	of	_
30-34	6356-6369	neurofeedback	_
30-35	6370-6383	interventions	_
30-36	6384-6386	in	_
30-37	6387-6390	AUD	_
30-38	6390-6391	.	_

#Text=In a study with non-treatment seeking heavy social drinkers, Kirsch et al. found that participants who received real feedback in comparison to a yoked feedback group and a sham control group were able to learn to downregulate their ventral striatum activation during presentation of pictures of alcoholic beverages.
31-1	6392-6394	In	_
31-2	6395-6396	a	_
31-3	6397-6402	study	_
31-4	6403-6407	with	_
31-5	6408-6421	non-treatment	_
31-6	6422-6429	seeking	_
31-7	6430-6435	heavy	_
31-8	6436-6442	social	_
31-9	6443-6451	drinkers	_
31-10	6451-6452	,	_
31-11	6453-6459	Kirsch	_
31-12	6460-6462	et	_
31-13	6463-6465	al	_
31-14	6465-6466	.	_
31-15	6467-6472	found	_
31-16	6473-6477	that	_
31-17	6478-6490	participants	_
31-18	6491-6494	who	_
31-19	6495-6503	received	_
31-20	6504-6508	real	_
31-21	6509-6517	feedback	_
31-22	6518-6520	in	_
31-23	6521-6531	comparison	_
31-24	6532-6534	to	_
31-25	6535-6536	a	_
31-26	6537-6542	yoked	_
31-27	6543-6551	feedback	_
31-28	6552-6557	group	_
31-29	6558-6561	and	_
31-30	6562-6563	a	_
31-31	6564-6568	sham	_
31-32	6569-6576	control	_
31-33	6577-6582	group	_
31-34	6583-6587	were	_
31-35	6588-6592	able	_
31-36	6593-6595	to	_
31-37	6596-6601	learn	_
31-38	6602-6604	to	_
31-39	6605-6617	downregulate	_
31-40	6618-6623	their	_
31-41	6624-6631	ventral	_
31-42	6632-6640	striatum	_
31-43	6641-6651	activation	_
31-44	6652-6658	during	_
31-45	6659-6671	presentation	_
31-46	6672-6674	of	_
31-47	6675-6683	pictures	_
31-48	6684-6686	of	_
31-49	6687-6696	alcoholic	_
31-50	6697-6706	beverages	_
31-51	6706-6707	.	_

#Text=They could further show that downregulation of the VS was correlated with activation in the right inferior frontal gyrus in the real feedback group, which is in accordance with the model of Naqvi & Morgenstern.
32-1	6708-6712	They	_
32-2	6713-6718	could	_
32-3	6719-6726	further	_
32-4	6727-6731	show	_
32-5	6732-6736	that	_
32-6	6737-6751	downregulation	_
32-7	6752-6754	of	_
32-8	6755-6758	the	_
32-9	6759-6761	VS	_
32-10	6762-6765	was	_
32-11	6766-6776	correlated	_
32-12	6777-6781	with	_
32-13	6782-6792	activation	_
32-14	6793-6795	in	_
32-15	6796-6799	the	_
32-16	6800-6805	right	_
32-17	6806-6814	inferior	_
32-18	6815-6822	frontal	_
32-19	6823-6828	gyrus	_
32-20	6829-6831	in	_
32-21	6832-6835	the	_
32-22	6836-6840	real	_
32-23	6841-6849	feedback	_
32-24	6850-6855	group	_
32-25	6855-6856	,	_
32-26	6857-6862	which	_
32-27	6863-6865	is	_
32-28	6866-6868	in	_
32-29	6869-6879	accordance	_
32-30	6880-6884	with	_
32-31	6885-6888	the	_
32-32	6889-6894	model	_
32-33	6895-6897	of	_
32-34	6898-6903	Naqvi	_
32-35	6904-6905	&	_
32-36	6906-6917	Morgenstern	_
32-37	6917-6918	.	_

#Text=In the Systems Biology of Alcohol Addiction (SyBil-AA) rtfRMI NFB study we are now testing whether neurofeedback training will have beneficial effects in heavily impaired AUD patients in a clinical setting.
33-1	6919-6921	In	_
33-2	6922-6925	the	_
33-3	6926-6933	Systems	_
33-4	6934-6941	Biology	_
33-5	6942-6944	of	_
33-6	6945-6952	Alcohol	_
33-7	6953-6962	Addiction	_
33-8	6963-6964	(	_
33-9	6964-6972	SyBil-AA	_
33-10	6972-6973	)	_
33-11	6974-6980	rtfRMI	_
33-12	6981-6984	NFB	_
33-13	6985-6990	study	_
33-14	6991-6993	we	_
33-15	6994-6997	are	_
33-16	6998-7001	now	_
33-17	7002-7009	testing	_
33-18	7010-7017	whether	_
33-19	7018-7031	neurofeedback	_
33-20	7032-7040	training	_
33-21	7041-7045	will	_
33-22	7046-7050	have	_
33-23	7051-7061	beneficial	_
33-24	7062-7069	effects	_
33-25	7070-7072	in	_
33-26	7073-7080	heavily	_
33-27	7081-7089	impaired	_
33-28	7090-7093	AUD	_
33-29	7094-7102	patients	_
33-30	7103-7105	in	_
33-31	7106-7107	a	_
33-32	7108-7116	clinical	_
33-33	7117-7124	setting	_
33-34	7124-7125	.	_

#Text=The results of this study will provide insights into the efficacy of NFB training in AUD, the involved brain systems, and might help to identify predictors of treatment success which could potentially be useful in developing personalized treatment approaches.
34-1	7126-7129	The	_
34-2	7130-7137	results	_
34-3	7138-7140	of	_
34-4	7141-7145	this	_
34-5	7146-7151	study	_
34-6	7152-7156	will	_
34-7	7157-7164	provide	_
34-8	7165-7173	insights	_
34-9	7174-7178	into	_
34-10	7179-7182	the	_
34-11	7183-7191	efficacy	_
34-12	7192-7194	of	_
34-13	7195-7198	NFB	_
34-14	7199-7207	training	_
34-15	7208-7210	in	_
34-16	7211-7214	AUD	_
34-17	7214-7215	,	_
34-18	7216-7219	the	_
34-19	7220-7228	involved	_
34-20	7229-7234	brain	_
34-21	7235-7242	systems	_
34-22	7242-7243	,	_
34-23	7244-7247	and	_
34-24	7248-7253	might	_
34-25	7254-7258	help	_
34-26	7259-7261	to	_
34-27	7262-7270	identify	_
34-28	7271-7281	predictors	_
34-29	7282-7284	of	_
34-30	7285-7294	treatment	_
34-31	7295-7302	success	_
34-32	7303-7308	which	_
34-33	7309-7314	could	_
34-34	7315-7326	potentially	_
34-35	7327-7329	be	_
34-36	7330-7336	useful	_
34-37	7337-7339	in	_
34-38	7340-7350	developing	_
34-39	7351-7363	personalized	_
34-40	7364-7373	treatment	_
34-41	7374-7384	approaches	_
34-42	7384-7385	.	_

#Text=Methods/Design
#Text=Study flow chart.
35-1	7386-7393	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]
35-2	7393-7394	/	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]
35-3	7394-7400	Design	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]
35-4	7401-7406	Study	_
35-5	7407-7411	flow	_
35-6	7412-7417	chart	_
35-7	7417-7418	.	_

#Text=N = 100 patients with a diagnosis of alcohol addiction from the local inpatient and outpatient addiction clinics are randomized to 5 single-blind groups, receive rtfMRI NFB treatment on 3 days within two weeks, and are followed up monthly for 3 months
#Text=To investigate the effect of rtfMRI NFB and identify the underlying neural mechanisms we will include N = 100 patients with a diagnosis of alcohol use disorder recruited from the outpatient and inpatient clinics of the Department of Addiction Behavior and Addiction Medicine at the Central Institute of Mental Health (CIMH), Mannheim, Germany.
36-1	7419-7420	N	_
36-2	7421-7422	=	_
36-3	7423-7426	100	_
36-4	7427-7435	patients	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]
36-5	7436-7440	with	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]
36-6	7441-7442	a	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]
36-7	7443-7452	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]
36-8	7453-7455	of	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]
36-9	7456-7463	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]
36-10	7464-7473	addiction	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]
36-11	7474-7478	from	_
36-12	7479-7482	the	_
36-13	7483-7488	local	_
36-14	7489-7498	inpatient	_
36-15	7499-7502	and	_
36-16	7503-7513	outpatient	_
36-17	7514-7523	addiction	_
36-18	7524-7531	clinics	_
36-19	7532-7535	are	_
36-20	7536-7546	randomized	_
36-21	7547-7549	to	_
36-22	7550-7551	5	_
36-23	7552-7564	single-blind	_
36-24	7565-7571	groups	_
36-25	7571-7572	,	_
36-26	7573-7580	receive	_
36-27	7581-7587	rtfMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
36-28	7588-7591	NFB	_
36-29	7592-7601	treatment	_
36-30	7602-7604	on	_
36-31	7605-7606	3	_
36-32	7606-7607	 	_
36-33	7607-7611	days	_
36-34	7612-7618	within	_
36-35	7619-7622	two	_
36-36	7623-7628	weeks	_
36-37	7628-7629	,	_
36-38	7630-7633	and	_
36-39	7634-7637	are	_
36-40	7638-7646	followed	_
36-41	7647-7649	up	_
36-42	7650-7657	monthly	_
36-43	7658-7661	for	_
36-44	7662-7663	3	_
36-45	7663-7664	 	_
36-46	7664-7670	months	_
36-47	7671-7673	To	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-48	7674-7685	investigate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-49	7686-7689	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-50	7690-7696	effect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-51	7697-7699	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-52	7700-7706	rtfMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-53	7707-7710	NFB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-54	7711-7714	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-55	7715-7723	identify	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-56	7724-7727	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-57	7728-7738	underlying	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-58	7739-7745	neural	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-59	7746-7756	mechanisms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-60	7757-7759	we	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-61	7760-7764	will	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-62	7765-7772	include	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-63	7773-7774	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-64	7775-7776	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-65	7777-7780	100	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-66	7781-7789	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-67	7790-7794	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-68	7795-7796	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-69	7797-7806	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-70	7807-7809	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-71	7810-7817	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[11]
36-72	7818-7821	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[11]
36-73	7822-7830	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[11]
36-74	7831-7840	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-75	7841-7845	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-76	7846-7849	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-77	7850-7860	outpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-78	7861-7864	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-79	7865-7874	inpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-80	7875-7882	clinics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-81	7883-7885	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-82	7886-7889	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-83	7890-7900	Department	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-84	7901-7903	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-85	7904-7913	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-86	7914-7922	Behavior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-87	7923-7926	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-88	7927-7936	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-89	7937-7945	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-90	7946-7948	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-91	7949-7952	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-92	7953-7960	Central	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-93	7961-7970	Institute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-94	7971-7973	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-95	7974-7980	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-96	7981-7987	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-97	7988-7989	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-98	7989-7993	CIMH	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-99	7993-7994	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-100	7994-7995	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-101	7996-8004	Mannheim	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-102	8004-8005	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-103	8006-8013	Germany	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
36-104	8013-8014	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]

#Text=Participants will be randomly assigned to one of 5 parallel groups.
37-1	8015-8027	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
37-2	8028-8032	will	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
37-3	8033-8035	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
37-4	8036-8044	randomly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
37-5	8045-8053	assigned	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
37-6	8054-8056	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
37-7	8057-8060	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
37-8	8061-8063	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
37-9	8064-8065	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
37-10	8066-8074	parallel	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
37-11	8075-8081	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]
37-12	8081-8082	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]

#Text=All groups will receive true rtfMRI NFB from different brain processes and will be followed up monthly for three months (Fig. 1).
38-1	8083-8086	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-2	8087-8093	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-3	8094-8098	will	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-4	8099-8106	receive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-5	8107-8111	true	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-6	8112-8118	rtfMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[14]
38-7	8119-8122	NFB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[14]
38-8	8123-8127	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-9	8128-8137	different	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-10	8138-8143	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-11	8144-8153	processes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-12	8154-8157	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-13	8158-8162	will	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-14	8163-8165	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-15	8166-8174	followed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-16	8175-8177	up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-17	8178-8185	monthly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-18	8186-8189	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-19	8190-8195	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-20	8196-8202	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-21	8203-8204	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-22	8204-8207	Fig	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-23	8207-8208	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-24	8208-8209	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-25	8209-8210	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-26	8210-8211	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
38-27	8211-8212	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]

#Text=Participant eligibility and recruitment
#Text=Eligible participants are between 18 and 65 years with normal or corrected-to-normal vision.
39-1	8213-8224	Participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-2	8225-8236	eligibility	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-3	8237-8240	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-4	8241-8252	recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-5	8253-8261	Eligible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-6	8262-8274	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-7	8275-8278	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-8	8279-8286	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-9	8287-8289	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-10	8290-8293	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-11	8294-8296	65	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-12	8296-8297	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-13	8297-8302	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-14	8303-8307	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-15	8308-8314	normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-16	8315-8317	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-17	8318-8337	corrected-to-normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-18	8338-8344	vision	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
39-19	8344-8345	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]

#Text=They are diagnosed with alcohol dependence according to the International Classification of Diseases, tenth edition (ICD-10: F10.2) with controlled abstinence for at least 5 and a maximum of 21 days prior to study inclusion.
40-1	8346-8350	They	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-2	8351-8354	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-3	8355-8364	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-4	8365-8369	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-5	8370-8377	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[17]
40-6	8378-8388	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[17]
40-7	8389-8398	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-8	8399-8401	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-9	8402-8405	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-10	8406-8419	International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-11	8420-8434	Classification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-12	8435-8437	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-13	8438-8446	Diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-14	8446-8447	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-15	8448-8453	tenth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-16	8454-8461	edition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-17	8462-8463	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-18	8463-8466	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-19	8466-8467	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-20	8467-8469	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-21	8469-8470	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-22	8471-8476	F10.2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-23	8476-8477	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-24	8478-8482	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-25	8483-8493	controlled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-26	8494-8504	abstinence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-27	8505-8508	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-28	8509-8511	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-29	8512-8517	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-30	8518-8519	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-31	8520-8523	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-32	8524-8525	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-33	8526-8533	maximum	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-34	8534-8536	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-35	8537-8539	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-36	8539-8540	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-37	8540-8544	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-38	8545-8550	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-39	8551-8553	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-40	8554-8559	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-41	8560-8569	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
40-42	8569-8570	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]

#Text=Additionally, a medically supervised detoxification program (treatment of withdrawal symptoms with short-acting benzodiazepines or clomethiazole) has to have been completed for at least 3 days.
41-1	8571-8583	Additionally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-2	8583-8584	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-3	8585-8586	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-4	8587-8596	medically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-5	8597-8607	supervised	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-6	8608-8622	detoxification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-7	8623-8630	program	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-8	8631-8632	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-9	8632-8641	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-10	8642-8644	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-11	8645-8655	withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-12	8656-8664	symptoms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-13	8665-8669	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-14	8670-8682	short-acting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-15	8683-8698	benzodiazepines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-16	8699-8701	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-17	8702-8715	clomethiazole	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-18	8715-8716	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-19	8717-8720	has	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-20	8721-8723	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-21	8724-8728	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-22	8729-8733	been	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-23	8734-8743	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-24	8744-8747	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-25	8748-8750	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-26	8751-8756	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-27	8757-8758	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-28	8758-8759	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-29	8759-8763	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]
41-30	8763-8764	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]

#Text=Exclusion criteria are: meeting the criteria of any axis I psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and the ICD-10 within the past 12 months, with the exception of alcohol and nicotine abuse/dependence and a mild depression related to alcohol consumption or detoxification.
42-1	8765-8774	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-2	8775-8783	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-3	8784-8787	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-4	8787-8788	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-5	8789-8796	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-6	8797-8800	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-7	8801-8809	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-8	8810-8812	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-9	8813-8816	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-10	8817-8821	axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-11	8822-8823	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-12	8824-8835	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-13	8836-8844	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-14	8845-8854	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-15	8855-8857	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-16	8858-8861	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-17	8862-8872	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-18	8873-8876	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-19	8877-8888	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-20	8889-8895	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-21	8896-8898	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-22	8899-8905	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-23	8906-8915	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-24	8915-8916	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-25	8917-8923	fourth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-26	8924-8931	edition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-27	8932-8933	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-28	8933-8939	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-29	8939-8940	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-30	8941-8944	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-31	8945-8948	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-32	8949-8952	ICD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-33	8952-8953	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-34	8953-8955	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-35	8956-8962	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-36	8963-8966	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-37	8967-8971	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-38	8972-8974	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-39	8974-8975	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-40	8975-8981	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-41	8981-8982	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-42	8983-8987	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-43	8988-8991	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-44	8992-9001	exception	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-45	9002-9004	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-46	9005-9012	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-47	9013-9016	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-48	9017-9025	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-49	9026-9031	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-50	9031-9032	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-51	9032-9042	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-52	9043-9046	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-53	9047-9048	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-54	9049-9053	mild	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-55	9054-9064	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-56	9065-9072	related	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-57	9073-9075	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-58	9076-9083	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-59	9084-9095	consumption	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-60	9096-9098	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-61	9099-9113	detoxification	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
42-62	9113-9114	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]

#Text=Further exclusion criteria are a positive urine drug screening, current use of psychotropic or anticonvulsive medications, epilepsy or neurological or severe medical illness, suicidal tendencies, pregnancy, and breastfeeding.
43-1	9115-9122	Further	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-2	9123-9132	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-3	9133-9141	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-4	9142-9145	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-5	9146-9147	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-6	9148-9156	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-7	9157-9162	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-8	9163-9167	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-9	9168-9177	screening	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-10	9177-9178	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-11	9179-9186	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-12	9187-9190	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-13	9191-9193	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-14	9194-9206	psychotropic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-15	9207-9209	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-16	9210-9224	anticonvulsive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-17	9225-9236	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-18	9236-9237	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-19	9238-9246	epilepsy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-20	9247-9249	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-21	9250-9262	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-22	9263-9265	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-23	9266-9272	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-24	9273-9280	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-25	9281-9288	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-26	9288-9289	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-27	9290-9298	suicidal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-28	9299-9309	tendencies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-29	9309-9310	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-30	9311-9320	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-31	9320-9321	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-32	9322-9325	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-33	9326-9339	breastfeeding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]
43-34	9339-9340	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]

#Text=For recruitment, participants are informed by a psychologist of the study team about the study purpose and are able to ask all questions concerning the study content.
44-1	9341-9344	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-2	9345-9356	recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-3	9356-9357	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-4	9358-9370	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-5	9371-9374	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-6	9375-9383	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-7	9384-9386	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-8	9387-9388	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-9	9389-9401	psychologist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-10	9402-9404	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-11	9405-9408	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-12	9409-9414	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-13	9415-9419	team	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-14	9420-9425	about	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-15	9426-9429	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-16	9430-9435	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-17	9436-9443	purpose	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-18	9444-9447	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-19	9448-9451	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-20	9452-9456	able	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-21	9457-9459	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-22	9460-9463	ask	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-23	9464-9467	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-24	9468-9477	questions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-25	9478-9488	concerning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-26	9489-9492	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-27	9493-9498	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-28	9499-9506	content	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]
44-29	9506-9507	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]

#Text=Participants are then asked to provide written informed consent before being screened for in- and exclusion criteria.
45-1	9508-9520	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-2	9521-9524	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-3	9525-9529	then	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-4	9530-9535	asked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-5	9536-9538	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-6	9539-9546	provide	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-7	9547-9554	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-8	9555-9563	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-9	9564-9571	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-10	9572-9578	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-11	9579-9584	being	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-12	9585-9593	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-13	9594-9597	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-14	9598-9600	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-15	9600-9601	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-16	9602-9605	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-17	9606-9615	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-18	9616-9624	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
45-19	9624-9625	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]

#Text=Participants are able to withdraw their consent at any time.
46-1	9626-9638	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
46-2	9639-9642	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
46-3	9643-9647	able	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
46-4	9648-9650	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
46-5	9651-9659	withdraw	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
46-6	9660-9665	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
46-7	9666-9673	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
46-8	9674-9676	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
46-9	9677-9680	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
46-10	9681-9685	time	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]
46-11	9685-9686	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]

#Text=Screening assessment & group allocation
#Text=Schedule of measurements conducted in the study
#Text=Measurement\tSa\tT0a\tMRI1a\tMRI2a\tMRI3a\tFU1/2b\tFU3a\t \tSociodemographic information\t\tX\t\t\t\t\t\t \tStructured Clinical Interview (SKID – I)\tX\t\t\t\t\t\t\t \tDrinking Assessment Interview (Form 90)\t\tX\t\t\t\t\t\t \tBlood sample (AUD-related markers)\tX\t\t\t\t\t\tX\t \tUrine sample (pregnancy, drugs)\tX\t\t\t\t\t\t\t \tCurrent medication\tX\t\t\t\t\tXc\tXc\t \tCurrent smoking behavior\t\tXc\tXc\tXc\tXc\tXc\tXc\t \tBreath alcohol test\t\t\t\t\t\t\tX\t \tCurrent drug use\t\t\t\t\t\tXc\tXc\t \tIncentive Conflict Task\t\tX\t\t\t\t\t\t \tClinical & Personality Questionnaires\t \t Edinburgh Inventory of Handedness\tX\t\t\t\t\t\t\t \t Beck Depression Inventory\t\tX\t\t\t\t\t\t \t State Trait Anxiety Inventory\t\tX\t\t\t\t\t\t \t Behavioral Inhibition/Approach System\t\tX\t\t\t\t\t\t \t Barratt Impulsiveness Scale\t\tX\t\t\t\t\t\t \t Fagerstrøm Test of Nicotine Dependence\t\tX\t\t\t\t\t\t \tAlcohol-Related Questionnaires\t \t Quick Drinking Assessment Interview (Form 90-AQ)\t\t\t\t\t\tX\tX\t \t Alcohol Dependence Scale\t\tX\t\t\t\t\t\t \t Alcohol Abstinence Self-Efficacy Scale\t\tX\t\t\tX\t\tX\t \t German Inventory of Drinking Situations\t\tX\t\t\t\t\t\t \t Obsessive Compulsive Drinking Scale\t\tX\t\t\tX\t\tX\t \t Alcohol Urge Questionnaire\t\tX\t\t\tX\t\tX\t \t Craving-Automatized-Scale-Alcohol\t\tX\t\t\tX\t\tX\t \tMRI\t \t Anatomical image (MPRAGE)\t\t\tX\tX\tX\t\t\t \t Resting state\t\t\tX\tX\tX\t\t\t \t Neurofeedback\t\t\tX\tX\tX\t\t\t \t Transfer run\t\t\tX\t\tX\t\t\t \t Craving (visual analog scale) pre & post scanning\t\t\tX\tX\tX\t\t\t \t Perceived control over NFB (visual analog scale)\t\t\tX\tX\tX\t\t\t \t
#Text=S screening assessment, T0 baseline assessment, MRI rtfMRI scanning days, FU monthly follow-up. aface-to-face; bvia telephone; cself-reported (if unclear)
#Text=Screening for in- and exclusion criteria includes the Structured Clinical Interview for DSM-IV (SKID-I) conducted by a clinical psychologist.
47-1	9687-9696	Screening	_
47-2	9697-9707	assessment	_
47-3	9708-9709	&	_
47-4	9710-9715	group	_
47-5	9716-9726	allocation	_
47-6	9727-9735	Schedule	_
47-7	9736-9738	of	_
47-8	9739-9751	measurements	_
47-9	9752-9761	conducted	_
47-10	9762-9764	in	_
47-11	9765-9768	the	_
47-12	9769-9774	study	_
47-13	9775-9786	Measurement	_
47-14	9787-9789	Sa	_
47-15	9790-9793	T0a	_
47-16	9794-9799	MRI1a	_
47-17	9800-9805	MRI2a	_
47-18	9806-9811	MRI3a	_
47-19	9812-9815	FU1	_
47-20	9815-9816	/	_
47-21	9816-9818	2b	_
47-22	9819-9823	FU3a	_
47-23	9826-9842	Sociodemographic	_
47-24	9843-9854	information	_
47-25	9856-9857	X	_
47-26	9865-9875	Structured	_
47-27	9876-9884	Clinical	_
47-28	9885-9894	Interview	_
47-29	9895-9896	(	_
47-30	9896-9900	SKID	_
47-31	9901-9902	–	_
47-32	9903-9904	I	_
47-33	9904-9905	)	_
47-34	9906-9907	X	_
47-35	9916-9924	Drinking	_
47-36	9925-9935	Assessment	_
47-37	9936-9945	Interview	_
47-38	9946-9947	(	_
47-39	9947-9951	Form	_
47-40	9952-9954	90	_
47-41	9954-9955	)	_
47-42	9957-9958	X	_
47-43	9966-9971	Blood	_
47-44	9972-9978	sample	_
47-45	9979-9980	(	_
47-46	9980-9991	AUD-related	_
47-47	9992-9999	markers	_
47-48	9999-10000	)	_
47-49	10001-10002	X	_
47-50	10008-10009	X	_
47-51	10012-10017	Urine	_
47-52	10018-10024	sample	_
47-53	10025-10026	(	_
47-54	10026-10035	pregnancy	_
47-55	10035-10036	,	_
47-56	10037-10042	drugs	_
47-57	10042-10043	)	_
47-58	10044-10045	X	_
47-59	10054-10061	Current	_
47-60	10062-10072	medication	_
47-61	10073-10074	X	_
47-62	10079-10081	Xc	_
47-63	10082-10084	Xc	_
47-64	10087-10094	Current	_
47-65	10095-10102	smoking	_
47-66	10103-10111	behavior	_
47-67	10113-10115	Xc	_
47-68	10116-10118	Xc	_
47-69	10119-10121	Xc	_
47-70	10122-10124	Xc	_
47-71	10125-10127	Xc	_
47-72	10128-10130	Xc	_
47-73	10133-10139	Breath	_
47-74	10140-10147	alcohol	_
47-75	10148-10152	test	_
47-76	10159-10160	X	_
47-77	10163-10170	Current	_
47-78	10171-10175	drug	_
47-79	10176-10179	use	_
47-80	10185-10187	Xc	_
47-81	10188-10190	Xc	_
47-82	10193-10202	Incentive	_
47-83	10203-10211	Conflict	_
47-84	10212-10216	Task	_
47-85	10218-10219	X	_
47-86	10227-10235	Clinical	_
47-87	10236-10237	&	_
47-88	10238-10249	Personality	_
47-89	10250-10264	Questionnaires	_
47-90	10268-10277	Edinburgh	_
47-91	10278-10287	Inventory	_
47-92	10288-10290	of	_
47-93	10291-10301	Handedness	_
47-94	10302-10303	X	_
47-95	10313-10317	Beck	_
47-96	10318-10328	Depression	_
47-97	10329-10338	Inventory	_
47-98	10340-10341	X	_
47-99	10350-10355	State	_
47-100	10356-10361	Trait	_
47-101	10362-10369	Anxiety	_
47-102	10370-10379	Inventory	_
47-103	10381-10382	X	_
47-104	10391-10401	Behavioral	_
47-105	10402-10412	Inhibition	_
47-106	10412-10413	/	_
47-107	10413-10421	Approach	_
47-108	10422-10428	System	_
47-109	10430-10431	X	_
47-110	10440-10447	Barratt	_
47-111	10448-10461	Impulsiveness	_
47-112	10462-10467	Scale	_
47-113	10469-10470	X	_
47-114	10479-10489	Fagerstrøm	_
47-115	10490-10494	Test	_
47-116	10495-10497	of	_
47-117	10498-10506	Nicotine	_
47-118	10507-10517	Dependence	_
47-119	10519-10520	X	_
47-120	10528-10543	Alcohol-Related	_
47-121	10544-10558	Questionnaires	_
47-122	10562-10567	Quick	_
47-123	10568-10576	Drinking	_
47-124	10577-10587	Assessment	_
47-125	10588-10597	Interview	_
47-126	10598-10599	(	_
47-127	10599-10603	Form	_
47-128	10604-10606	90	_
47-129	10606-10607	-	_
47-130	10607-10609	AQ	_
47-131	10609-10610	)	_
47-132	10616-10617	X	_
47-133	10618-10619	X	_
47-134	10623-10630	Alcohol	_
47-135	10631-10641	Dependence	_
47-136	10642-10647	Scale	_
47-137	10649-10650	X	_
47-138	10659-10666	Alcohol	_
47-139	10667-10677	Abstinence	_
47-140	10678-10691	Self-Efficacy	_
47-141	10692-10697	Scale	_
47-142	10699-10700	X	_
47-143	10703-10704	X	_
47-144	10706-10707	X	_
47-145	10711-10717	German	_
47-146	10718-10727	Inventory	_
47-147	10728-10730	of	_
47-148	10731-10739	Drinking	_
47-149	10740-10750	Situations	_
47-150	10752-10753	X	_
47-151	10762-10771	Obsessive	_
47-152	10772-10782	Compulsive	_
47-153	10783-10791	Drinking	_
47-154	10792-10797	Scale	_
47-155	10799-10800	X	_
47-156	10803-10804	X	_
47-157	10806-10807	X	_
47-158	10811-10818	Alcohol	_
47-159	10819-10823	Urge	_
47-160	10824-10837	Questionnaire	_
47-161	10839-10840	X	_
47-162	10843-10844	X	_
47-163	10846-10847	X	_
47-164	10851-10884	Craving-Automatized-Scale-Alcohol	_
47-165	10886-10887	X	_
47-166	10890-10891	X	_
47-167	10893-10894	X	_
47-168	10897-10900	MRI	_
47-169	10904-10914	Anatomical	_
47-170	10915-10920	image	_
47-171	10921-10922	(	_
47-172	10922-10928	MPRAGE	_
47-173	10928-10929	)	_
47-174	10932-10933	X	_
47-175	10934-10935	X	_
47-176	10936-10937	X	_
47-177	10943-10950	Resting	_
47-178	10951-10956	state	_
47-179	10959-10960	X	_
47-180	10961-10962	X	_
47-181	10963-10964	X	_
47-182	10970-10983	Neurofeedback	_
47-183	10986-10987	X	_
47-184	10988-10989	X	_
47-185	10990-10991	X	_
47-186	10997-11005	Transfer	_
47-187	11006-11009	run	_
47-188	11012-11013	X	_
47-189	11015-11016	X	_
47-190	11022-11029	Craving	_
47-191	11030-11031	(	_
47-192	11031-11037	visual	_
47-193	11038-11044	analog	_
47-194	11045-11050	scale	_
47-195	11050-11051	)	_
47-196	11052-11055	pre	_
47-197	11056-11057	&	_
47-198	11058-11062	post	_
47-199	11063-11071	scanning	_
47-200	11074-11075	X	_
47-201	11076-11077	X	_
47-202	11078-11079	X	_
47-203	11085-11094	Perceived	_
47-204	11095-11102	control	_
47-205	11103-11107	over	_
47-206	11108-11111	NFB	_
47-207	11112-11113	(	_
47-208	11113-11119	visual	_
47-209	11120-11126	analog	_
47-210	11127-11132	scale	_
47-211	11132-11133	)	_
47-212	11136-11137	X	_
47-213	11138-11139	X	_
47-214	11140-11141	X	_
47-215	11147-11148	S	_
47-216	11149-11158	screening	_
47-217	11159-11169	assessment	_
47-218	11169-11170	,	_
47-219	11171-11173	T0	_
47-220	11174-11182	baseline	_
47-221	11183-11193	assessment	_
47-222	11193-11194	,	_
47-223	11195-11198	MRI	_
47-224	11199-11205	rtfMRI	_
47-225	11206-11214	scanning	_
47-226	11215-11219	days	_
47-227	11219-11220	,	_
47-228	11221-11223	FU	_
47-229	11224-11231	monthly	_
47-230	11232-11241	follow-up	_
47-231	11241-11242	.	_
47-232	11243-11256	aface-to-face	_
47-233	11256-11257	;	_
47-234	11258-11262	bvia	_
47-235	11263-11272	telephone	_
47-236	11272-11273	;	_
47-237	11274-11288	cself-reported	_
47-238	11289-11290	(	_
47-239	11290-11292	if	_
47-240	11293-11300	unclear	_
47-241	11300-11301	)	_
47-242	11302-11311	Screening	_
47-243	11312-11315	for	_
47-244	11316-11318	in	_
47-245	11318-11319	-	_
47-246	11320-11323	and	_
47-247	11324-11333	exclusion	_
47-248	11334-11342	criteria	_
47-249	11343-11351	includes	_
47-250	11352-11355	the	_
47-251	11356-11366	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
47-252	11367-11375	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
47-253	11376-11385	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
47-254	11386-11389	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
47-255	11390-11396	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
47-256	11397-11398	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
47-257	11398-11404	SKID-I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
47-258	11404-11405	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[24]
47-259	11406-11415	conducted	_
47-260	11416-11418	by	_
47-261	11419-11420	a	_
47-262	11421-11429	clinical	_
47-263	11430-11442	psychologist	_
47-264	11442-11443	.	_

#Text=Either during the detoxification program or the screening assessment a drug and pregnancy test is conducted.
48-1	11444-11450	Either	_
48-2	11451-11457	during	_
48-3	11458-11461	the	_
48-4	11462-11476	detoxification	_
48-5	11477-11484	program	_
48-6	11485-11487	or	_
48-7	11488-11491	the	_
48-8	11492-11501	screening	_
48-9	11502-11512	assessment	_
48-10	11513-11514	a	_
48-11	11515-11519	drug	_
48-12	11520-11523	and	_
48-13	11524-11533	pregnancy	_
48-14	11534-11538	test	_
48-15	11539-11541	is	_
48-16	11542-11551	conducted	_
48-17	11551-11552	.	_

#Text=Please see Table 1 for further information on the schedule of measurements.
49-1	11553-11559	Please	_
49-2	11560-11563	see	_
49-3	11564-11569	Table	_
49-4	11569-11570	 	_
49-5	11570-11571	1	_
49-6	11572-11575	for	_
49-7	11576-11583	further	_
49-8	11584-11595	information	_
49-9	11596-11598	on	_
49-10	11599-11602	the	_
49-11	11603-11611	schedule	_
49-12	11612-11614	of	_
49-13	11615-11627	measurements	_
49-14	11627-11628	.	_

#Text=Participants who meet inclusion criteria are randomly assigned to one of five groups: three experimental and two control groups, respectively.
50-1	11629-11641	Participants	_
50-2	11642-11645	who	_
50-3	11646-11650	meet	_
50-4	11651-11660	inclusion	_
50-5	11661-11669	criteria	_
50-6	11670-11673	are	_
50-7	11674-11682	randomly	_
50-8	11683-11691	assigned	_
50-9	11692-11694	to	_
50-10	11695-11698	one	_
50-11	11699-11701	of	_
50-12	11702-11706	five	_
50-13	11707-11713	groups	_
50-14	11713-11714	:	_
50-15	11715-11720	three	_
50-16	11721-11733	experimental	_
50-17	11734-11737	and	_
50-18	11738-11741	two	_
50-19	11742-11749	control	_
50-20	11750-11756	groups	_
50-21	11756-11757	,	_
50-22	11758-11770	respectively	_
50-23	11770-11771	.	_

#Text=Each group has to fulfil different tasks with either downregulating the ventral striatum, upregulating the right inferior frontal gyrus (rIFG), increasing the connectivity (negative correlation) between rIFG and VS, downregulating the auditory cortex (downregulation control) or upregulating the auditory cortex (upregulation control).
51-1	11772-11776	Each	_
51-2	11777-11782	group	_
51-3	11783-11786	has	_
51-4	11787-11789	to	_
51-5	11790-11796	fulfil	_
51-6	11797-11806	different	_
51-7	11807-11812	tasks	_
51-8	11813-11817	with	_
51-9	11818-11824	either	_
51-10	11825-11839	downregulating	_
51-11	11840-11843	the	_
51-12	11844-11851	ventral	_
51-13	11852-11860	striatum	_
51-14	11860-11861	,	_
51-15	11862-11874	upregulating	_
51-16	11875-11878	the	_
51-17	11879-11884	right	_
51-18	11885-11893	inferior	_
51-19	11894-11901	frontal	_
51-20	11902-11907	gyrus	_
51-21	11908-11909	(	_
51-22	11909-11913	rIFG	_
51-23	11913-11914	)	_
51-24	11914-11915	,	_
51-25	11916-11926	increasing	_
51-26	11927-11930	the	_
51-27	11931-11943	connectivity	_
51-28	11944-11945	(	_
51-29	11945-11953	negative	_
51-30	11954-11965	correlation	_
51-31	11965-11966	)	_
51-32	11967-11974	between	_
51-33	11975-11979	rIFG	_
51-34	11980-11983	and	_
51-35	11984-11986	VS	_
51-36	11986-11987	,	_
51-37	11988-12002	downregulating	_
51-38	12003-12006	the	_
51-39	12007-12015	auditory	_
51-40	12016-12022	cortex	_
51-41	12023-12024	(	_
51-42	12024-12038	downregulation	_
51-43	12039-12046	control	_
51-44	12046-12047	)	_
51-45	12048-12050	or	_
51-46	12051-12063	upregulating	_
51-47	12064-12067	the	_
51-48	12068-12076	auditory	_
51-49	12077-12083	cortex	_
51-50	12084-12085	(	_
51-51	12085-12097	upregulation	_
51-52	12098-12105	control	_
51-53	12105-12106	)	_
51-54	12106-12107	.	_

#Text=The auditory cortex was chosen as control region because it is not involved in cue-reactivity.
52-1	12108-12111	The	_
52-2	12112-12120	auditory	_
52-3	12121-12127	cortex	_
52-4	12128-12131	was	_
52-5	12132-12138	chosen	_
52-6	12139-12141	as	_
52-7	12142-12149	control	_
52-8	12150-12156	region	_
52-9	12157-12164	because	_
52-10	12165-12167	it	_
52-11	12168-12170	is	_
52-12	12171-12174	not	_
52-13	12175-12183	involved	_
52-14	12184-12186	in	_
52-15	12187-12201	cue-reactivity	_
52-16	12201-12202	.	_

#Text=Group allocation of included participants is conducted by the study team with a computer-generated random list based on the sequence of inclusion.
53-1	12203-12208	Group	_
53-2	12209-12219	allocation	_
53-3	12220-12222	of	_
53-4	12223-12231	included	_
53-5	12232-12244	participants	_
53-6	12245-12247	is	_
53-7	12248-12257	conducted	_
53-8	12258-12260	by	_
53-9	12261-12264	the	_
53-10	12265-12270	study	_
53-11	12271-12275	team	_
53-12	12276-12280	with	_
53-13	12281-12282	a	_
53-14	12283-12301	computer-generated	_
53-15	12302-12308	random	_
53-16	12309-12313	list	_
53-17	12314-12319	based	_
53-18	12320-12322	on	_
53-19	12323-12326	the	_
53-20	12327-12335	sequence	_
53-21	12336-12338	of	_
53-22	12339-12348	inclusion	_
53-23	12348-12349	.	_

#Text=No stratification factors are used in the allocation process.
54-1	12350-12352	No	_
54-2	12353-12367	stratification	_
54-3	12368-12375	factors	_
54-4	12376-12379	are	_
54-5	12380-12384	used	_
54-6	12385-12387	in	_
54-7	12388-12391	the	_
54-8	12392-12402	allocation	_
54-9	12403-12410	process	_
54-10	12410-12411	.	_

#Text=Baseline assessment
#Text=After group allocation, all participants take part in a baseline assessment about demographic questions, alcohol use, actual medication, personality, and clinical symptoms (see Table 1).
55-1	12412-12420	Baseline	_
55-2	12421-12431	assessment	_
55-3	12432-12437	After	_
55-4	12438-12443	group	_
55-5	12444-12454	allocation	_
55-6	12454-12455	,	_
55-7	12456-12459	all	_
55-8	12460-12472	participants	_
55-9	12473-12477	take	_
55-10	12478-12482	part	_
55-11	12483-12485	in	_
55-12	12486-12487	a	_
55-13	12488-12496	baseline	_
55-14	12497-12507	assessment	_
55-15	12508-12513	about	_
55-16	12514-12525	demographic	_
55-17	12526-12535	questions	_
55-18	12535-12536	,	_
55-19	12537-12544	alcohol	_
55-20	12545-12548	use	_
55-21	12548-12549	,	_
55-22	12550-12556	actual	_
55-23	12557-12567	medication	_
55-24	12567-12568	,	_
55-25	12569-12580	personality	_
55-26	12580-12581	,	_
55-27	12582-12585	and	_
55-28	12586-12594	clinical	_
55-29	12595-12603	symptoms	_
55-30	12604-12605	(	_
55-31	12605-12608	see	_
55-32	12609-12614	Table	_
55-33	12615-12616	1	_
55-34	12616-12617	)	_
55-35	12617-12618	.	_

#Text=In addition, participants conduct the computer-based Incentive Conflict Task (ICT,) during the baseline assessment.
56-1	12619-12621	In	_
56-2	12622-12630	addition	_
56-3	12630-12631	,	_
56-4	12632-12644	participants	_
56-5	12645-12652	conduct	_
56-6	12653-12656	the	_
56-7	12657-12671	computer-based	_
56-8	12672-12681	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[25]
56-9	12682-12690	Conflict	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[25]
56-10	12691-12695	Task	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[25]
56-11	12696-12697	(	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[25]
56-12	12697-12700	ICT	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[25]
56-13	12700-12701	,	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[25]
56-14	12701-12702	)	_
56-15	12703-12709	during	_
56-16	12710-12713	the	_
56-17	12714-12722	baseline	_
56-18	12723-12733	assessment	_
56-19	12733-12734	.	_

#Text=Neurofeedback setup
#Text=rtfMRI NFB is conducted at Siemens 3 T Tim Trio scanners (Siemens Healthineers, Erlangen, Germany) at the Central Institute of Mental Health in Mannheim, Germany.
57-1	12735-12748	Neurofeedback	_
57-2	12749-12754	setup	_
57-3	12755-12761	rtfMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[26]
57-4	12762-12765	NFB	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[26]
57-5	12766-12768	is	_
57-6	12769-12778	conducted	_
57-7	12779-12781	at	_
57-8	12782-12789	Siemens	_
57-9	12790-12791	3	_
57-10	12791-12792	 	_
57-11	12792-12793	T	_
57-12	12794-12797	Tim	_
57-13	12798-12802	Trio	_
57-14	12803-12811	scanners	_
57-15	12812-12813	(	_
57-16	12813-12820	Siemens	_
57-17	12821-12833	Healthineers	_
57-18	12833-12834	,	_
57-19	12835-12843	Erlangen	_
57-20	12843-12844	,	_
57-21	12845-12852	Germany	_
57-22	12852-12853	)	_
57-23	12854-12856	at	_
57-24	12857-12860	the	_
57-25	12861-12868	Central	_
57-26	12869-12878	Institute	_
57-27	12879-12881	of	_
57-28	12882-12888	Mental	_
57-29	12889-12895	Health	_
57-30	12896-12898	in	_
57-31	12899-12907	Mannheim	_
57-32	12907-12908	,	_
57-33	12909-12916	Germany	_
57-34	12916-12917	.	_

#Text=Each participant receives neurofeedback training on three scanning days within a period of two weeks.
58-1	12918-12922	Each	_
58-2	12923-12934	participant	_
58-3	12935-12943	receives	_
58-4	12944-12957	neurofeedback	_
58-5	12958-12966	training	_
58-6	12967-12969	on	_
58-7	12970-12975	three	_
58-8	12976-12984	scanning	_
58-9	12985-12989	days	_
58-10	12990-12996	within	_
58-11	12997-12998	a	_
58-12	12999-13005	period	_
58-13	13006-13008	of	_
58-14	13009-13012	two	_
58-15	13013-13018	weeks	_
58-16	13018-13019	.	_

#Text=On each day a 5:21 min T1-weighted anatomical MPRAGE scan, a 12:00 min functional resting state scan with eyes closed, and three neurofeedback runs of 9:29 min are conducted.
59-1	13020-13022	On	_
59-2	13023-13027	each	_
59-3	13028-13031	day	_
59-4	13032-13033	a	_
59-5	13034-13035	5	_
59-6	13035-13036	:	_
59-7	13036-13038	21	_
59-8	13038-13039	 	_
59-9	13039-13042	min	_
59-10	13043-13045	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]
59-11	13045-13046	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]
59-12	13046-13054	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]
59-13	13055-13065	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]
59-14	13066-13072	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]
59-15	13073-13077	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[27]
59-16	13077-13078	,	_
59-17	13079-13080	a	_
59-18	13081-13083	12	_
59-19	13083-13084	:	_
59-20	13084-13086	00	_
59-21	13086-13087	 	_
59-22	13087-13090	min	_
59-23	13091-13101	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[28]
59-24	13102-13109	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[28]
59-25	13110-13115	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[28]
59-26	13116-13120	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[28]
59-27	13121-13125	with	_
59-28	13126-13130	eyes	_
59-29	13131-13137	closed	_
59-30	13137-13138	,	_
59-31	13139-13142	and	_
59-32	13143-13148	three	_
59-33	13149-13162	neurofeedback	_
59-34	13163-13167	runs	_
59-35	13168-13170	of	_
59-36	13171-13172	9	_
59-37	13172-13173	:	_
59-38	13173-13175	29	_
59-39	13175-13176	 	_
59-40	13176-13179	min	_
59-41	13180-13183	are	_
59-42	13184-13193	conducted	_
59-43	13193-13194	.	_

#Text=At the beginning of each session an MPRAGE image is acquired with a time of repetition (TR) of 2.3 s, an echo time (TE) of 3.03 ms, 9° flip angle, a field of view of 256 mm with 192 sagittal slice, a matrix size of 256 × 256 mm, 1x1x1 mm voxel size, and GRAPPA with iPAT = 2.
60-1	13195-13197	At	_
60-2	13198-13201	the	_
60-3	13202-13211	beginning	_
60-4	13212-13214	of	_
60-5	13215-13219	each	_
60-6	13220-13227	session	_
60-7	13228-13230	an	_
60-8	13231-13237	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]
60-9	13238-13243	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]
60-10	13244-13246	is	_
60-11	13247-13255	acquired	_
60-12	13256-13260	with	_
60-13	13261-13262	a	_
60-14	13263-13267	time	_
60-15	13268-13270	of	_
60-16	13271-13281	repetition	_
60-17	13282-13283	(	_
60-18	13283-13285	TR	_
60-19	13285-13286	)	_
60-20	13287-13289	of	_
60-21	13290-13293	2.3	_
60-22	13293-13294	 	_
60-23	13294-13295	s	_
60-24	13295-13296	,	_
60-25	13297-13299	an	_
60-26	13300-13304	echo	_
60-27	13305-13309	time	_
60-28	13310-13311	(	_
60-29	13311-13313	TE	_
60-30	13313-13314	)	_
60-31	13315-13317	of	_
60-32	13318-13322	3.03	_
60-33	13322-13323	 	_
60-34	13323-13325	ms	_
60-35	13325-13326	,	_
60-36	13327-13328	9	_
60-37	13328-13329	°	_
60-38	13330-13334	flip	_
60-39	13335-13340	angle	_
60-40	13340-13341	,	_
60-41	13342-13343	a	_
60-42	13344-13349	field	_
60-43	13350-13352	of	_
60-44	13353-13357	view	_
60-45	13358-13360	of	_
60-46	13361-13364	256	_
60-47	13364-13365	 	_
60-48	13365-13367	mm	_
60-49	13368-13372	with	_
60-50	13373-13376	192	_
60-51	13377-13385	sagittal	_
60-52	13386-13391	slice	_
60-53	13391-13392	,	_
60-54	13393-13394	a	_
60-55	13395-13401	matrix	_
60-56	13402-13406	size	_
60-57	13407-13409	of	_
60-58	13410-13413	256	_
60-59	13414-13415	×	_
60-60	13416-13419	256	_
60-61	13420-13422	mm	_
60-62	13422-13423	,	_
60-63	13424-13429	1x1x1	_
60-64	13430-13432	mm	_
60-65	13433-13438	voxel	_
60-66	13439-13443	size	_
60-67	13443-13444	,	_
60-68	13445-13448	and	_
60-69	13449-13455	GRAPPA	_
60-70	13456-13460	with	_
60-71	13461-13465	iPAT	_
60-72	13466-13467	=	_
60-73	13468-13469	2	_
60-74	13469-13470	.	_

#Text=Resting state and NFB sessions are scanned with echo-planar imaging (EPI) sequences with a TR of 1.64 s, a TE of 30 ms, 73° flip angle, a field of view of 192 mm, 3x3x3 mm voxel size, 33 slices of 3 mm thickness with a distance factor of 33%, and GRAPPA with iPAT = 2.
61-1	13471-13478	Resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[30]
61-2	13479-13484	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[30]
61-3	13485-13488	and	_
61-4	13489-13492	NFB	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
61-5	13493-13501	sessions	_
61-6	13502-13505	are	_
61-7	13506-13513	scanned	_
61-8	13514-13518	with	_
61-9	13519-13530	echo-planar	_
61-10	13531-13538	imaging	_
61-11	13539-13540	(	_
61-12	13540-13543	EPI	_
61-13	13543-13544	)	_
61-14	13545-13554	sequences	_
61-15	13555-13559	with	_
61-16	13560-13561	a	_
61-17	13562-13564	TR	_
61-18	13565-13567	of	_
61-19	13568-13572	1.64	_
61-20	13572-13573	 	_
61-21	13573-13574	s	_
61-22	13574-13575	,	_
61-23	13576-13577	a	_
61-24	13578-13580	TE	_
61-25	13581-13583	of	_
61-26	13584-13586	30	_
61-27	13586-13587	 	_
61-28	13587-13589	ms	_
61-29	13589-13590	,	_
61-30	13591-13593	73	_
61-31	13593-13594	°	_
61-32	13595-13599	flip	_
61-33	13600-13605	angle	_
61-34	13605-13606	,	_
61-35	13607-13608	a	_
61-36	13609-13614	field	_
61-37	13615-13617	of	_
61-38	13618-13622	view	_
61-39	13623-13625	of	_
61-40	13626-13629	192	_
61-41	13629-13630	 	_
61-42	13630-13632	mm	_
61-43	13632-13633	,	_
61-44	13634-13639	3x3x3	_
61-45	13640-13642	mm	_
61-46	13643-13648	voxel	_
61-47	13649-13653	size	_
61-48	13653-13654	,	_
61-49	13655-13657	33	_
61-50	13658-13664	slices	_
61-51	13665-13667	of	_
61-52	13668-13669	3	_
61-53	13669-13670	 	_
61-54	13670-13672	mm	_
61-55	13673-13682	thickness	_
61-56	13683-13687	with	_
61-57	13688-13689	a	_
61-58	13690-13698	distance	_
61-59	13699-13705	factor	_
61-60	13706-13708	of	_
61-61	13709-13712	33%	_
61-62	13712-13713	,	_
61-63	13714-13717	and	_
61-64	13718-13724	GRAPPA	_
61-65	13725-13729	with	_
61-66	13730-13734	iPAT	_
61-67	13735-13736	=	_
61-68	13737-13738	2	_
61-69	13738-13739	.	_

#Text=Real-time fMRI neurofeedback setup.
62-1	13740-13749	Real-time	_
62-2	13750-13754	fMRI	_
62-3	13755-13768	neurofeedback	_
62-4	13769-13774	setup	_
62-5	13774-13775	.	_

#Text=Acquired images are reconstructed and send to a laptop running in-house MATLAB (MathWorks Inc., Sherborn, MA, USA) scripts based on SPM8 (Wellcome Department of Cognitive Neurology, London, UK) functions to preprocess the images and extract the neurofeedback signal.
63-1	13776-13784	Acquired	_
63-2	13785-13791	images	_
63-3	13792-13795	are	_
63-4	13796-13809	reconstructed	_
63-5	13810-13813	and	_
63-6	13814-13818	send	_
63-7	13819-13821	to	_
63-8	13822-13823	a	_
63-9	13824-13830	laptop	_
63-10	13831-13838	running	_
63-11	13839-13847	in-house	_
63-12	13848-13854	MATLAB	_
63-13	13855-13856	(	_
63-14	13856-13865	MathWorks	_
63-15	13866-13869	Inc	_
63-16	13869-13870	.	_
63-17	13870-13871	,	_
63-18	13872-13880	Sherborn	_
63-19	13880-13881	,	_
63-20	13882-13884	MA	_
63-21	13884-13885	,	_
63-22	13886-13889	USA	_
63-23	13889-13890	)	_
63-24	13891-13898	scripts	_
63-25	13899-13904	based	_
63-26	13905-13907	on	_
63-27	13908-13912	SPM8	_
63-28	13913-13914	(	_
63-29	13914-13922	Wellcome	_
63-30	13923-13933	Department	_
63-31	13934-13936	of	_
63-32	13937-13946	Cognitive	_
63-33	13947-13956	Neurology	_
63-34	13956-13957	,	_
63-35	13958-13964	London	_
63-36	13964-13965	,	_
63-37	13966-13968	UK	_
63-38	13968-13969	)	_
63-39	13970-13979	functions	_
63-40	13980-13982	to	_
63-41	13983-13993	preprocess	_
63-42	13994-13997	the	_
63-43	13998-14004	images	_
63-44	14005-14008	and	_
63-45	14009-14016	extract	_
63-46	14017-14020	the	_
63-47	14021-14034	neurofeedback	_
63-48	14035-14041	signal	_
63-49	14041-14042	.	_

#Text=The feedback value is send to a computer running Presentation software (Neurobehavioral Systems, Inc., Albany, CA, USA) and presented to the participant in the scanner as a thermometer value besides a picture of an alcoholic beverage
#Text=During NFB scans, reconstructed DICOM images are transferred from the imaging computer to a laptop that preprocesses the images and extracts the neurofeedback signal by means of an in-house software.
64-1	14043-14046	The	_
64-2	14047-14055	feedback	_
64-3	14056-14061	value	_
64-4	14062-14064	is	_
64-5	14065-14069	send	_
64-6	14070-14072	to	_
64-7	14073-14074	a	_
64-8	14075-14083	computer	_
64-9	14084-14091	running	_
64-10	14092-14104	Presentation	_
64-11	14105-14113	software	_
64-12	14114-14115	(	_
64-13	14115-14130	Neurobehavioral	_
64-14	14131-14138	Systems	_
64-15	14138-14139	,	_
64-16	14140-14143	Inc	_
64-17	14143-14144	.	_
64-18	14144-14145	,	_
64-19	14146-14152	Albany	_
64-20	14152-14153	,	_
64-21	14154-14156	CA	_
64-22	14156-14157	,	_
64-23	14158-14161	USA	_
64-24	14161-14162	)	_
64-25	14163-14166	and	_
64-26	14167-14176	presented	_
64-27	14177-14179	to	_
64-28	14180-14183	the	_
64-29	14184-14195	participant	_
64-30	14196-14198	in	_
64-31	14199-14202	the	_
64-32	14203-14210	scanner	_
64-33	14211-14213	as	_
64-34	14214-14215	a	_
64-35	14216-14227	thermometer	_
64-36	14228-14233	value	_
64-37	14234-14241	besides	_
64-38	14242-14243	a	_
64-39	14244-14251	picture	_
64-40	14252-14254	of	_
64-41	14255-14257	an	_
64-42	14258-14267	alcoholic	_
64-43	14268-14276	beverage	_
64-44	14277-14283	During	_
64-45	14284-14287	NFB	_
64-46	14288-14293	scans	_
64-47	14293-14294	,	_
64-48	14295-14308	reconstructed	_
64-49	14309-14314	DICOM	_
64-50	14315-14321	images	_
64-51	14322-14325	are	_
64-52	14326-14337	transferred	_
64-53	14338-14342	from	_
64-54	14343-14346	the	_
64-55	14347-14354	imaging	_
64-56	14355-14363	computer	_
64-57	14364-14366	to	_
64-58	14367-14368	a	_
64-59	14369-14375	laptop	_
64-60	14376-14380	that	_
64-61	14381-14393	preprocesses	_
64-62	14394-14397	the	_
64-63	14398-14404	images	_
64-64	14405-14408	and	_
64-65	14409-14417	extracts	_
64-66	14418-14421	the	_
64-67	14422-14435	neurofeedback	_
64-68	14436-14442	signal	_
64-69	14443-14445	by	_
64-70	14446-14451	means	_
64-71	14452-14454	of	_
64-72	14455-14457	an	_
64-73	14458-14466	in-house	_
64-74	14467-14475	software	_
64-75	14475-14476	.	_

#Text=The feedback value is then send to a presentation computer and shown to the participant in the scanner as a thermometer value besides the picture of an alcoholic beverage preferred by the participant (beer, wine, or both).
65-1	14477-14480	The	_
65-2	14481-14489	feedback	_
65-3	14490-14495	value	_
65-4	14496-14498	is	_
65-5	14499-14503	then	_
65-6	14504-14508	send	_
65-7	14509-14511	to	_
65-8	14512-14513	a	_
65-9	14514-14526	presentation	_
65-10	14527-14535	computer	_
65-11	14536-14539	and	_
65-12	14540-14545	shown	_
65-13	14546-14548	to	_
65-14	14549-14552	the	_
65-15	14553-14564	participant	_
65-16	14565-14567	in	_
65-17	14568-14571	the	_
65-18	14572-14579	scanner	_
65-19	14580-14582	as	_
65-20	14583-14584	a	_
65-21	14585-14596	thermometer	_
65-22	14597-14602	value	_
65-23	14603-14610	besides	_
65-24	14611-14614	the	_
65-25	14615-14622	picture	_
65-26	14623-14625	of	_
65-27	14626-14628	an	_
65-28	14629-14638	alcoholic	_
65-29	14639-14647	beverage	_
65-30	14648-14657	preferred	_
65-31	14658-14660	by	_
65-32	14661-14664	the	_
65-33	14665-14676	participant	_
65-34	14677-14678	(	_
65-35	14678-14682	beer	_
65-36	14682-14683	,	_
65-37	14684-14688	wine	_
65-38	14688-14689	,	_
65-39	14690-14692	or	_
65-40	14693-14697	both	_
65-41	14697-14698	)	_
65-42	14698-14699	.	_

#Text=See Fig. 2 for an illustration.
66-1	14700-14703	See	_
66-2	14704-14707	Fig	_
66-3	14707-14708	.	_
66-4	14709-14710	2	_
66-5	14711-14714	for	_
66-6	14715-14717	an	_
66-7	14718-14730	illustration	_
66-8	14730-14731	.	_

#Text=The thermometer is updated with every new volume.
67-1	14732-14735	The	_
67-2	14736-14747	thermometer	_
67-3	14748-14750	is	_
67-4	14751-14758	updated	_
67-5	14759-14763	with	_
67-6	14764-14769	every	_
67-7	14770-14773	new	_
67-8	14774-14780	volume	_
67-9	14780-14781	.	_

#Text=The order of pictures is randomized between participants.
#Text=rtfMRI NFB is conducted with in-house MATLAB (MathWorks Inc., Sherborn, MA, USA) scripts based on SPM8 functions (Wellcome Department of Cognitive Neurology, London, UK), and Presentation software (Neurobehavioral Systems, Inc., Albany, CA, USA) to present pictures and the feedback signal.
68-1	14782-14785	The	_
68-2	14786-14791	order	_
68-3	14792-14794	of	_
68-4	14795-14803	pictures	_
68-5	14804-14806	is	_
68-6	14807-14817	randomized	_
68-7	14818-14825	between	_
68-8	14826-14838	participants	_
68-9	14838-14839	.	_
68-10	14840-14846	rtfMRI	_
68-11	14847-14850	NFB	_
68-12	14851-14853	is	_
68-13	14854-14863	conducted	_
68-14	14864-14868	with	_
68-15	14869-14877	in-house	_
68-16	14878-14884	MATLAB	_
68-17	14885-14886	(	_
68-18	14886-14895	MathWorks	_
68-19	14896-14899	Inc	_
68-20	14899-14900	.	_
68-21	14900-14901	,	_
68-22	14902-14910	Sherborn	_
68-23	14910-14911	,	_
68-24	14912-14914	MA	_
68-25	14914-14915	,	_
68-26	14916-14919	USA	_
68-27	14919-14920	)	_
68-28	14921-14928	scripts	_
68-29	14929-14934	based	_
68-30	14935-14937	on	_
68-31	14938-14942	SPM8	_
68-32	14943-14952	functions	_
68-33	14953-14954	(	_
68-34	14954-14962	Wellcome	_
68-35	14963-14973	Department	_
68-36	14974-14976	of	_
68-37	14977-14986	Cognitive	_
68-38	14987-14996	Neurology	_
68-39	14996-14997	,	_
68-40	14998-15004	London	_
68-41	15004-15005	,	_
68-42	15006-15008	UK	_
68-43	15008-15009	)	_
68-44	15009-15010	,	_
68-45	15011-15014	and	_
68-46	15015-15027	Presentation	_
68-47	15028-15036	software	_
68-48	15037-15038	(	_
68-49	15038-15053	Neurobehavioral	_
68-50	15054-15061	Systems	_
68-51	15061-15062	,	_
68-52	15063-15066	Inc	_
68-53	15066-15067	.	_
68-54	15067-15068	,	_
68-55	15069-15075	Albany	_
68-56	15075-15076	,	_
68-57	15077-15079	CA	_
68-58	15079-15080	,	_
68-59	15081-15084	USA	_
68-60	15084-15085	)	_
68-61	15086-15088	to	_
68-62	15089-15096	present	_
68-63	15097-15105	pictures	_
68-64	15106-15109	and	_
68-65	15110-15113	the	_
68-66	15114-15122	feedback	_
68-67	15123-15129	signal	_
68-68	15129-15130	.	_

#Text=On each scanning day, the acquired anatomical image is first segmented and normalized to MNI standard space.
69-1	15131-15133	On	_
69-2	15134-15138	each	_
69-3	15139-15147	scanning	_
69-4	15148-15151	day	_
69-5	15151-15152	,	_
69-6	15153-15156	the	_
69-7	15157-15165	acquired	_
69-8	15166-15176	anatomical	_
69-9	15177-15182	image	_
69-10	15183-15185	is	_
69-11	15186-15191	first	_
69-12	15192-15201	segmented	_
69-13	15202-15205	and	_
69-14	15206-15216	normalized	_
69-15	15217-15219	to	_
69-16	15220-15223	MNI	_
69-17	15224-15232	standard	_
69-18	15233-15238	space	_
69-19	15238-15239	.	_

#Text=The inverse deformations of the normalization are then applied to warp the masks of the target regions into subject space.
70-1	15240-15243	The	_
70-2	15244-15251	inverse	_
70-3	15252-15264	deformations	_
70-4	15265-15267	of	_
70-5	15268-15271	the	_
70-6	15272-15285	normalization	_
70-7	15286-15289	are	_
70-8	15290-15294	then	_
70-9	15295-15302	applied	_
70-10	15303-15305	to	_
70-11	15306-15310	warp	_
70-12	15311-15314	the	_
70-13	15315-15320	masks	_
70-14	15321-15323	of	_
70-15	15324-15327	the	_
70-16	15328-15334	target	_
70-17	15335-15342	regions	_
70-18	15343-15347	into	_
70-19	15348-15355	subject	_
70-20	15356-15361	space	_
70-21	15361-15362	.	_

#Text=During rtfMRI NFB scanning, functional images are realigned to the mean of the first 10 functional images and resliced.
71-1	15363-15369	During	_
71-2	15370-15376	rtfMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[31]
71-3	15377-15380	NFB	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[31]
71-4	15381-15389	scanning	_
71-5	15389-15390	,	_
71-6	15391-15401	functional	_
71-7	15402-15408	images	_
71-8	15409-15412	are	_
71-9	15413-15422	realigned	_
71-10	15423-15425	to	_
71-11	15426-15429	the	_
71-12	15430-15434	mean	_
71-13	15435-15437	of	_
71-14	15438-15441	the	_
71-15	15442-15447	first	_
71-16	15448-15450	10	_
71-17	15451-15461	functional	_
71-18	15462-15468	images	_
71-19	15469-15472	and	_
71-20	15473-15481	resliced	_
71-21	15481-15482	.	_

#Text=Then, the mask images are resampled to the space of the current image and mean intensity values from the voxels in the target regions are extracted.
72-1	15483-15487	Then	_
72-2	15487-15488	,	_
72-3	15489-15492	the	_
72-4	15493-15497	mask	_
72-5	15498-15504	images	_
72-6	15505-15508	are	_
72-7	15509-15518	resampled	_
72-8	15519-15521	to	_
72-9	15522-15525	the	_
72-10	15526-15531	space	_
72-11	15532-15534	of	_
72-12	15535-15538	the	_
72-13	15539-15546	current	_
72-14	15547-15552	image	_
72-15	15553-15556	and	_
72-16	15557-15561	mean	_
72-17	15562-15571	intensity	_
72-18	15572-15578	values	_
72-19	15579-15583	from	_
72-20	15584-15587	the	_
72-21	15588-15594	voxels	_
72-22	15595-15597	in	_
72-23	15598-15601	the	_
72-24	15602-15608	target	_
72-25	15609-15616	regions	_
72-26	15617-15620	are	_
72-27	15621-15630	extracted	_
72-28	15630-15631	.	_

#Text=For activation NFB, intensity values during presentation of alcohol images are averaged over the last three volumes (moving average) to stabilize the feedback signal and percent signal change with regard to the preceding fixation cross block is calculated.
73-1	15632-15635	For	_
73-2	15636-15646	activation	_
73-3	15647-15650	NFB	_
73-4	15650-15651	,	_
73-5	15652-15661	intensity	_
73-6	15662-15668	values	_
73-7	15669-15675	during	_
73-8	15676-15688	presentation	_
73-9	15689-15691	of	_
73-10	15692-15699	alcohol	_
73-11	15700-15706	images	_
73-12	15707-15710	are	_
73-13	15711-15719	averaged	_
73-14	15720-15724	over	_
73-15	15725-15728	the	_
73-16	15729-15733	last	_
73-17	15734-15739	three	_
73-18	15740-15747	volumes	_
73-19	15748-15749	(	_
73-20	15749-15755	moving	_
73-21	15756-15763	average	_
73-22	15763-15764	)	_
73-23	15765-15767	to	_
73-24	15768-15777	stabilize	_
73-25	15778-15781	the	_
73-26	15782-15790	feedback	_
73-27	15791-15797	signal	_
73-28	15798-15801	and	_
73-29	15802-15809	percent	_
73-30	15810-15816	signal	_
73-31	15817-15823	change	_
73-32	15824-15828	with	_
73-33	15829-15835	regard	_
73-34	15836-15838	to	_
73-35	15839-15842	the	_
73-36	15843-15852	preceding	_
73-37	15853-15861	fixation	_
73-38	15862-15867	cross	_
73-39	15868-15873	block	_
73-40	15874-15876	is	_
73-41	15877-15887	calculated	_
73-42	15887-15888	.	_

#Text=The scale of the feedback thermometer is adaptively adjusted to the maximum absolute signal change and the feedback signal is presented to the participant.
74-1	15889-15892	The	_
74-2	15893-15898	scale	_
74-3	15899-15901	of	_
74-4	15902-15905	the	_
74-5	15906-15914	feedback	_
74-6	15915-15926	thermometer	_
74-7	15927-15929	is	_
74-8	15930-15940	adaptively	_
74-9	15941-15949	adjusted	_
74-10	15950-15952	to	_
74-11	15953-15956	the	_
74-12	15957-15964	maximum	_
74-13	15965-15973	absolute	_
74-14	15974-15980	signal	_
74-15	15981-15987	change	_
74-16	15988-15991	and	_
74-17	15992-15995	the	_
74-18	15996-16004	feedback	_
74-19	16005-16011	signal	_
74-20	16012-16014	is	_
74-21	16015-16024	presented	_
74-22	16025-16027	to	_
74-23	16028-16031	the	_
74-24	16032-16043	participant	_
74-25	16043-16044	.	_

#Text=For connectivity NFB, partial correlations between the intensity values of the VS and right IFG adjusted for the cerebro-spinal fluid signal over the last 15 volumes are used to calculate the feedback signal.
75-1	16045-16048	For	_
75-2	16049-16061	connectivity	_
75-3	16062-16065	NFB	_
75-4	16065-16066	,	_
75-5	16067-16074	partial	_
75-6	16075-16087	correlations	_
75-7	16088-16095	between	_
75-8	16096-16099	the	_
75-9	16100-16109	intensity	_
75-10	16110-16116	values	_
75-11	16117-16119	of	_
75-12	16120-16123	the	_
75-13	16124-16126	VS	_
75-14	16127-16130	and	_
75-15	16131-16136	right	_
75-16	16137-16140	IFG	_
75-17	16141-16149	adjusted	_
75-18	16150-16153	for	_
75-19	16154-16157	the	_
75-20	16158-16172	cerebro-spinal	_
75-21	16173-16178	fluid	_
75-22	16179-16185	signal	_
75-23	16186-16190	over	_
75-24	16191-16194	the	_
75-25	16195-16199	last	_
75-26	16200-16202	15	_
75-27	16203-16210	volumes	_
75-28	16211-16214	are	_
75-29	16215-16219	used	_
75-30	16220-16222	to	_
75-31	16223-16232	calculate	_
75-32	16233-16236	the	_
75-33	16237-16245	feedback	_
75-34	16246-16252	signal	_
75-35	16252-16253	.	_

#Text=Again, the scale of the feedback thermometer is adaptively adjusted to the maximum absolute value reached.
76-1	16254-16259	Again	_
76-2	16259-16260	,	_
76-3	16261-16264	the	_
76-4	16265-16270	scale	_
76-5	16271-16273	of	_
76-6	16274-16277	the	_
76-7	16278-16286	feedback	_
76-8	16287-16298	thermometer	_
76-9	16299-16301	is	_
76-10	16302-16312	adaptively	_
76-11	16313-16321	adjusted	_
76-12	16322-16324	to	_
76-13	16325-16328	the	_
76-14	16329-16336	maximum	_
76-15	16337-16345	absolute	_
76-16	16346-16351	value	_
76-17	16352-16359	reached	_
76-18	16359-16360	.	_

#Text=In this exploratory group, the goal of the intervention is to increase the inhibiting influence of the rIFG to the VS and the participants are instructed to downregulate the depicted process.
77-1	16361-16363	In	_
77-2	16364-16368	this	_
77-3	16369-16380	exploratory	_
77-4	16381-16386	group	_
77-5	16386-16387	,	_
77-6	16388-16391	the	_
77-7	16392-16396	goal	_
77-8	16397-16399	of	_
77-9	16400-16403	the	_
77-10	16404-16416	intervention	_
77-11	16417-16419	is	_
77-12	16420-16422	to	_
77-13	16423-16431	increase	_
77-14	16432-16435	the	_
77-15	16436-16446	inhibiting	_
77-16	16447-16456	influence	_
77-17	16457-16459	of	_
77-18	16460-16463	the	_
77-19	16464-16468	rIFG	_
77-20	16469-16471	to	_
77-21	16472-16475	the	_
77-22	16476-16478	VS	_
77-23	16479-16482	and	_
77-24	16483-16486	the	_
77-25	16487-16499	participants	_
77-26	16500-16503	are	_
77-27	16504-16514	instructed	_
77-28	16515-16517	to	_
77-29	16518-16530	downregulate	_
77-30	16531-16534	the	_
77-31	16535-16543	depicted	_
77-32	16544-16551	process	_
77-33	16551-16552	.	_

#Text=However, a negative correlation between VS and rIFG could arise from the desired state, but also from an inverse behavior of the system with increased VS and diminished frontal activity.
78-1	16553-16560	However	_
78-2	16560-16561	,	_
78-3	16562-16563	a	_
78-4	16564-16572	negative	_
78-5	16573-16584	correlation	_
78-6	16585-16592	between	_
78-7	16593-16595	VS	_
78-8	16596-16599	and	_
78-9	16600-16604	rIFG	_
78-10	16605-16610	could	_
78-11	16611-16616	arise	_
78-12	16617-16621	from	_
78-13	16622-16625	the	_
78-14	16626-16633	desired	_
78-15	16634-16639	state	_
78-16	16639-16640	,	_
78-17	16641-16644	but	_
78-18	16645-16649	also	_
78-19	16650-16654	from	_
78-20	16655-16657	an	_
78-21	16658-16665	inverse	_
78-22	16666-16674	behavior	_
78-23	16675-16677	of	_
78-24	16678-16681	the	_
78-25	16682-16688	system	_
78-26	16689-16693	with	_
78-27	16694-16703	increased	_
78-28	16704-16706	VS	_
78-29	16707-16710	and	_
78-30	16711-16721	diminished	_
78-31	16722-16729	frontal	_
78-32	16730-16738	activity	_
78-33	16738-16739	.	_

#Text=To enforce the top-down inhibitory state of the system we included the additional constraints in the connectivity feedback that the VS should be downregulated and the rIFG should be upregulated and switch negative feedback values to positive if these constraints are not met.
79-1	16740-16742	To	_
79-2	16743-16750	enforce	_
79-3	16751-16754	the	_
79-4	16755-16763	top-down	_
79-5	16764-16774	inhibitory	_
79-6	16775-16780	state	_
79-7	16781-16783	of	_
79-8	16784-16787	the	_
79-9	16788-16794	system	_
79-10	16795-16797	we	_
79-11	16798-16806	included	_
79-12	16807-16810	the	_
79-13	16811-16821	additional	_
79-14	16822-16833	constraints	_
79-15	16834-16836	in	_
79-16	16837-16840	the	_
79-17	16841-16853	connectivity	_
79-18	16854-16862	feedback	_
79-19	16863-16867	that	_
79-20	16868-16871	the	_
79-21	16872-16874	VS	_
79-22	16875-16881	should	_
79-23	16882-16884	be	_
79-24	16885-16898	downregulated	_
79-25	16899-16902	and	_
79-26	16903-16906	the	_
79-27	16907-16911	rIFG	_
79-28	16912-16918	should	_
79-29	16919-16921	be	_
79-30	16922-16933	upregulated	_
79-31	16934-16937	and	_
79-32	16938-16944	switch	_
79-33	16945-16953	negative	_
79-34	16954-16962	feedback	_
79-35	16963-16969	values	_
79-36	16970-16972	to	_
79-37	16973-16981	positive	_
79-38	16982-16984	if	_
79-39	16985-16990	these	_
79-40	16991-17002	constraints	_
79-41	17003-17006	are	_
79-42	17007-17010	not	_
79-43	17011-17014	met	_
79-44	17014-17015	.	_

#Text=Task design
#Text=Experimental design.
80-1	17016-17020	Task	_
80-2	17021-17027	design	_
80-3	17028-17040	Experimental	_
80-4	17041-17047	design	_
80-5	17047-17048	.	_

#Text=Design of neurofeedback (left) and transfer (right) tasks.
81-1	17049-17055	Design	_
81-2	17056-17058	of	_
81-3	17059-17072	neurofeedback	_
81-4	17073-17074	(	_
81-5	17074-17078	left	_
81-6	17078-17079	)	_
81-7	17080-17083	and	_
81-8	17084-17092	transfer	_
81-9	17093-17094	(	_
81-10	17094-17099	right	_
81-11	17099-17100	)	_
81-12	17101-17106	tasks	_
81-13	17106-17107	.	_

#Text=Each run consists of 6 repetitions of the displayed sequences.
82-1	17108-17112	Each	_
82-2	17113-17116	run	_
82-3	17117-17125	consists	_
82-4	17126-17128	of	_
82-5	17129-17130	6	_
82-6	17131-17142	repetitions	_
82-7	17143-17145	of	_
82-8	17146-17149	the	_
82-9	17150-17159	displayed	_
82-10	17160-17169	sequences	_
82-11	17169-17170	.	_

#Text=The last (third) runs on the first and third scanning day are conducted as transfer sessions without the neurofeedback signal.
83-1	17171-17174	The	_
83-2	17175-17179	last	_
83-3	17180-17181	(	_
83-4	17181-17186	third	_
83-5	17186-17187	)	_
83-6	17188-17192	runs	_
83-7	17193-17195	on	_
83-8	17196-17199	the	_
83-9	17200-17205	first	_
83-10	17206-17209	and	_
83-11	17210-17215	third	_
83-12	17216-17224	scanning	_
83-13	17225-17228	day	_
83-14	17229-17232	are	_
83-15	17233-17242	conducted	_
83-16	17243-17245	as	_
83-17	17246-17254	transfer	_
83-18	17255-17263	sessions	_
83-19	17264-17271	without	_
83-20	17272-17275	the	_
83-21	17276-17289	neurofeedback	_
83-22	17290-17296	signal	_
83-23	17296-17297	.	_

#Text=TR: Time of Repetition (1 TR = 1.64 s)
#Text=NFB sessions have a block design with alternating presentation of a fixation cross (baseline; 41 s) and a picture of a preferred alcoholic beverage (beer, wine, or both; approx. 51 s), each for 6 times.
84-1	17298-17300	TR	_
84-2	17300-17301	:	_
84-3	17302-17306	Time	_
84-4	17307-17309	of	_
84-5	17310-17320	Repetition	_
84-6	17321-17322	(	_
84-7	17322-17323	1	_
84-8	17324-17326	TR	_
84-9	17327-17328	=	_
84-10	17329-17333	1.64	_
84-11	17333-17334	 	_
84-12	17334-17335	s	_
84-13	17335-17336	)	_
84-14	17337-17340	NFB	_
84-15	17341-17349	sessions	_
84-16	17350-17354	have	_
84-17	17355-17356	a	_
84-18	17357-17362	block	_
84-19	17363-17369	design	_
84-20	17370-17374	with	_
84-21	17375-17386	alternating	_
84-22	17387-17399	presentation	_
84-23	17400-17402	of	_
84-24	17403-17404	a	_
84-25	17405-17413	fixation	_
84-26	17414-17419	cross	_
84-27	17420-17421	(	_
84-28	17421-17429	baseline	_
84-29	17429-17430	;	_
84-30	17431-17433	41	_
84-31	17433-17434	 	_
84-32	17434-17435	s	_
84-33	17435-17436	)	_
84-34	17437-17440	and	_
84-35	17441-17442	a	_
84-36	17443-17450	picture	_
84-37	17451-17453	of	_
84-38	17454-17455	a	_
84-39	17456-17465	preferred	_
84-40	17466-17475	alcoholic	_
84-41	17476-17484	beverage	_
84-42	17485-17486	(	_
84-43	17486-17490	beer	_
84-44	17490-17491	,	_
84-45	17492-17496	wine	_
84-46	17496-17497	,	_
84-47	17498-17500	or	_
84-48	17501-17505	both	_
84-49	17505-17506	;	_
84-50	17507-17513	approx	_
84-51	17513-17514	.	_
84-52	17515-17517	51	_
84-53	17517-17518	 	_
84-54	17518-17519	s	_
84-55	17519-17520	)	_
84-56	17520-17521	,	_
84-57	17522-17526	each	_
84-58	17527-17530	for	_
84-59	17531-17532	6	_
84-60	17533-17538	times	_
84-61	17538-17539	.	_

#Text=Approximately 10 s after onset of the alcoholic pictures a feedback thermometer is shown on both sides of the picture and updated every TR (feedback; 41 s).
85-1	17540-17553	Approximately	_
85-2	17554-17556	10	_
85-3	17556-17557	 	_
85-4	17557-17558	s	_
85-5	17559-17564	after	_
85-6	17565-17570	onset	_
85-7	17571-17573	of	_
85-8	17574-17577	the	_
85-9	17578-17587	alcoholic	_
85-10	17588-17596	pictures	_
85-11	17597-17598	a	_
85-12	17599-17607	feedback	_
85-13	17608-17619	thermometer	_
85-14	17620-17622	is	_
85-15	17623-17628	shown	_
85-16	17629-17631	on	_
85-17	17632-17636	both	_
85-18	17637-17642	sides	_
85-19	17643-17645	of	_
85-20	17646-17649	the	_
85-21	17650-17657	picture	_
85-22	17658-17661	and	_
85-23	17662-17669	updated	_
85-24	17670-17675	every	_
85-25	17676-17678	TR	_
85-26	17679-17680	(	_
85-27	17680-17688	feedback	_
85-28	17688-17689	;	_
85-29	17690-17692	41	_
85-30	17692-17693	 	_
85-31	17693-17694	s	_
85-32	17694-17695	)	_
85-33	17695-17696	.	_

#Text=On the first and third day, the last (third) run is conducted as a transfer run without presentation of the feedback signal (Fig. 3).
86-1	17697-17699	On	_
86-2	17700-17703	the	_
86-3	17704-17709	first	_
86-4	17710-17713	and	_
86-5	17714-17719	third	_
86-6	17720-17723	day	_
86-7	17723-17724	,	_
86-8	17725-17728	the	_
86-9	17729-17733	last	_
86-10	17734-17735	(	_
86-11	17735-17740	third	_
86-12	17740-17741	)	_
86-13	17742-17745	run	_
86-14	17746-17748	is	_
86-15	17749-17758	conducted	_
86-16	17759-17761	as	_
86-17	17762-17763	a	_
86-18	17764-17772	transfer	_
86-19	17773-17776	run	_
86-20	17777-17784	without	_
86-21	17785-17797	presentation	_
86-22	17798-17800	of	_
86-23	17801-17804	the	_
86-24	17805-17813	feedback	_
86-25	17814-17820	signal	_
86-26	17821-17822	(	_
86-27	17822-17825	Fig	_
86-28	17825-17826	.	_
86-29	17826-17827	 	_
86-30	17827-17828	3	_
86-31	17828-17829	)	_
86-32	17829-17830	.	_

#Text=On each scanning day participants rate their craving on a visual analog scale directly before and after scanning.
87-1	17831-17833	On	_
87-2	17834-17838	each	_
87-3	17839-17847	scanning	_
87-4	17848-17851	day	_
87-5	17852-17864	participants	_
87-6	17865-17869	rate	_
87-7	17870-17875	their	_
87-8	17876-17883	craving	_
87-9	17884-17886	on	_
87-10	17887-17888	a	_
87-11	17889-17895	visual	_
87-12	17896-17902	analog	_
87-13	17903-17908	scale	_
87-14	17909-17917	directly	_
87-15	17918-17924	before	_
87-16	17925-17928	and	_
87-17	17929-17934	after	_
87-18	17935-17943	scanning	_
87-19	17943-17944	.	_

#Text=After completing the third MRI scanning session, participants are asked to answer alcohol-related questionnaires (see Table 1).
88-1	17945-17950	After	_
88-2	17951-17961	completing	_
88-3	17962-17965	the	_
88-4	17966-17971	third	_
88-5	17972-17975	MRI	_
88-6	17976-17984	scanning	_
88-7	17985-17992	session	_
88-8	17992-17993	,	_
88-9	17994-18006	participants	_
88-10	18007-18010	are	_
88-11	18011-18016	asked	_
88-12	18017-18019	to	_
88-13	18020-18026	answer	_
88-14	18027-18042	alcohol-related	_
88-15	18043-18057	questionnaires	_
88-16	18058-18059	(	_
88-17	18059-18062	see	_
88-18	18063-18068	Table	_
88-19	18069-18070	1	_
88-20	18070-18071	)	_
88-21	18071-18072	.	_

#Text=Follow-up assessments
#Text=Follow-up assessments take place monthly after the last MRI session over a period of three months.
89-1	18073-18082	Follow-up	_
89-2	18083-18094	assessments	_
89-3	18095-18104	Follow-up	_
89-4	18105-18116	assessments	_
89-5	18117-18121	take	_
89-6	18122-18127	place	_
89-7	18128-18135	monthly	_
89-8	18136-18141	after	_
89-9	18142-18145	the	_
89-10	18146-18150	last	_
89-11	18151-18154	MRI	_
89-12	18155-18162	session	_
89-13	18163-18167	over	_
89-14	18168-18169	a	_
89-15	18170-18176	period	_
89-16	18177-18179	of	_
89-17	18180-18185	three	_
89-18	18186-18192	months	_
89-19	18192-18193	.	_

#Text=At the first two time points participants are contacted by phone and asked about their current medication, their abuse of tobacco, nicotine and drugs and a potential alcohol relapse (see Table 1).
90-1	18194-18196	At	_
90-2	18197-18200	the	_
90-3	18201-18206	first	_
90-4	18207-18210	two	_
90-5	18211-18215	time	_
90-6	18216-18222	points	_
90-7	18223-18235	participants	_
90-8	18236-18239	are	_
90-9	18240-18249	contacted	_
90-10	18250-18252	by	_
90-11	18253-18258	phone	_
90-12	18259-18262	and	_
90-13	18263-18268	asked	_
90-14	18269-18274	about	_
90-15	18275-18280	their	_
90-16	18281-18288	current	_
90-17	18289-18299	medication	_
90-18	18299-18300	,	_
90-19	18301-18306	their	_
90-20	18307-18312	abuse	_
90-21	18313-18315	of	_
90-22	18316-18323	tobacco	_
90-23	18323-18324	,	_
90-24	18325-18333	nicotine	_
90-25	18334-18337	and	_
90-26	18338-18343	drugs	_
90-27	18344-18347	and	_
90-28	18348-18349	a	_
90-29	18350-18359	potential	_
90-30	18360-18367	alcohol	_
90-31	18368-18375	relapse	_
90-32	18376-18377	(	_
90-33	18377-18380	see	_
90-34	18381-18386	Table	_
90-35	18387-18388	1	_
90-36	18388-18389	)	_
90-37	18389-18390	.	_

#Text=Three months after the last MRI session, patients are invited to a final appointment at the CIMH.
91-1	18391-18396	Three	_
91-2	18397-18403	months	_
91-3	18404-18409	after	_
91-4	18410-18413	the	_
91-5	18414-18418	last	_
91-6	18419-18422	MRI	_
91-7	18423-18430	session	_
91-8	18430-18431	,	_
91-9	18432-18440	patients	_
91-10	18441-18444	are	_
91-11	18445-18452	invited	_
91-12	18453-18455	to	_
91-13	18456-18457	a	_
91-14	18458-18463	final	_
91-15	18464-18475	appointment	_
91-16	18476-18478	at	_
91-17	18479-18482	the	_
91-18	18483-18487	CIMH	_
91-19	18487-18488	.	_

#Text=During this session, blood samples are collected and participants are asked about substance use and answer alcohol-related questionnaires (see Table 1).
92-1	18489-18495	During	_
92-2	18496-18500	this	_
92-3	18501-18508	session	_
92-4	18508-18509	,	_
92-5	18510-18515	blood	_
92-6	18516-18523	samples	_
92-7	18524-18527	are	_
92-8	18528-18537	collected	_
92-9	18538-18541	and	_
92-10	18542-18554	participants	_
92-11	18555-18558	are	_
92-12	18559-18564	asked	_
92-13	18565-18570	about	_
92-14	18571-18580	substance	_
92-15	18581-18584	use	_
92-16	18585-18588	and	_
92-17	18589-18595	answer	_
92-18	18596-18611	alcohol-related	_
92-19	18612-18626	questionnaires	_
92-20	18627-18628	(	_
92-21	18628-18631	see	_
92-22	18632-18637	Table	_
92-23	18638-18639	1	_
92-24	18639-18640	)	_
92-25	18640-18641	.	_

#Text=For the final appointment, patients receive a monetary compensation of 50 €.
93-1	18642-18645	For	_
93-2	18646-18649	the	_
93-3	18650-18655	final	_
93-4	18656-18667	appointment	_
93-5	18667-18668	,	_
93-6	18669-18677	patients	_
93-7	18678-18685	receive	_
93-8	18686-18687	a	_
93-9	18688-18696	monetary	_
93-10	18697-18709	compensation	_
93-11	18710-18712	of	_
93-12	18713-18715	50	_
93-13	18716-18717	€	_
93-14	18717-18718	.	_

#Text=Statistical analyses
#Text=As primary outcome analysis we will conduct group comparisons of relapse rates with survival analysis and assess reduction of alcohol intake during the follow-up phase.
94-1	18719-18730	Statistical	_
94-2	18731-18739	analyses	_
94-3	18740-18742	As	_
94-4	18743-18750	primary	_
94-5	18751-18758	outcome	_
94-6	18759-18767	analysis	_
94-7	18768-18770	we	_
94-8	18771-18775	will	_
94-9	18776-18783	conduct	_
94-10	18784-18789	group	_
94-11	18790-18801	comparisons	_
94-12	18802-18804	of	_
94-13	18805-18812	relapse	_
94-14	18813-18818	rates	_
94-15	18819-18823	with	_
94-16	18824-18832	survival	_
94-17	18833-18841	analysis	_
94-18	18842-18845	and	_
94-19	18846-18852	assess	_
94-20	18853-18862	reduction	_
94-21	18863-18865	of	_
94-22	18866-18873	alcohol	_
94-23	18874-18880	intake	_
94-24	18881-18887	during	_
94-25	18888-18891	the	_
94-26	18892-18901	follow-up	_
94-27	18902-18907	phase	_
94-28	18907-18908	.	_

#Text=As secondary and exploratory outcome measures we will assess whether rtfMRI NFB reduces alcohol craving during the NFB sessions, how brain activation and brain connectivity changes within and between the sessions, whether functional or structural MRI markers can be identified that predict neurofeedback learning and the success of the intervention, and whether differences in efficacy of the group-specific interventions do exist.
95-1	18909-18911	As	_
95-2	18912-18921	secondary	_
95-3	18922-18925	and	_
95-4	18926-18937	exploratory	_
95-5	18938-18945	outcome	_
95-6	18946-18954	measures	_
95-7	18955-18957	we	_
95-8	18958-18962	will	_
95-9	18963-18969	assess	_
95-10	18970-18977	whether	_
95-11	18978-18984	rtfMRI	_
95-12	18985-18988	NFB	_
95-13	18989-18996	reduces	_
95-14	18997-19004	alcohol	_
95-15	19005-19012	craving	_
95-16	19013-19019	during	_
95-17	19020-19023	the	_
95-18	19024-19027	NFB	_
95-19	19028-19036	sessions	_
95-20	19036-19037	,	_
95-21	19038-19041	how	_
95-22	19042-19047	brain	_
95-23	19048-19058	activation	_
95-24	19059-19062	and	_
95-25	19063-19068	brain	_
95-26	19069-19081	connectivity	_
95-27	19082-19089	changes	_
95-28	19090-19096	within	_
95-29	19097-19100	and	_
95-30	19101-19108	between	_
95-31	19109-19112	the	_
95-32	19113-19121	sessions	_
95-33	19121-19122	,	_
95-34	19123-19130	whether	_
95-35	19131-19141	functional	_
95-36	19142-19144	or	_
95-37	19145-19155	structural	_
95-38	19156-19159	MRI	_
95-39	19160-19167	markers	_
95-40	19168-19171	can	_
95-41	19172-19174	be	_
95-42	19175-19185	identified	_
95-43	19186-19190	that	_
95-44	19191-19198	predict	_
95-45	19199-19212	neurofeedback	_
95-46	19213-19221	learning	_
95-47	19222-19225	and	_
95-48	19226-19229	the	_
95-49	19230-19237	success	_
95-50	19238-19240	of	_
95-51	19241-19244	the	_
95-52	19245-19257	intervention	_
95-53	19257-19258	,	_
95-54	19259-19262	and	_
95-55	19263-19270	whether	_
95-56	19271-19282	differences	_
95-57	19283-19285	in	_
95-58	19286-19294	efficacy	_
95-59	19295-19297	of	_
95-60	19298-19301	the	_
95-61	19302-19316	group-specific	_
95-62	19317-19330	interventions	_
95-63	19331-19333	do	_
95-64	19334-19339	exist	_
95-65	19339-19340	.	_

#Text=To analyze the effects of rtfMRI NFB, offline data analysis will be conducted with MATLAB and SPM.
96-1	19341-19343	To	_
96-2	19344-19351	analyze	_
96-3	19352-19355	the	_
96-4	19356-19363	effects	_
96-5	19364-19366	of	_
96-6	19367-19373	rtfMRI	_
96-7	19374-19377	NFB	_
96-8	19377-19378	,	_
96-9	19379-19386	offline	_
96-10	19387-19391	data	_
96-11	19392-19400	analysis	_
96-12	19401-19405	will	_
96-13	19406-19408	be	_
96-14	19409-19418	conducted	_
96-15	19419-19423	with	_
96-16	19424-19430	MATLAB	_
96-17	19431-19434	and	_
96-18	19435-19438	SPM	_
96-19	19438-19439	.	_

#Text=Data preprocessing will consist of slice-time correction, realignment, segmentation of the anatomical image, normalization to the MNI space, smoothing, and identification of outlier volumes with excessive head motion.
97-1	19440-19444	Data	_
97-2	19445-19458	preprocessing	_
97-3	19459-19463	will	_
97-4	19464-19471	consist	_
97-5	19472-19474	of	_
97-6	19475-19485	slice-time	_
97-7	19486-19496	correction	_
97-8	19496-19497	,	_
97-9	19498-19509	realignment	_
97-10	19509-19510	,	_
97-11	19511-19523	segmentation	_
97-12	19524-19526	of	_
97-13	19527-19530	the	_
97-14	19531-19541	anatomical	_
97-15	19542-19547	image	_
97-16	19547-19548	,	_
97-17	19549-19562	normalization	_
97-18	19563-19565	to	_
97-19	19566-19569	the	_
97-20	19570-19573	MNI	_
97-21	19574-19579	space	_
97-22	19579-19580	,	_
97-23	19581-19590	smoothing	_
97-24	19590-19591	,	_
97-25	19592-19595	and	_
97-26	19596-19610	identification	_
97-27	19611-19613	of	_
97-28	19614-19621	outlier	_
97-29	19622-19629	volumes	_
97-30	19630-19634	with	_
97-31	19635-19644	excessive	_
97-32	19645-19649	head	_
97-33	19650-19656	motion	_
97-34	19656-19657	.	_

#Text=The preprocessed data will be used in first level single subject analyses in which the time courses of the experimental conditions will be convolved with the canonical hemodynamic response function and used in a general linear model to estimate brain responses during rtfMRI NFB.
98-1	19658-19661	The	_
98-2	19662-19674	preprocessed	_
98-3	19675-19679	data	_
98-4	19680-19684	will	_
98-5	19685-19687	be	_
98-6	19688-19692	used	_
98-7	19693-19695	in	_
98-8	19696-19701	first	_
98-9	19702-19707	level	_
98-10	19708-19714	single	_
98-11	19715-19722	subject	_
98-12	19723-19731	analyses	_
98-13	19732-19734	in	_
98-14	19735-19740	which	_
98-15	19741-19744	the	_
98-16	19745-19749	time	_
98-17	19750-19757	courses	_
98-18	19758-19760	of	_
98-19	19761-19764	the	_
98-20	19765-19777	experimental	_
98-21	19778-19788	conditions	_
98-22	19789-19793	will	_
98-23	19794-19796	be	_
98-24	19797-19806	convolved	_
98-25	19807-19811	with	_
98-26	19812-19815	the	_
98-27	19816-19825	canonical	_
98-28	19826-19837	hemodynamic	_
98-29	19838-19846	response	_
98-30	19847-19855	function	_
98-31	19856-19859	and	_
98-32	19860-19864	used	_
98-33	19865-19867	in	_
98-34	19868-19869	a	_
98-35	19870-19877	general	_
98-36	19878-19884	linear	_
98-37	19885-19890	model	_
98-38	19891-19893	to	_
98-39	19894-19902	estimate	_
98-40	19903-19908	brain	_
98-41	19909-19918	responses	_
98-42	19919-19925	during	_
98-43	19926-19932	rtfMRI	_
98-44	19933-19936	NFB	_
98-45	19936-19937	.	_

#Text=Then, first level results will be used in second level group comparisons to estimate differential activation between groups, test for associations with clinical variables, and assess the predictive value of imaging markers for the future course of the disease.
99-1	19938-19942	Then	_
99-2	19942-19943	,	_
99-3	19944-19949	first	_
99-4	19950-19955	level	_
99-5	19956-19963	results	_
99-6	19964-19968	will	_
99-7	19969-19971	be	_
99-8	19972-19976	used	_
99-9	19977-19979	in	_
99-10	19980-19986	second	_
99-11	19987-19992	level	_
99-12	19993-19998	group	_
99-13	19999-20010	comparisons	_
99-14	20011-20013	to	_
99-15	20014-20022	estimate	_
99-16	20023-20035	differential	_
99-17	20036-20046	activation	_
99-18	20047-20054	between	_
99-19	20055-20061	groups	_
99-20	20061-20062	,	_
99-21	20063-20067	test	_
99-22	20068-20071	for	_
99-23	20072-20084	associations	_
99-24	20085-20089	with	_
99-25	20090-20098	clinical	_
99-26	20099-20108	variables	_
99-27	20108-20109	,	_
99-28	20110-20113	and	_
99-29	20114-20120	assess	_
99-30	20121-20124	the	_
99-31	20125-20135	predictive	_
99-32	20136-20141	value	_
99-33	20142-20144	of	_
99-34	20145-20152	imaging	_
99-35	20153-20160	markers	_
99-36	20161-20164	for	_
99-37	20165-20168	the	_
99-38	20169-20175	future	_
99-39	20176-20182	course	_
99-40	20183-20185	of	_
99-41	20186-20189	the	_
99-42	20190-20197	disease	_
99-43	20197-20198	.	_

#Text=Additionally, large-scale adaptations in functional networks during rtfMRI NFB will be assessed by whole-brain psychophysiological interaction analysis.
100-1	20199-20211	Additionally	_
100-2	20211-20212	,	_
100-3	20213-20224	large-scale	_
100-4	20225-20236	adaptations	_
100-5	20237-20239	in	_
100-6	20240-20250	functional	_
100-7	20251-20259	networks	_
100-8	20260-20266	during	_
100-9	20267-20273	rtfMRI	_
100-10	20274-20277	NFB	_
100-11	20278-20282	will	_
100-12	20283-20285	be	_
100-13	20286-20294	assessed	_
100-14	20295-20297	by	_
100-15	20298-20309	whole-brain	_
100-16	20310-20329	psychophysiological	_
100-17	20330-20341	interaction	_
100-18	20342-20350	analysis	_
100-19	20350-20351	.	_

#Text=Depending on the type of the data, missing data will either be left out from the analyses (e.g. fMRI data), or imputed (e.g. missing questionnaire items).
101-1	20352-20361	Depending	_
101-2	20362-20364	on	_
101-3	20365-20368	the	_
101-4	20369-20373	type	_
101-5	20374-20376	of	_
101-6	20377-20380	the	_
101-7	20381-20385	data	_
101-8	20385-20386	,	_
101-9	20387-20394	missing	_
101-10	20395-20399	data	_
101-11	20400-20404	will	_
101-12	20405-20411	either	_
101-13	20412-20414	be	_
101-14	20415-20419	left	_
101-15	20420-20423	out	_
101-16	20424-20428	from	_
101-17	20429-20432	the	_
101-18	20433-20441	analyses	_
101-19	20442-20443	(	_
101-20	20443-20446	e.g	_
101-21	20446-20447	.	_
101-22	20448-20452	fMRI	_
101-23	20453-20457	data	_
101-24	20457-20458	)	_
101-25	20458-20459	,	_
101-26	20460-20462	or	_
101-27	20463-20470	imputed	_
101-28	20471-20472	(	_
101-29	20472-20475	e.g	_
101-30	20475-20476	.	_
101-31	20477-20484	missing	_
101-32	20485-20498	questionnaire	_
101-33	20499-20504	items	_
101-34	20504-20505	)	_
101-35	20505-20506	.	_

#Text=Power calculations
#Text=Power calculations were conducted with the G*Power software package.
102-1	20507-20512	Power	_
102-2	20513-20525	calculations	_
102-3	20526-20531	Power	_
102-4	20532-20544	calculations	_
102-5	20545-20549	were	_
102-6	20550-20559	conducted	_
102-7	20560-20564	with	_
102-8	20565-20568	the	_
102-9	20569-20570	G	_
102-10	20570-20571	*	_
102-11	20571-20576	Power	_
102-12	20577-20585	software	_
102-13	20586-20593	package	_
102-14	20593-20594	.	_

#Text=In the clinical analysis (follow-up measures) the power for detecting group differences at p < .05 under the assumption of a medium effect size (Cohen’s d = .5) is 78% with two sample t-tests when treatment (n = 60) and control groups (n = 40) are pooled.
103-1	20595-20597	In	_
103-2	20598-20601	the	_
103-3	20602-20610	clinical	_
103-4	20611-20619	analysis	_
103-5	20620-20621	(	_
103-6	20621-20630	follow-up	_
103-7	20631-20639	measures	_
103-8	20639-20640	)	_
103-9	20641-20644	the	_
103-10	20645-20650	power	_
103-11	20651-20654	for	_
103-12	20655-20664	detecting	_
103-13	20665-20670	group	_
103-14	20671-20682	differences	_
103-15	20683-20685	at	_
103-16	20686-20687	p	_
103-17	20688-20689	<	_
103-18	20690-20693	.05	_
103-19	20694-20699	under	_
103-20	20700-20703	the	_
103-21	20704-20714	assumption	_
103-22	20715-20717	of	_
103-23	20718-20719	a	_
103-24	20720-20726	medium	_
103-25	20727-20733	effect	_
103-26	20734-20738	size	_
103-27	20739-20740	(	_
103-28	20740-20745	Cohen	_
103-29	20745-20746	’	_
103-30	20746-20747	s	_
103-31	20748-20749	d	_
103-32	20750-20751	=	_
103-33	20752-20754	.5	_
103-34	20754-20755	)	_
103-35	20756-20758	is	_
103-36	20759-20762	78%	_
103-37	20763-20767	with	_
103-38	20768-20771	two	_
103-39	20772-20778	sample	_
103-40	20779-20786	t-tests	_
103-41	20787-20791	when	_
103-42	20792-20801	treatment	_
103-43	20802-20803	(	_
103-44	20803-20804	n	_
103-45	20805-20806	=	_
103-46	20807-20809	60	_
103-47	20809-20810	)	_
103-48	20811-20814	and	_
103-49	20815-20822	control	_
103-50	20823-20829	groups	_
103-51	20830-20831	(	_
103-52	20831-20832	n	_
103-53	20833-20834	=	_
103-54	20835-20837	40	_
103-55	20837-20838	)	_
103-56	20839-20842	are	_
103-57	20843-20849	pooled	_
103-58	20849-20850	.	_

#Text=Assuming an effect size of f = .61 as observed for the neurofeedback effect on VS reduction in our pilot study, the neurofeedback analyses based on an ANOVA repeated measures model with a group x time contrast has a power of 89% in the VS and of 88% in the rIFG to detect FWE (Bonferroni) corrected significant results in the respective ROI analyses.
104-1	20851-20859	Assuming	_
104-2	20860-20862	an	_
104-3	20863-20869	effect	_
104-4	20870-20874	size	_
104-5	20875-20877	of	_
104-6	20878-20879	f	_
104-7	20880-20881	=	_
104-8	20882-20885	.61	_
104-9	20886-20888	as	_
104-10	20889-20897	observed	_
104-11	20898-20901	for	_
104-12	20902-20905	the	_
104-13	20906-20919	neurofeedback	_
104-14	20920-20926	effect	_
104-15	20927-20929	on	_
104-16	20930-20932	VS	_
104-17	20933-20942	reduction	_
104-18	20943-20945	in	_
104-19	20946-20949	our	_
104-20	20950-20955	pilot	_
104-21	20956-20961	study	_
104-22	20961-20962	,	_
104-23	20963-20966	the	_
104-24	20967-20980	neurofeedback	_
104-25	20981-20989	analyses	_
104-26	20990-20995	based	_
104-27	20996-20998	on	_
104-28	20999-21001	an	_
104-29	21002-21007	ANOVA	_
104-30	21008-21016	repeated	_
104-31	21017-21025	measures	_
104-32	21026-21031	model	_
104-33	21032-21036	with	_
104-34	21037-21038	a	_
104-35	21039-21044	group	_
104-36	21045-21046	x	_
104-37	21047-21051	time	_
104-38	21052-21060	contrast	_
104-39	21061-21064	has	_
104-40	21065-21066	a	_
104-41	21067-21072	power	_
104-42	21073-21075	of	_
104-43	21076-21079	89%	_
104-44	21080-21082	in	_
104-45	21083-21086	the	_
104-46	21087-21089	VS	_
104-47	21090-21093	and	_
104-48	21094-21096	of	_
104-49	21097-21100	88%	_
104-50	21101-21103	in	_
104-51	21104-21107	the	_
104-52	21108-21112	rIFG	_
104-53	21113-21115	to	_
104-54	21116-21122	detect	_
104-55	21123-21126	FWE	_
104-56	21127-21128	(	_
104-57	21128-21138	Bonferroni	_
104-58	21138-21139	)	_
104-59	21140-21149	corrected	_
104-60	21150-21161	significant	_
104-61	21162-21169	results	_
104-62	21170-21172	in	_
104-63	21173-21176	the	_
104-64	21177-21187	respective	_
104-65	21188-21191	ROI	_
104-66	21192-21200	analyses	_
104-67	21200-21201	.	_

#Text=Data management and dissemination
#Text=To ensure data quality, questionnaires are automatically scanned and entered into the study data base.
105-1	21202-21206	Data	_
105-2	21207-21217	management	_
105-3	21218-21221	and	_
105-4	21222-21235	dissemination	_
105-5	21236-21238	To	_
105-6	21239-21245	ensure	_
105-7	21246-21250	data	_
105-8	21251-21258	quality	_
105-9	21258-21259	,	_
105-10	21260-21274	questionnaires	_
105-11	21275-21278	are	_
105-12	21279-21292	automatically	_
105-13	21293-21300	scanned	_
105-14	21301-21304	and	_
105-15	21305-21312	entered	_
105-16	21313-21317	into	_
105-17	21318-21321	the	_
105-18	21322-21327	study	_
105-19	21328-21332	data	_
105-20	21333-21337	base	_
105-21	21337-21338	.	_

#Text=Data management and monitoring is conducted by the study team.
106-1	21339-21343	Data	_
106-2	21344-21354	management	_
106-3	21355-21358	and	_
106-4	21359-21369	monitoring	_
106-5	21370-21372	is	_
106-6	21373-21382	conducted	_
106-7	21383-21385	by	_
106-8	21386-21389	the	_
106-9	21390-21395	study	_
106-10	21396-21400	team	_
106-11	21400-21401	.	_

#Text=Study data will be stored on servers of the Central Institute of Mental Health separated from personal information of the participants.
107-1	21402-21407	Study	_
107-2	21408-21412	data	_
107-3	21413-21417	will	_
107-4	21418-21420	be	_
107-5	21421-21427	stored	_
107-6	21428-21430	on	_
107-7	21431-21438	servers	_
107-8	21439-21441	of	_
107-9	21442-21445	the	_
107-10	21446-21453	Central	_
107-11	21454-21463	Institute	_
107-12	21464-21466	of	_
107-13	21467-21473	Mental	_
107-14	21474-21480	Health	_
107-15	21481-21490	separated	_
107-16	21491-21495	from	_
107-17	21496-21504	personal	_
107-18	21505-21516	information	_
107-19	21517-21519	of	_
107-20	21520-21523	the	_
107-21	21524-21536	participants	_
107-22	21536-21537	.	_

#Text=At the end of the study personal information will be deleted.
108-1	21538-21540	At	_
108-2	21541-21544	the	_
108-3	21545-21548	end	_
108-4	21549-21551	of	_
108-5	21552-21555	the	_
108-6	21556-21561	study	_
108-7	21562-21570	personal	_
108-8	21571-21582	information	_
108-9	21583-21587	will	_
108-10	21588-21590	be	_
108-11	21591-21598	deleted	_
108-12	21598-21599	.	_

#Text=The procedures comply with German data privacy laws.
109-1	21600-21603	The	_
109-2	21604-21614	procedures	_
109-3	21615-21621	comply	_
109-4	21622-21626	with	_
109-5	21627-21633	German	_
109-6	21634-21638	data	_
109-7	21639-21646	privacy	_
109-8	21647-21651	laws	_
109-9	21651-21652	.	_

#Text=We will conduct interim analyses on the acquired data to present the study to scientific audiences (e.g. at conferences, meetings, etc.) during the data acquisition phase.
110-1	21653-21655	We	_
110-2	21656-21660	will	_
110-3	21661-21668	conduct	_
110-4	21669-21676	interim	_
110-5	21677-21685	analyses	_
110-6	21686-21688	on	_
110-7	21689-21692	the	_
110-8	21693-21701	acquired	_
110-9	21702-21706	data	_
110-10	21707-21709	to	_
110-11	21710-21717	present	_
110-12	21718-21721	the	_
110-13	21722-21727	study	_
110-14	21728-21730	to	_
110-15	21731-21741	scientific	_
110-16	21742-21751	audiences	_
110-17	21752-21753	(	_
110-18	21753-21756	e.g	_
110-19	21756-21757	.	_
110-20	21758-21760	at	_
110-21	21761-21772	conferences	_
110-22	21772-21773	,	_
110-23	21774-21782	meetings	_
110-24	21782-21783	,	_
110-25	21784-21787	etc	_
110-26	21787-21788	.	_
110-27	21788-21789	)	_
110-28	21790-21796	during	_
110-29	21797-21800	the	_
110-30	21801-21805	data	_
110-31	21806-21817	acquisition	_
110-32	21818-21823	phase	_
110-33	21823-21824	.	_

#Text=Results of the final analyses will be published in scientific journals and presented on scientific conferences.
111-1	21825-21832	Results	_
111-2	21833-21835	of	_
111-3	21836-21839	the	_
111-4	21840-21845	final	_
111-5	21846-21854	analyses	_
111-6	21855-21859	will	_
111-7	21860-21862	be	_
111-8	21863-21872	published	_
111-9	21873-21875	in	_
111-10	21876-21886	scientific	_
111-11	21887-21895	journals	_
111-12	21896-21899	and	_
111-13	21900-21909	presented	_
111-14	21910-21912	on	_
111-15	21913-21923	scientific	_
111-16	21924-21935	conferences	_
111-17	21935-21936	.	_

#Text=Authorship will be defined in accordance to the German Research Foundation’s recommendations for safeguarding good scientific practice.
112-1	21937-21947	Authorship	_
112-2	21948-21952	will	_
112-3	21953-21955	be	_
112-4	21956-21963	defined	_
112-5	21964-21966	in	_
112-6	21967-21977	accordance	_
112-7	21978-21980	to	_
112-8	21981-21984	the	_
112-9	21985-21991	German	_
112-10	21992-22000	Research	_
112-11	22001-22011	Foundation	_
112-12	22011-22012	’	_
112-13	22012-22013	s	_
112-14	22014-22029	recommendations	_
112-15	22030-22033	for	_
112-16	22034-22046	safeguarding	_
112-17	22047-22051	good	_
112-18	22052-22062	scientific	_
112-19	22063-22071	practice	_
112-20	22071-22072	.	_

#Text=Study conduct is reported and audited in interim and final reports of the SyBil-AA consortium to the funding agency.
113-1	22073-22078	Study	_
113-2	22079-22086	conduct	_
113-3	22087-22089	is	_
113-4	22090-22098	reported	_
113-5	22099-22102	and	_
113-6	22103-22110	audited	_
113-7	22111-22113	in	_
113-8	22114-22121	interim	_
113-9	22122-22125	and	_
113-10	22126-22131	final	_
113-11	22132-22139	reports	_
113-12	22140-22142	of	_
113-13	22143-22146	the	_
113-14	22147-22155	SyBil-AA	_
113-15	22156-22166	consortium	_
113-16	22167-22169	to	_
113-17	22170-22173	the	_
113-18	22174-22181	funding	_
113-19	22182-22188	agency	_
113-20	22188-22189	.	_

#Text=Discussion
#Text=In the Systems Biology of Alcohol Addiction (SyBil-AA) rtfRMI NFB study we are assessing the efficacy of rtfRMI NFB on ventral striatal cue-reactivity and frontal control processes in the treatment of alcohol use disorder.
114-1	22190-22200	Discussion	_
114-2	22201-22203	In	_
114-3	22204-22207	the	_
114-4	22208-22215	Systems	_
114-5	22216-22223	Biology	_
114-6	22224-22226	of	_
114-7	22227-22234	Alcohol	_
114-8	22235-22244	Addiction	_
114-9	22245-22246	(	_
114-10	22246-22254	SyBil-AA	_
114-11	22254-22255	)	_
114-12	22256-22262	rtfRMI	_
114-13	22263-22266	NFB	_
114-14	22267-22272	study	_
114-15	22273-22275	we	_
114-16	22276-22279	are	_
114-17	22280-22289	assessing	_
114-18	22290-22293	the	_
114-19	22294-22302	efficacy	_
114-20	22303-22305	of	_
114-21	22306-22312	rtfRMI	_
114-22	22313-22316	NFB	_
114-23	22317-22319	on	_
114-24	22320-22327	ventral	_
114-25	22328-22336	striatal	_
114-26	22337-22351	cue-reactivity	_
114-27	22352-22355	and	_
114-28	22356-22363	frontal	_
114-29	22364-22371	control	_
114-30	22372-22381	processes	_
114-31	22382-22384	in	_
114-32	22385-22388	the	_
114-33	22389-22398	treatment	_
114-34	22399-22401	of	_
114-35	22402-22409	alcohol	_
114-36	22410-22413	use	_
114-37	22414-22422	disorder	_
114-38	22422-22423	.	_

#Text=To the best of our knowledge, the study is one of two ongoing clinical trials of rtfMRI NFB in AUD (see Cox et al. for a description of the other trial), and will contribute to the understanding of the use of rtfMRI NFB as a clinical application in the context of a clinical treatment program for AUD.
115-1	22424-22426	To	_
115-2	22427-22430	the	_
115-3	22431-22435	best	_
115-4	22436-22438	of	_
115-5	22439-22442	our	_
115-6	22443-22452	knowledge	_
115-7	22452-22453	,	_
115-8	22454-22457	the	_
115-9	22458-22463	study	_
115-10	22464-22466	is	_
115-11	22467-22470	one	_
115-12	22471-22473	of	_
115-13	22474-22477	two	_
115-14	22478-22485	ongoing	_
115-15	22486-22494	clinical	_
115-16	22495-22501	trials	_
115-17	22502-22504	of	_
115-18	22505-22511	rtfMRI	_
115-19	22512-22515	NFB	_
115-20	22516-22518	in	_
115-21	22519-22522	AUD	_
115-22	22523-22524	(	_
115-23	22524-22527	see	_
115-24	22528-22531	Cox	_
115-25	22532-22534	et	_
115-26	22535-22537	al	_
115-27	22537-22538	.	_
115-28	22539-22542	for	_
115-29	22543-22544	a	_
115-30	22545-22556	description	_
115-31	22557-22559	of	_
115-32	22560-22563	the	_
115-33	22564-22569	other	_
115-34	22570-22575	trial	_
115-35	22575-22576	)	_
115-36	22576-22577	,	_
115-37	22578-22581	and	_
115-38	22582-22586	will	_
115-39	22587-22597	contribute	_
115-40	22598-22600	to	_
115-41	22601-22604	the	_
115-42	22605-22618	understanding	_
115-43	22619-22621	of	_
115-44	22622-22625	the	_
115-45	22626-22629	use	_
115-46	22630-22632	of	_
115-47	22633-22639	rtfMRI	_
115-48	22640-22643	NFB	_
115-49	22644-22646	as	_
115-50	22647-22648	a	_
115-51	22649-22657	clinical	_
115-52	22658-22669	application	_
115-53	22670-22672	in	_
115-54	22673-22676	the	_
115-55	22677-22684	context	_
115-56	22685-22687	of	_
115-57	22688-22689	a	_
115-58	22690-22698	clinical	_
115-59	22699-22708	treatment	_
115-60	22709-22716	program	_
115-61	22717-22720	for	_
115-62	22721-22724	AUD	_
115-63	22724-22725	.	_

#Text=Besides the primary goal of testing clinical effects, the study will provide data which will be useful to investigate how rtfMRI NFB is leading to changes in the brain, whether intervention success can be predicted by means of neurobiological signatures and clinical variables, and for which patients rtfMRI might be beneficial.
116-1	22726-22733	Besides	_
116-2	22734-22737	the	_
116-3	22738-22745	primary	_
116-4	22746-22750	goal	_
116-5	22751-22753	of	_
116-6	22754-22761	testing	_
116-7	22762-22770	clinical	_
116-8	22771-22778	effects	_
116-9	22778-22779	,	_
116-10	22780-22783	the	_
116-11	22784-22789	study	_
116-12	22790-22794	will	_
116-13	22795-22802	provide	_
116-14	22803-22807	data	_
116-15	22808-22813	which	_
116-16	22814-22818	will	_
116-17	22819-22821	be	_
116-18	22822-22828	useful	_
116-19	22829-22831	to	_
116-20	22832-22843	investigate	_
116-21	22844-22847	how	_
116-22	22848-22854	rtfMRI	_
116-23	22855-22858	NFB	_
116-24	22859-22861	is	_
116-25	22862-22869	leading	_
116-26	22870-22872	to	_
116-27	22873-22880	changes	_
116-28	22881-22883	in	_
116-29	22884-22887	the	_
116-30	22888-22893	brain	_
116-31	22893-22894	,	_
116-32	22895-22902	whether	_
116-33	22903-22915	intervention	_
116-34	22916-22923	success	_
116-35	22924-22927	can	_
116-36	22928-22930	be	_
116-37	22931-22940	predicted	_
116-38	22941-22943	by	_
116-39	22944-22949	means	_
116-40	22950-22952	of	_
116-41	22953-22968	neurobiological	_
116-42	22969-22979	signatures	_
116-43	22980-22983	and	_
116-44	22984-22992	clinical	_
116-45	22993-23002	variables	_
116-46	23002-23003	,	_
116-47	23004-23007	and	_
116-48	23008-23011	for	_
116-49	23012-23017	which	_
116-50	23018-23026	patients	_
116-51	23027-23033	rtfMRI	_
116-52	23034-23039	might	_
116-53	23040-23042	be	_
116-54	23043-23053	beneficial	_
116-55	23053-23054	.	_

#Text=Since we focus on ventral striatal activation to alcohol cues and its prefrontal control, it could be expected that particularly those patients will profit from the intervention that show substantial ventral striatal cue reactivity to alcohol cues prior to the intervention as it has been shown for other treatments before.
117-1	23055-23060	Since	_
117-2	23061-23063	we	_
117-3	23064-23069	focus	_
117-4	23070-23072	on	_
117-5	23073-23080	ventral	_
117-6	23081-23089	striatal	_
117-7	23090-23100	activation	_
117-8	23101-23103	to	_
117-9	23104-23111	alcohol	_
117-10	23112-23116	cues	_
117-11	23117-23120	and	_
117-12	23121-23124	its	_
117-13	23125-23135	prefrontal	_
117-14	23136-23143	control	_
117-15	23143-23144	,	_
117-16	23145-23147	it	_
117-17	23148-23153	could	_
117-18	23154-23156	be	_
117-19	23157-23165	expected	_
117-20	23166-23170	that	_
117-21	23171-23183	particularly	_
117-22	23184-23189	those	_
117-23	23190-23198	patients	_
117-24	23199-23203	will	_
117-25	23204-23210	profit	_
117-26	23211-23215	from	_
117-27	23216-23219	the	_
117-28	23220-23232	intervention	_
117-29	23233-23237	that	_
117-30	23238-23242	show	_
117-31	23243-23254	substantial	_
117-32	23255-23262	ventral	_
117-33	23263-23271	striatal	_
117-34	23272-23275	cue	_
117-35	23276-23286	reactivity	_
117-36	23287-23289	to	_
117-37	23290-23297	alcohol	_
117-38	23298-23302	cues	_
117-39	23303-23308	prior	_
117-40	23309-23311	to	_
117-41	23312-23315	the	_
117-42	23316-23328	intervention	_
117-43	23329-23331	as	_
117-44	23332-23334	it	_
117-45	23335-23338	has	_
117-46	23339-23343	been	_
117-47	23344-23349	shown	_
117-48	23350-23353	for	_
117-49	23354-23359	other	_
117-50	23360-23370	treatments	_
117-51	23371-23377	before	_
117-52	23377-23378	.	_

#Text=However, it has been shown that AUD is often associated with a shift of cue reactivity from ventral to dorsal striatum.
118-1	23379-23386	However	_
118-2	23386-23387	,	_
118-3	23388-23390	it	_
118-4	23391-23394	has	_
118-5	23395-23399	been	_
118-6	23400-23405	shown	_
118-7	23406-23410	that	_
118-8	23411-23414	AUD	_
118-9	23415-23417	is	_
118-10	23418-23423	often	_
118-11	23424-23434	associated	_
118-12	23435-23439	with	_
118-13	23440-23441	a	_
118-14	23442-23447	shift	_
118-15	23448-23450	of	_
118-16	23451-23454	cue	_
118-17	23455-23465	reactivity	_
118-18	23466-23470	from	_
118-19	23471-23478	ventral	_
118-20	23479-23481	to	_
118-21	23482-23488	dorsal	_
118-22	23489-23497	striatum	_
118-23	23497-23498	.	_

#Text=For those patients, showing a more habit like addiction behavior, instead of the ventral striatum, the dorsal striatum might be an interesting target for NFB interventions in AUD.
119-1	23499-23502	For	_
119-2	23503-23508	those	_
119-3	23509-23517	patients	_
119-4	23517-23518	,	_
119-5	23519-23526	showing	_
119-6	23527-23528	a	_
119-7	23529-23533	more	_
119-8	23534-23539	habit	_
119-9	23540-23544	like	_
119-10	23545-23554	addiction	_
119-11	23555-23563	behavior	_
119-12	23563-23564	,	_
119-13	23565-23572	instead	_
119-14	23573-23575	of	_
119-15	23576-23579	the	_
119-16	23580-23587	ventral	_
119-17	23588-23596	striatum	_
119-18	23596-23597	,	_
119-19	23598-23601	the	_
119-20	23602-23608	dorsal	_
119-21	23609-23617	striatum	_
119-22	23618-23623	might	_
119-23	23624-23626	be	_
119-24	23627-23629	an	_
119-25	23630-23641	interesting	_
119-26	23642-23648	target	_
119-27	23649-23652	for	_
119-28	23653-23656	NFB	_
119-29	23657-23670	interventions	_
119-30	23671-23673	in	_
119-31	23674-23677	AUD	_
119-32	23677-23678	.	_

#Text=Nevertheless, there is no doubt, that prefrontal control regions play a central role in craving and relapse.
120-1	23679-23691	Nevertheless	_
120-2	23691-23692	,	_
120-3	23693-23698	there	_
120-4	23699-23701	is	_
120-5	23702-23704	no	_
120-6	23705-23710	doubt	_
120-7	23710-23711	,	_
120-8	23712-23716	that	_
120-9	23717-23727	prefrontal	_
120-10	23728-23735	control	_
120-11	23736-23743	regions	_
120-12	23744-23748	play	_
120-13	23749-23750	a	_
120-14	23751-23758	central	_
120-15	23759-23763	role	_
120-16	23764-23766	in	_
120-17	23767-23774	craving	_
120-18	23775-23778	and	_
120-19	23779-23786	relapse	_
120-20	23786-23787	.	_

#Text=Therefore, it could be speculated that patients receiving a PFC upregulation feedback might benefit from the NF treatment even if they do not show strong ventral but increased dorsal striatal activation to alcohol related cues.
121-1	23788-23797	Therefore	_
121-2	23797-23798	,	_
121-3	23799-23801	it	_
121-4	23802-23807	could	_
121-5	23808-23810	be	_
121-6	23811-23821	speculated	_
121-7	23822-23826	that	_
121-8	23827-23835	patients	_
121-9	23836-23845	receiving	_
121-10	23846-23847	a	_
121-11	23848-23851	PFC	_
121-12	23852-23864	upregulation	_
121-13	23865-23873	feedback	_
121-14	23874-23879	might	_
121-15	23880-23887	benefit	_
121-16	23888-23892	from	_
121-17	23893-23896	the	_
121-18	23897-23899	NF	_
121-19	23900-23909	treatment	_
121-20	23910-23914	even	_
121-21	23915-23917	if	_
121-22	23918-23922	they	_
121-23	23923-23925	do	_
121-24	23926-23929	not	_
121-25	23930-23934	show	_
121-26	23935-23941	strong	_
121-27	23942-23949	ventral	_
121-28	23950-23953	but	_
121-29	23954-23963	increased	_
121-30	23964-23970	dorsal	_
121-31	23971-23979	striatal	_
121-32	23980-23990	activation	_
121-33	23991-23993	to	_
121-34	23994-24001	alcohol	_
121-35	24002-24009	related	_
121-36	24010-24014	cues	_
121-37	24014-24015	.	_

#Text=An innovative condition in the present study is the connectivity feedback condition.
122-1	24016-24018	An	_
122-2	24019-24029	innovative	_
122-3	24030-24039	condition	_
122-4	24040-24042	in	_
122-5	24043-24046	the	_
122-6	24047-24054	present	_
122-7	24055-24060	study	_
122-8	24061-24063	is	_
122-9	24064-24067	the	_
122-10	24068-24080	connectivity	_
122-11	24081-24089	feedback	_
122-12	24090-24099	condition	_
122-13	24099-24100	.	_

#Text=It has been shown in the context of nicotine addiction that adding connectivity information to the feedback signal increases efficiency and reduces cigarette craving but this has neither been shown for alcohol patients nor with respect a long-term outcome of a treatment.
123-1	24101-24103	It	_
123-2	24104-24107	has	_
123-3	24108-24112	been	_
123-4	24113-24118	shown	_
123-5	24119-24121	in	_
123-6	24122-24125	the	_
123-7	24126-24133	context	_
123-8	24134-24136	of	_
123-9	24137-24145	nicotine	_
123-10	24146-24155	addiction	_
123-11	24156-24160	that	_
123-12	24161-24167	adding	_
123-13	24168-24180	connectivity	_
123-14	24181-24192	information	_
123-15	24193-24195	to	_
123-16	24196-24199	the	_
123-17	24200-24208	feedback	_
123-18	24209-24215	signal	_
123-19	24216-24225	increases	_
123-20	24226-24236	efficiency	_
123-21	24237-24240	and	_
123-22	24241-24248	reduces	_
123-23	24249-24258	cigarette	_
123-24	24259-24266	craving	_
123-25	24267-24270	but	_
123-26	24271-24275	this	_
123-27	24276-24279	has	_
123-28	24280-24287	neither	_
123-29	24288-24292	been	_
123-30	24293-24298	shown	_
123-31	24299-24302	for	_
123-32	24303-24310	alcohol	_
123-33	24311-24319	patients	_
123-34	24320-24323	nor	_
123-35	24324-24328	with	_
123-36	24329-24336	respect	_
123-37	24337-24338	a	_
123-38	24339-24348	long-term	_
123-39	24349-24356	outcome	_
123-40	24357-24359	of	_
123-41	24360-24361	a	_
123-42	24362-24371	treatment	_
123-43	24371-24372	.	_

#Text=However, the results from Kirsch et al. could also imply that a critical factor for the treatment effect could be whether patients get the impression that they are able to actively control their own brain response to alcohol cues.
124-1	24373-24380	However	_
124-2	24380-24381	,	_
124-3	24382-24385	the	_
124-4	24386-24393	results	_
124-5	24394-24398	from	_
124-6	24399-24405	Kirsch	_
124-7	24406-24408	et	_
124-8	24409-24411	al	_
124-9	24411-24412	.	_
124-10	24413-24418	could	_
124-11	24419-24423	also	_
124-12	24424-24429	imply	_
124-13	24430-24434	that	_
124-14	24435-24436	a	_
124-15	24437-24445	critical	_
124-16	24446-24452	factor	_
124-17	24453-24456	for	_
124-18	24457-24460	the	_
124-19	24461-24470	treatment	_
124-20	24471-24477	effect	_
124-21	24478-24483	could	_
124-22	24484-24486	be	_
124-23	24487-24494	whether	_
124-24	24495-24503	patients	_
124-25	24504-24507	get	_
124-26	24508-24511	the	_
124-27	24512-24522	impression	_
124-28	24523-24527	that	_
124-29	24528-24532	they	_
124-30	24533-24536	are	_
124-31	24537-24541	able	_
124-32	24542-24544	to	_
124-33	24545-24553	actively	_
124-34	24554-24561	control	_
124-35	24562-24567	their	_
124-36	24568-24571	own	_
124-37	24572-24577	brain	_
124-38	24578-24586	response	_
124-39	24587-24589	to	_
124-40	24590-24597	alcohol	_
124-41	24598-24602	cues	_
124-42	24602-24603	.	_

#Text=Since patients can assume that the intention of the training is the reduction of alcohol cue associated craving, they might apply strategies to reduce this craving and, accordingly, to downregulate the feedback signal.
125-1	24604-24609	Since	_
125-2	24610-24618	patients	_
125-3	24619-24622	can	_
125-4	24623-24629	assume	_
125-5	24630-24634	that	_
125-6	24635-24638	the	_
125-7	24639-24648	intention	_
125-8	24649-24651	of	_
125-9	24652-24655	the	_
125-10	24656-24664	training	_
125-11	24665-24667	is	_
125-12	24668-24671	the	_
125-13	24672-24681	reduction	_
125-14	24682-24684	of	_
125-15	24685-24692	alcohol	_
125-16	24693-24696	cue	_
125-17	24697-24707	associated	_
125-18	24708-24715	craving	_
125-19	24715-24716	,	_
125-20	24717-24721	they	_
125-21	24722-24727	might	_
125-22	24728-24733	apply	_
125-23	24734-24744	strategies	_
125-24	24745-24747	to	_
125-25	24748-24754	reduce	_
125-26	24755-24759	this	_
125-27	24760-24767	craving	_
125-28	24768-24771	and	_
125-29	24771-24772	,	_
125-30	24773-24784	accordingly	_
125-31	24784-24785	,	_
125-32	24786-24788	to	_
125-33	24789-24801	downregulate	_
125-34	24802-24805	the	_
125-35	24806-24814	feedback	_
125-36	24815-24821	signal	_
125-37	24821-24822	.	_

#Text=Kirsch et al. showed that successful VS downregulation was accompanied by the application of specific cognitive strategies, which might have let to the concurrent increase of prefrontal activation, although this activation was not fed back to the participants.
126-1	24823-24829	Kirsch	_
126-2	24830-24832	et	_
126-3	24833-24835	al	_
126-4	24835-24836	.	_
126-5	24837-24843	showed	_
126-6	24844-24848	that	_
126-7	24849-24859	successful	_
126-8	24860-24862	VS	_
126-9	24863-24877	downregulation	_
126-10	24878-24881	was	_
126-11	24882-24893	accompanied	_
126-12	24894-24896	by	_
126-13	24897-24900	the	_
126-14	24901-24912	application	_
126-15	24913-24915	of	_
126-16	24916-24924	specific	_
126-17	24925-24934	cognitive	_
126-18	24935-24945	strategies	_
126-19	24945-24946	,	_
126-20	24947-24952	which	_
126-21	24953-24958	might	_
126-22	24959-24963	have	_
126-23	24964-24967	let	_
126-24	24968-24970	to	_
126-25	24971-24974	the	_
126-26	24975-24985	concurrent	_
126-27	24986-24994	increase	_
126-28	24995-24997	of	_
126-29	24998-25008	prefrontal	_
126-30	25009-25019	activation	_
126-31	25019-25020	,	_
126-32	25021-25029	although	_
126-33	25030-25034	this	_
126-34	25035-25045	activation	_
126-35	25046-25049	was	_
126-36	25050-25053	not	_
126-37	25054-25057	fed	_
126-38	25058-25062	back	_
126-39	25063-25065	to	_
126-40	25066-25069	the	_
126-41	25070-25082	participants	_
126-42	25082-25083	.	_

#Text=Thus, the direction of the signal modulation could be a critical point in NFB, and patients receiving the downregulation instruction might show more effects than those receiving the upregulation instruction.
127-1	25084-25088	Thus	_
127-2	25088-25089	,	_
127-3	25090-25093	the	_
127-4	25094-25103	direction	_
127-5	25104-25106	of	_
127-6	25107-25110	the	_
127-7	25111-25117	signal	_
127-8	25118-25128	modulation	_
127-9	25129-25134	could	_
127-10	25135-25137	be	_
127-11	25138-25139	a	_
127-12	25140-25148	critical	_
127-13	25149-25154	point	_
127-14	25155-25157	in	_
127-15	25158-25161	NFB	_
127-16	25161-25162	,	_
127-17	25163-25166	and	_
127-18	25167-25175	patients	_
127-19	25176-25185	receiving	_
127-20	25186-25189	the	_
127-21	25190-25204	downregulation	_
127-22	25205-25216	instruction	_
127-23	25217-25222	might	_
127-24	25223-25227	show	_
127-25	25228-25232	more	_
127-26	25233-25240	effects	_
127-27	25241-25245	than	_
127-28	25246-25251	those	_
127-29	25252-25261	receiving	_
127-30	25262-25265	the	_
127-31	25266-25278	upregulation	_
127-32	25279-25290	instruction	_
127-33	25290-25291	.	_

#Text=Future studies could further elaborate the effect of instruction by converting the feedback signal in upregulation conditions and instructing all participants to downregulate the signal, which from our experience seems to be the natural direction expected by patients in a cue-reactivity addiction context.
128-1	25292-25298	Future	_
128-2	25299-25306	studies	_
128-3	25307-25312	could	_
128-4	25313-25320	further	_
128-5	25321-25330	elaborate	_
128-6	25331-25334	the	_
128-7	25335-25341	effect	_
128-8	25342-25344	of	_
128-9	25345-25356	instruction	_
128-10	25357-25359	by	_
128-11	25360-25370	converting	_
128-12	25371-25374	the	_
128-13	25375-25383	feedback	_
128-14	25384-25390	signal	_
128-15	25391-25393	in	_
128-16	25394-25406	upregulation	_
128-17	25407-25417	conditions	_
128-18	25418-25421	and	_
128-19	25422-25433	instructing	_
128-20	25434-25437	all	_
128-21	25438-25450	participants	_
128-22	25451-25453	to	_
128-23	25454-25466	downregulate	_
128-24	25467-25470	the	_
128-25	25471-25477	signal	_
128-26	25477-25478	,	_
128-27	25479-25484	which	_
128-28	25485-25489	from	_
128-29	25490-25493	our	_
128-30	25494-25504	experience	_
128-31	25505-25510	seems	_
128-32	25511-25513	to	_
128-33	25514-25516	be	_
128-34	25517-25520	the	_
128-35	25521-25528	natural	_
128-36	25529-25538	direction	_
128-37	25539-25547	expected	_
128-38	25548-25550	by	_
128-39	25551-25559	patients	_
128-40	25560-25562	in	_
128-41	25563-25564	a	_
128-42	25565-25579	cue-reactivity	_
128-43	25580-25589	addiction	_
128-44	25590-25597	context	_
128-45	25597-25598	.	_

#Text=This would also allow blinding the patients completely, not only with respect to the group (experimental vs. control) but also the kind of regulation they are expected to apply.
129-1	25599-25603	This	_
129-2	25604-25609	would	_
129-3	25610-25614	also	_
129-4	25615-25620	allow	_
129-5	25621-25629	blinding	_
129-6	25630-25633	the	_
129-7	25634-25642	patients	_
129-8	25643-25653	completely	_
129-9	25653-25654	,	_
129-10	25655-25658	not	_
129-11	25659-25663	only	_
129-12	25664-25668	with	_
129-13	25669-25676	respect	_
129-14	25677-25679	to	_
129-15	25680-25683	the	_
129-16	25684-25689	group	_
129-17	25690-25691	(	_
129-18	25691-25703	experimental	_
129-19	25704-25706	vs	_
129-20	25706-25707	.	_
129-21	25708-25715	control	_
129-22	25715-25716	)	_
129-23	25717-25720	but	_
129-24	25721-25725	also	_
129-25	25726-25729	the	_
129-26	25730-25734	kind	_
129-27	25735-25737	of	_
129-28	25738-25748	regulation	_
129-29	25749-25753	they	_
129-30	25754-25757	are	_
129-31	25758-25766	expected	_
129-32	25767-25769	to	_
129-33	25770-25775	apply	_
129-34	25775-25776	.	_

#Text=The study could also reveal additional mechanistic information about the mode of action of rtFMRI NF.
130-1	25777-25780	The	_
130-2	25781-25786	study	_
130-3	25787-25792	could	_
130-4	25793-25797	also	_
130-5	25798-25804	reveal	_
130-6	25805-25815	additional	_
130-7	25816-25827	mechanistic	_
130-8	25828-25839	information	_
130-9	25840-25845	about	_
130-10	25846-25849	the	_
130-11	25850-25854	mode	_
130-12	25855-25857	of	_
130-13	25858-25864	action	_
130-14	25865-25867	of	_
130-15	25868-25874	rtFMRI	_
130-16	25875-25877	NF	_
130-17	25877-25878	.	_

#Text=Importantly, we conduct fMRI scans with whole-brain coverage, which will allow us to investigate the role of other brain regions like amygdala, insula cortex, or ventromedial PFC which were not directly targeted with NFB in our study but play important roles alcohol-related cue-reactivity.
131-1	25879-25890	Importantly	_
131-2	25890-25891	,	_
131-3	25892-25894	we	_
131-4	25895-25902	conduct	_
131-5	25903-25907	fMRI	_
131-6	25908-25913	scans	_
131-7	25914-25918	with	_
131-8	25919-25930	whole-brain	_
131-9	25931-25939	coverage	_
131-10	25939-25940	,	_
131-11	25941-25946	which	_
131-12	25947-25951	will	_
131-13	25952-25957	allow	_
131-14	25958-25960	us	_
131-15	25961-25963	to	_
131-16	25964-25975	investigate	_
131-17	25976-25979	the	_
131-18	25980-25984	role	_
131-19	25985-25987	of	_
131-20	25988-25993	other	_
131-21	25994-25999	brain	_
131-22	26000-26007	regions	_
131-23	26008-26012	like	_
131-24	26013-26021	amygdala	_
131-25	26021-26022	,	_
131-26	26023-26029	insula	_
131-27	26030-26036	cortex	_
131-28	26036-26037	,	_
131-29	26038-26040	or	_
131-30	26041-26053	ventromedial	_
131-31	26054-26057	PFC	_
131-32	26058-26063	which	_
131-33	26064-26068	were	_
131-34	26069-26072	not	_
131-35	26073-26081	directly	_
131-36	26082-26090	targeted	_
131-37	26091-26095	with	_
131-38	26096-26099	NFB	_
131-39	26100-26102	in	_
131-40	26103-26106	our	_
131-41	26107-26112	study	_
131-42	26113-26116	but	_
131-43	26117-26121	play	_
131-44	26122-26131	important	_
131-45	26132-26137	roles	_
131-46	26138-26153	alcohol-related	_
131-47	26154-26168	cue-reactivity	_
131-48	26168-26169	.	_

#Text=Another interesting aspect which might have an influence on the results is the type of control for neurofeedback (see e.g.).
132-1	26170-26177	Another	_
132-2	26178-26189	interesting	_
132-3	26190-26196	aspect	_
132-4	26197-26202	which	_
132-5	26203-26208	might	_
132-6	26209-26213	have	_
132-7	26214-26216	an	_
132-8	26217-26226	influence	_
132-9	26227-26229	on	_
132-10	26230-26233	the	_
132-11	26234-26241	results	_
132-12	26242-26244	is	_
132-13	26245-26248	the	_
132-14	26249-26253	type	_
132-15	26254-26256	of	_
132-16	26257-26264	control	_
132-17	26265-26268	for	_
132-18	26269-26282	neurofeedback	_
132-19	26283-26284	(	_
132-20	26284-26287	see	_
132-21	26288-26291	e.g	_
132-22	26291-26292	.	_
132-23	26292-26293	)	_
132-24	26293-26294	.	_

#Text=We chose an active type of control in the NFB study in which participants from the control group receive a real feedback signal from a control region, which in our case is the auditory cortex that is not involved in cue-reactivity.
133-1	26295-26297	We	_
133-2	26298-26303	chose	_
133-3	26304-26306	an	_
133-4	26307-26313	active	_
133-5	26314-26318	type	_
133-6	26319-26321	of	_
133-7	26322-26329	control	_
133-8	26330-26332	in	_
133-9	26333-26336	the	_
133-10	26337-26340	NFB	_
133-11	26341-26346	study	_
133-12	26347-26349	in	_
133-13	26350-26355	which	_
133-14	26356-26368	participants	_
133-15	26369-26373	from	_
133-16	26374-26377	the	_
133-17	26378-26385	control	_
133-18	26386-26391	group	_
133-19	26392-26399	receive	_
133-20	26400-26401	a	_
133-21	26402-26406	real	_
133-22	26407-26415	feedback	_
133-23	26416-26422	signal	_
133-24	26423-26427	from	_
133-25	26428-26429	a	_
133-26	26430-26437	control	_
133-27	26438-26444	region	_
133-28	26444-26445	,	_
133-29	26446-26451	which	_
133-30	26452-26454	in	_
133-31	26455-26458	our	_
133-32	26459-26463	case	_
133-33	26464-26466	is	_
133-34	26467-26470	the	_
133-35	26471-26479	auditory	_
133-36	26480-26486	cortex	_
133-37	26487-26491	that	_
133-38	26492-26494	is	_
133-39	26495-26498	not	_
133-40	26499-26507	involved	_
133-41	26508-26510	in	_
133-42	26511-26525	cue-reactivity	_
133-43	26525-26526	.	_

#Text=Other possibilities would be to use a control group without feedback, a group that just views feedback signal of other participants without instructions, or a yoke-control group that is told to regulate the process but receives feedback from another person.
134-1	26527-26532	Other	_
134-2	26533-26546	possibilities	_
134-3	26547-26552	would	_
134-4	26553-26555	be	_
134-5	26556-26558	to	_
134-6	26559-26562	use	_
134-7	26563-26564	a	_
134-8	26565-26572	control	_
134-9	26573-26578	group	_
134-10	26579-26586	without	_
134-11	26587-26595	feedback	_
134-12	26595-26596	,	_
134-13	26597-26598	a	_
134-14	26599-26604	group	_
134-15	26605-26609	that	_
134-16	26610-26614	just	_
134-17	26615-26620	views	_
134-18	26621-26629	feedback	_
134-19	26630-26636	signal	_
134-20	26637-26639	of	_
134-21	26640-26645	other	_
134-22	26646-26658	participants	_
134-23	26659-26666	without	_
134-24	26667-26679	instructions	_
134-25	26679-26680	,	_
134-26	26681-26683	or	_
134-27	26684-26685	a	_
134-28	26686-26698	yoke-control	_
134-29	26699-26704	group	_
134-30	26705-26709	that	_
134-31	26710-26712	is	_
134-32	26713-26717	told	_
134-33	26718-26720	to	_
134-34	26721-26729	regulate	_
134-35	26730-26733	the	_
134-36	26734-26741	process	_
134-37	26742-26745	but	_
134-38	26746-26754	receives	_
134-39	26755-26763	feedback	_
134-40	26764-26768	from	_
134-41	26769-26776	another	_
134-42	26777-26783	person	_
134-43	26783-26784	.	_

#Text=For task comparability we decided against the first two options, and for ethical reasons a yoke-control group in which participants would receive fake instructions is questionable.
135-1	26785-26788	For	_
135-2	26789-26793	task	_
135-3	26794-26807	comparability	_
135-4	26808-26810	we	_
135-5	26811-26818	decided	_
135-6	26819-26826	against	_
135-7	26827-26830	the	_
135-8	26831-26836	first	_
135-9	26837-26840	two	_
135-10	26841-26848	options	_
135-11	26848-26849	,	_
135-12	26850-26853	and	_
135-13	26854-26857	for	_
135-14	26858-26865	ethical	_
135-15	26866-26873	reasons	_
135-16	26874-26875	a	_
135-17	26876-26888	yoke-control	_
135-18	26889-26894	group	_
135-19	26895-26897	in	_
135-20	26898-26903	which	_
135-21	26904-26916	participants	_
135-22	26917-26922	would	_
135-23	26923-26930	receive	_
135-24	26931-26935	fake	_
135-25	26936-26948	instructions	_
135-26	26949-26951	is	_
135-27	26952-26964	questionable	_
135-28	26964-26965	.	_

#Text=Our active-control groups will lead to results based on specific target brain processes, and not per se on brain regulation through NFB.
136-1	26966-26969	Our	_
136-2	26970-26984	active-control	_
136-3	26985-26991	groups	_
136-4	26992-26996	will	_
136-5	26997-27001	lead	_
136-6	27002-27004	to	_
136-7	27005-27012	results	_
136-8	27013-27018	based	_
136-9	27019-27021	on	_
136-10	27022-27030	specific	_
136-11	27031-27037	target	_
136-12	27038-27043	brain	_
136-13	27044-27053	processes	_
136-14	27053-27054	,	_
136-15	27055-27058	and	_
136-16	27059-27062	not	_
136-17	27063-27066	per	_
136-18	27067-27069	se	_
136-19	27070-27072	on	_
136-20	27073-27078	brain	_
136-21	27079-27089	regulation	_
136-22	27090-27097	through	_
136-23	27098-27101	NFB	_
136-24	27101-27102	.	_

#Text=However, differences between groups might still be related to differences in regulation difficulty.
137-1	27103-27110	However	_
137-2	27110-27111	,	_
137-3	27112-27123	differences	_
137-4	27124-27131	between	_
137-5	27132-27138	groups	_
137-6	27139-27144	might	_
137-7	27145-27150	still	_
137-8	27151-27153	be	_
137-9	27154-27161	related	_
137-10	27162-27164	to	_
137-11	27165-27176	differences	_
137-12	27177-27179	in	_
137-13	27180-27190	regulation	_
137-14	27191-27201	difficulty	_
137-15	27201-27202	.	_

#Text=There are some shortcomings of the protocol.
138-1	27203-27208	There	_
138-2	27209-27212	are	_
138-3	27213-27217	some	_
138-4	27218-27230	shortcomings	_
138-5	27231-27233	of	_
138-6	27234-27237	the	_
138-7	27238-27246	protocol	_
138-8	27246-27247	.	_

#Text=First, the study is only single-blind.
139-1	27248-27253	First	_
139-2	27253-27254	,	_
139-3	27255-27258	the	_
139-4	27259-27264	study	_
139-5	27265-27267	is	_
139-6	27268-27272	only	_
139-7	27273-27285	single-blind	_
139-8	27285-27286	.	_

#Text=The staff members must prepare the individual feedback set up (definition of ROI, definition of direction) and are therefore not blinded.
140-1	27287-27290	The	_
140-2	27291-27296	staff	_
140-3	27297-27304	members	_
140-4	27305-27309	must	_
140-5	27310-27317	prepare	_
140-6	27318-27321	the	_
140-7	27322-27332	individual	_
140-8	27333-27341	feedback	_
140-9	27342-27345	set	_
140-10	27346-27348	up	_
140-11	27349-27350	(	_
140-12	27350-27360	definition	_
140-13	27361-27363	of	_
140-14	27364-27367	ROI	_
140-15	27367-27368	,	_
140-16	27369-27379	definition	_
140-17	27380-27382	of	_
140-18	27383-27392	direction	_
140-19	27392-27393	)	_
140-20	27394-27397	and	_
140-21	27398-27401	are	_
140-22	27402-27411	therefore	_
140-23	27412-27415	not	_
140-24	27416-27423	blinded	_
140-25	27423-27424	.	_

#Text=In future studies, a double-blind protocol could be implemented by separating staff that prepares the individual NF setup and staff that instructs the participants.
141-1	27425-27427	In	_
141-2	27428-27434	future	_
141-3	27435-27442	studies	_
141-4	27442-27443	,	_
141-5	27444-27445	a	_
141-6	27446-27458	double-blind	_
141-7	27459-27467	protocol	_
141-8	27468-27473	could	_
141-9	27474-27476	be	_
141-10	27477-27488	implemented	_
141-11	27489-27491	by	_
141-12	27492-27502	separating	_
141-13	27503-27508	staff	_
141-14	27509-27513	that	_
141-15	27514-27522	prepares	_
141-16	27523-27526	the	_
141-17	27527-27537	individual	_
141-18	27538-27540	NF	_
141-19	27541-27546	setup	_
141-20	27547-27550	and	_
141-21	27551-27556	staff	_
141-22	27557-27561	that	_
141-23	27562-27571	instructs	_
141-24	27572-27575	the	_
141-25	27576-27588	participants	_
141-26	27588-27589	.	_

#Text=However, we think it is worth to test the general applicability of rtfMRI NF to AUD patients before setting up such an extensive study protocol.
142-1	27590-27597	However	_
142-2	27597-27598	,	_
142-3	27599-27601	we	_
142-4	27602-27607	think	_
142-5	27608-27610	it	_
142-6	27611-27613	is	_
142-7	27614-27619	worth	_
142-8	27620-27622	to	_
142-9	27623-27627	test	_
142-10	27628-27631	the	_
142-11	27632-27639	general	_
142-12	27640-27653	applicability	_
142-13	27654-27656	of	_
142-14	27657-27663	rtfMRI	_
142-15	27664-27666	NF	_
142-16	27667-27669	to	_
142-17	27670-27673	AUD	_
142-18	27674-27682	patients	_
142-19	27683-27689	before	_
142-20	27690-27697	setting	_
142-21	27698-27700	up	_
142-22	27701-27705	such	_
142-23	27706-27708	an	_
142-24	27709-27718	extensive	_
142-25	27719-27724	study	_
142-26	27725-27733	protocol	_
142-27	27733-27734	.	_

#Text=Second, the study was retrospectively registered in the German Clinical Trials Register (DRKS00010253; WHO Universal Trial Number (UTN): U1111–1181-4218).
143-1	27735-27741	Second	_
143-2	27741-27742	,	_
143-3	27743-27746	the	_
143-4	27747-27752	study	_
143-5	27753-27756	was	_
143-6	27757-27772	retrospectively	_
143-7	27773-27783	registered	_
143-8	27784-27786	in	_
143-9	27787-27790	the	_
143-10	27791-27797	German	_
143-11	27798-27806	Clinical	_
143-12	27807-27813	Trials	_
143-13	27814-27822	Register	_
143-14	27823-27824	(	_
143-15	27824-27836	DRKS00010253	_
143-16	27836-27837	;	_
143-17	27838-27841	WHO	_
143-18	27842-27851	Universal	_
143-19	27852-27857	Trial	_
143-20	27858-27864	Number	_
143-21	27865-27866	(	_
143-22	27866-27869	UTN	_
143-23	27869-27870	)	_
143-24	27870-27871	:	_
143-25	27872-27877	U1111	_
143-26	27877-27878	–	_
143-27	27878-27882	1181	_
143-28	27882-27883	-	_
143-29	27883-27887	4218	_
143-30	27887-27888	)	_
143-31	27888-27889	.	_

#Text=Due to fast inclusion of the first patient, registration was conducted shortly after the begin of the study, but before any data was processed or analyzed (Inclusion of first patient: 03/30/2016; application for registration: 04/26/2016; registration date: 05/10/2016).
144-1	27890-27893	Due	_
144-2	27894-27896	to	_
144-3	27897-27901	fast	_
144-4	27902-27911	inclusion	_
144-5	27912-27914	of	_
144-6	27915-27918	the	_
144-7	27919-27924	first	_
144-8	27925-27932	patient	_
144-9	27932-27933	,	_
144-10	27934-27946	registration	_
144-11	27947-27950	was	_
144-12	27951-27960	conducted	_
144-13	27961-27968	shortly	_
144-14	27969-27974	after	_
144-15	27975-27978	the	_
144-16	27979-27984	begin	_
144-17	27985-27987	of	_
144-18	27988-27991	the	_
144-19	27992-27997	study	_
144-20	27997-27998	,	_
144-21	27999-28002	but	_
144-22	28003-28009	before	_
144-23	28010-28013	any	_
144-24	28014-28018	data	_
144-25	28019-28022	was	_
144-26	28023-28032	processed	_
144-27	28033-28035	or	_
144-28	28036-28044	analyzed	_
144-29	28045-28046	(	_
144-30	28046-28055	Inclusion	_
144-31	28056-28058	of	_
144-32	28059-28064	first	_
144-33	28065-28072	patient	_
144-34	28072-28073	:	_
144-35	28074-28076	03	_
144-36	28076-28077	/	_
144-37	28077-28079	30	_
144-38	28079-28080	/	_
144-39	28080-28084	2016	_
144-40	28084-28085	;	_
144-41	28086-28097	application	_
144-42	28098-28101	for	_
144-43	28102-28114	registration	_
144-44	28114-28115	:	_
144-45	28116-28118	04	_
144-46	28118-28119	/	_
144-47	28119-28121	26	_
144-48	28121-28122	/	_
144-49	28122-28126	2016	_
144-50	28126-28127	;	_
144-51	28128-28140	registration	_
144-52	28141-28145	date	_
144-53	28145-28146	:	_
144-54	28147-28149	05	_
144-55	28149-28150	/	_
144-56	28150-28152	10	_
144-57	28152-28153	/	_
144-58	28153-28157	2016	_
144-59	28157-28158	)	_
144-60	28158-28159	.	_

#Text=However, the registration complies with the goals of the study described in the grant proposal and the study protocol will not be altered during the study.
145-1	28160-28167	However	_
145-2	28167-28168	,	_
145-3	28169-28172	the	_
145-4	28173-28185	registration	_
145-5	28186-28194	complies	_
145-6	28195-28199	with	_
145-7	28200-28203	the	_
145-8	28204-28209	goals	_
145-9	28210-28212	of	_
145-10	28213-28216	the	_
145-11	28217-28222	study	_
145-12	28223-28232	described	_
145-13	28233-28235	in	_
145-14	28236-28239	the	_
145-15	28240-28245	grant	_
145-16	28246-28254	proposal	_
145-17	28255-28258	and	_
145-18	28259-28262	the	_
145-19	28263-28268	study	_
145-20	28269-28277	protocol	_
145-21	28278-28282	will	_
145-22	28283-28286	not	_
145-23	28287-28289	be	_
145-24	28290-28297	altered	_
145-25	28298-28304	during	_
145-26	28305-28308	the	_
145-27	28309-28314	study	_
145-28	28314-28315	.	_

#Text=Finally, we have not defined stopping criteria, because we do not expect side effects besides those that can be expected from fMRI scanning, which is a safe and well-established technique.
146-1	28316-28323	Finally	_
146-2	28323-28324	,	_
146-3	28325-28327	we	_
146-4	28328-28332	have	_
146-5	28333-28336	not	_
146-6	28337-28344	defined	_
146-7	28345-28353	stopping	_
146-8	28354-28362	criteria	_
146-9	28362-28363	,	_
146-10	28364-28371	because	_
146-11	28372-28374	we	_
146-12	28375-28377	do	_
146-13	28378-28381	not	_
146-14	28382-28388	expect	_
146-15	28389-28393	side	_
146-16	28394-28401	effects	_
146-17	28402-28409	besides	_
146-18	28410-28415	those	_
146-19	28416-28420	that	_
146-20	28421-28424	can	_
146-21	28425-28427	be	_
146-22	28428-28436	expected	_
146-23	28437-28441	from	_
146-24	28442-28446	fMRI	_
146-25	28447-28455	scanning	_
146-26	28455-28456	,	_
146-27	28457-28462	which	_
146-28	28463-28465	is	_
146-29	28466-28467	a	_
146-30	28468-28472	safe	_
146-31	28473-28476	and	_
146-32	28477-28493	well-established	_
146-33	28494-28503	technique	_
146-34	28503-28504	.	_

#Text=However, the principle investigators will decide whether to continue or terminate the study or specific parts of it if side effects were reported by the participants.
147-1	28505-28512	However	_
147-2	28512-28513	,	_
147-3	28514-28517	the	_
147-4	28518-28527	principle	_
147-5	28528-28541	investigators	_
147-6	28542-28546	will	_
147-7	28547-28553	decide	_
147-8	28554-28561	whether	_
147-9	28562-28564	to	_
147-10	28565-28573	continue	_
147-11	28574-28576	or	_
147-12	28577-28586	terminate	_
147-13	28587-28590	the	_
147-14	28591-28596	study	_
147-15	28597-28599	or	_
147-16	28600-28608	specific	_
147-17	28609-28614	parts	_
147-18	28615-28617	of	_
147-19	28618-28620	it	_
147-20	28621-28623	if	_
147-21	28624-28628	side	_
147-22	28629-28636	effects	_
147-23	28637-28641	were	_
147-24	28642-28650	reported	_
147-25	28651-28653	by	_
147-26	28654-28657	the	_
147-27	28658-28670	participants	_
147-28	28670-28671	.	_

#Text=Overall, the study is well suited to provide valuable data on the efficacy of rtfMRI NFB as an add-on treatment for AUD in a clinical setting.
148-1	28672-28679	Overall	_
148-2	28679-28680	,	_
148-3	28681-28684	the	_
148-4	28685-28690	study	_
148-5	28691-28693	is	_
148-6	28694-28698	well	_
148-7	28699-28705	suited	_
148-8	28706-28708	to	_
148-9	28709-28716	provide	_
148-10	28717-28725	valuable	_
148-11	28726-28730	data	_
148-12	28731-28733	on	_
148-13	28734-28737	the	_
148-14	28738-28746	efficacy	_
148-15	28747-28749	of	_
148-16	28750-28756	rtfMRI	_
148-17	28757-28760	NFB	_
148-18	28761-28763	as	_
148-19	28764-28766	an	_
148-20	28767-28773	add-on	_
148-21	28774-28783	treatment	_
148-22	28784-28787	for	_
148-23	28788-28791	AUD	_
148-24	28792-28794	in	_
148-25	28795-28796	a	_
148-26	28797-28805	clinical	_
148-27	28806-28813	setting	_
148-28	28813-28814	.	_

#Text=Furthermore, the large amount of imaging data collected on the three scanning days will be helpful to better understand how rtfMRI NFB is working, and to identify factors that predict its clinical effects and could potentially be useful for developing personalized treatment approaches.
149-1	28815-28826	Furthermore	_
149-2	28826-28827	,	_
149-3	28828-28831	the	_
149-4	28832-28837	large	_
149-5	28838-28844	amount	_
149-6	28845-28847	of	_
149-7	28848-28855	imaging	_
149-8	28856-28860	data	_
149-9	28861-28870	collected	_
149-10	28871-28873	on	_
149-11	28874-28877	the	_
149-12	28878-28883	three	_
149-13	28884-28892	scanning	_
149-14	28893-28897	days	_
149-15	28898-28902	will	_
149-16	28903-28905	be	_
149-17	28906-28913	helpful	_
149-18	28914-28916	to	_
149-19	28917-28923	better	_
149-20	28924-28934	understand	_
149-21	28935-28938	how	_
149-22	28939-28945	rtfMRI	_
149-23	28946-28949	NFB	_
149-24	28950-28952	is	_
149-25	28953-28960	working	_
149-26	28960-28961	,	_
149-27	28962-28965	and	_
149-28	28966-28968	to	_
149-29	28969-28977	identify	_
149-30	28978-28985	factors	_
149-31	28986-28990	that	_
149-32	28991-28998	predict	_
149-33	28999-29002	its	_
149-34	29003-29011	clinical	_
149-35	29012-29019	effects	_
149-36	29020-29023	and	_
149-37	29024-29029	could	_
149-38	29030-29041	potentially	_
149-39	29042-29044	be	_
149-40	29045-29051	useful	_
149-41	29052-29055	for	_
149-42	29056-29066	developing	_
149-43	29067-29079	personalized	_
149-44	29080-29089	treatment	_
149-45	29090-29100	approaches	_
149-46	29100-29101	.	_

#Text=Abbreviations
#Text=ACC
#Text=anterior cingulate cortex
#Text=AUD
#Text=Alcohol Use Disorder
#Text=CIMH
#Text=Central Institute of Mental Health
#Text=DBS
#Text=Deep Brain Stimulation
#Text=DSM
#Text=Diagnostic and Statistical Manual of Mental Disorders
#Text=EPI
#Text=echo-planar imaging
#Text=ICD
#Text=International Classification of Diseases
#Text=ICT
#Text=Incentive Conflict Task
#Text=NFB
#Text=neurofeedback
#Text=rIFG
#Text=right inferior frontal gyrus
#Text=rtfMRI
#Text=real-time functional magnetic resonance imaging
#Text=SKID
#Text=Structured Clinical Interview for DSM-IV
#Text=tDCS
#Text=transcranial Direct Current Stimulation
#Text=TE
#Text=echo time
#Text=TMS
#Text=transcranial magnetic stimulation
#Text=TR
#Text=time of repetition
#Text=vmPFC
#Text=ventromedial prefrontal cortex
#Text=VS
#Text=ventral striatum
#Text=Authors’ contributions
#Text=MK, PK, & FK designed the study.
150-1	29102-29115	Abbreviations	_
150-2	29116-29119	ACC	_
150-3	29120-29128	anterior	_
150-4	29129-29138	cingulate	_
150-5	29139-29145	cortex	_
150-6	29146-29149	AUD	_
150-7	29150-29157	Alcohol	_
150-8	29158-29161	Use	_
150-9	29162-29170	Disorder	_
150-10	29171-29175	CIMH	_
150-11	29176-29183	Central	_
150-12	29184-29193	Institute	_
150-13	29194-29196	of	_
150-14	29197-29203	Mental	_
150-15	29204-29210	Health	_
150-16	29211-29214	DBS	_
150-17	29215-29219	Deep	_
150-18	29220-29225	Brain	_
150-19	29226-29237	Stimulation	_
150-20	29238-29241	DSM	_
150-21	29242-29252	Diagnostic	_
150-22	29253-29256	and	_
150-23	29257-29268	Statistical	_
150-24	29269-29275	Manual	_
150-25	29276-29278	of	_
150-26	29279-29285	Mental	_
150-27	29286-29295	Disorders	_
150-28	29296-29299	EPI	_
150-29	29300-29311	echo-planar	_
150-30	29312-29319	imaging	_
150-31	29320-29323	ICD	_
150-32	29324-29337	International	_
150-33	29338-29352	Classification	_
150-34	29353-29355	of	_
150-35	29356-29364	Diseases	_
150-36	29365-29368	ICT	_
150-37	29369-29378	Incentive	_
150-38	29379-29387	Conflict	_
150-39	29388-29392	Task	_
150-40	29393-29396	NFB	_
150-41	29397-29410	neurofeedback	_
150-42	29411-29415	rIFG	_
150-43	29416-29421	right	_
150-44	29422-29430	inferior	_
150-45	29431-29438	frontal	_
150-46	29439-29444	gyrus	_
150-47	29445-29451	rtfMRI	_
150-48	29452-29461	real-time	_
150-49	29462-29472	functional	_
150-50	29473-29481	magnetic	_
150-51	29482-29491	resonance	_
150-52	29492-29499	imaging	_
150-53	29500-29504	SKID	_
150-54	29505-29515	Structured	_
150-55	29516-29524	Clinical	_
150-56	29525-29534	Interview	_
150-57	29535-29538	for	_
150-58	29539-29545	DSM-IV	_
150-59	29546-29550	tDCS	_
150-60	29551-29563	transcranial	_
150-61	29564-29570	Direct	_
150-62	29571-29578	Current	_
150-63	29579-29590	Stimulation	_
150-64	29591-29593	TE	_
150-65	29594-29598	echo	_
150-66	29599-29603	time	_
150-67	29604-29607	TMS	_
150-68	29608-29620	transcranial	_
150-69	29621-29629	magnetic	_
150-70	29630-29641	stimulation	_
150-71	29642-29644	TR	_
150-72	29645-29649	time	_
150-73	29650-29652	of	_
150-74	29653-29663	repetition	_
150-75	29664-29669	vmPFC	_
150-76	29670-29682	ventromedial	_
150-77	29683-29693	prefrontal	_
150-78	29694-29700	cortex	_
150-79	29701-29703	VS	_
150-80	29704-29711	ventral	_
150-81	29712-29720	striatum	_
150-82	29721-29728	Authors	_
150-83	29728-29729	’	_
150-84	29730-29743	contributions	_
150-85	29744-29746	MK	_
150-86	29746-29747	,	_
150-87	29748-29750	PK	_
150-88	29750-29751	,	_
150-89	29752-29753	&	_
150-90	29754-29756	FK	_
150-91	29757-29765	designed	_
150-92	29766-29769	the	_
150-93	29770-29775	study	_
150-94	29775-29776	.	_

#Text=MFG, NB, PH, SG, & PK wrote the manuscript.
151-1	29777-29780	MFG	_
151-2	29780-29781	,	_
151-3	29782-29784	NB	_
151-4	29784-29785	,	_
151-5	29786-29788	PH	_
151-6	29788-29789	,	_
151-7	29790-29792	SG	_
151-8	29792-29793	,	_
151-9	29794-29795	&	_
151-10	29796-29798	PK	_
151-11	29799-29804	wrote	_
151-12	29805-29808	the	_
151-13	29809-29819	manuscript	_
151-14	29819-29820	.	_

#Text=AS & MFG developed the rtfMRI NFB setup.
152-1	29821-29823	AS	_
152-2	29824-29825	&	_
152-3	29826-29829	MFG	_
152-4	29830-29839	developed	_
152-5	29840-29843	the	_
152-6	29844-29850	rtfMRI	_
152-7	29851-29854	NFB	_
152-8	29855-29860	setup	_
152-9	29860-29861	.	_

#Text=WS planned the SyBil-AA consortium.
153-1	29862-29864	WS	_
153-2	29865-29872	planned	_
153-3	29873-29876	the	_
153-4	29877-29885	SyBil-AA	_
153-5	29886-29896	consortium	_
153-6	29896-29897	.	_

#Text=All authors read and approved the manuscript.
154-1	29898-29901	All	_
154-2	29902-29909	authors	_
154-3	29910-29914	read	_
154-4	29915-29918	and	_
154-5	29919-29927	approved	_
154-6	29928-29931	the	_
154-7	29932-29942	manuscript	_
154-8	29942-29943	.	_

#Text=Ethics approval and consent to participate
#Text=The study was approved by the local Ethics Committee of the Medical Faculty Mannheim at the University of Heidelberg, Germany (reference number: 2015-613N-MA).
155-1	29944-29950	Ethics	_
155-2	29951-29959	approval	_
155-3	29960-29963	and	_
155-4	29964-29971	consent	_
155-5	29972-29974	to	_
155-6	29975-29986	participate	_
155-7	29987-29990	The	_
155-8	29991-29996	study	_
155-9	29997-30000	was	_
155-10	30001-30009	approved	_
155-11	30010-30012	by	_
155-12	30013-30016	the	_
155-13	30017-30022	local	_
155-14	30023-30029	Ethics	_
155-15	30030-30039	Committee	_
155-16	30040-30042	of	_
155-17	30043-30046	the	_
155-18	30047-30054	Medical	_
155-19	30055-30062	Faculty	_
155-20	30063-30071	Mannheim	_
155-21	30072-30074	at	_
155-22	30075-30078	the	_
155-23	30079-30089	University	_
155-24	30090-30092	of	_
155-25	30093-30103	Heidelberg	_
155-26	30103-30104	,	_
155-27	30105-30112	Germany	_
155-28	30113-30114	(	_
155-29	30114-30123	reference	_
155-30	30124-30130	number	_
155-31	30130-30131	:	_
155-32	30132-30136	2015	_
155-33	30136-30137	-	_
155-34	30137-30144	613N-MA	_
155-35	30144-30145	)	_
155-36	30145-30146	.	_

#Text=All participants provide written informed consent after a detailed explanation of all procedures and are able to withdraw their consent at any time without negative consequences.
156-1	30147-30150	All	_
156-2	30151-30163	participants	_
156-3	30164-30171	provide	_
156-4	30172-30179	written	_
156-5	30180-30188	informed	_
156-6	30189-30196	consent	_
156-7	30197-30202	after	_
156-8	30203-30204	a	_
156-9	30205-30213	detailed	_
156-10	30214-30225	explanation	_
156-11	30226-30228	of	_
156-12	30229-30232	all	_
156-13	30233-30243	procedures	_
156-14	30244-30247	and	_
156-15	30248-30251	are	_
156-16	30252-30256	able	_
156-17	30257-30259	to	_
156-18	30260-30268	withdraw	_
156-19	30269-30274	their	_
156-20	30275-30282	consent	_
156-21	30283-30285	at	_
156-22	30286-30289	any	_
156-23	30290-30294	time	_
156-24	30295-30302	without	_
156-25	30303-30311	negative	_
156-26	30312-30324	consequences	_
156-27	30324-30325	.	_

#Text=Consent for publication
#Text=Not applicable.
157-1	30326-30333	Consent	_
157-2	30334-30337	for	_
157-3	30338-30349	publication	_
157-4	30350-30353	Not	_
157-5	30354-30364	applicable	_
157-6	30364-30365	.	_

#Text=Competing interests
#Text=The authors declare no competing interests.
158-1	30366-30375	Competing	_
158-2	30376-30385	interests	_
158-3	30386-30389	The	_
158-4	30390-30397	authors	_
158-5	30398-30405	declare	_
158-6	30406-30408	no	_
158-7	30409-30418	competing	_
158-8	30419-30428	interests	_
158-9	30428-30429	.	_

#Text=Publisher’s Note
#Text=Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
159-1	30430-30439	Publisher	_
159-2	30439-30440	’	_
159-3	30440-30441	s	_
159-4	30442-30446	Note	_
159-5	30447-30455	Springer	_
159-6	30456-30462	Nature	_
159-7	30463-30470	remains	_
159-8	30471-30478	neutral	_
159-9	30479-30483	with	_
159-10	30484-30490	regard	_
159-11	30491-30493	to	_
159-12	30494-30508	jurisdictional	_
159-13	30509-30515	claims	_
159-14	30516-30518	in	_
159-15	30519-30528	published	_
159-16	30529-30533	maps	_
159-17	30534-30537	and	_
159-18	30538-30551	institutional	_
159-19	30552-30564	affiliations	_
159-20	30564-30565	.	_

#Text=References
#Text=Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders
#Text=Epidemiology of DSM-5 alcohol use disorder: results from the National Epidemiologic Survey on alcohol and related conditions III
#Text=Rehm J, Anderson P, Barry J, Dimitrov P, Elekes Z, Feijao F, Frick U, Gual A, Gmel G, Jr., Kraus L et al.: Prevalence of and potential influencing factors for alcohol dependence in Europe.
160-1	30566-30576	References	_
160-2	30577-30583	Global	_
160-3	30584-30590	burden	_
160-4	30591-30593	of	_
160-5	30594-30601	disease	_
160-6	30602-30605	and	_
160-7	30606-30612	injury	_
160-8	30613-30616	and	_
160-9	30617-30625	economic	_
160-10	30626-30630	cost	_
160-11	30631-30643	attributable	_
160-12	30644-30646	to	_
160-13	30647-30654	alcohol	_
160-14	30655-30658	use	_
160-15	30659-30662	and	_
160-16	30663-30674	alcohol-use	_
160-17	30675-30684	disorders	_
160-18	30685-30697	Epidemiology	_
160-19	30698-30700	of	_
160-20	30701-30704	DSM	_
160-21	30704-30705	-	_
160-22	30705-30706	5	_
160-23	30707-30714	alcohol	_
160-24	30715-30718	use	_
160-25	30719-30727	disorder	_
160-26	30727-30728	:	_
160-27	30729-30736	results	_
160-28	30737-30741	from	_
160-29	30742-30745	the	_
160-30	30746-30754	National	_
160-31	30755-30768	Epidemiologic	_
160-32	30769-30775	Survey	_
160-33	30776-30778	on	_
160-34	30779-30786	alcohol	_
160-35	30787-30790	and	_
160-36	30791-30798	related	_
160-37	30799-30809	conditions	_
160-38	30810-30813	III	_
160-39	30814-30818	Rehm	_
160-40	30819-30820	J	_
160-41	30820-30821	,	_
160-42	30822-30830	Anderson	_
160-43	30831-30832	P	_
160-44	30832-30833	,	_
160-45	30834-30839	Barry	_
160-46	30840-30841	J	_
160-47	30841-30842	,	_
160-48	30843-30851	Dimitrov	_
160-49	30852-30853	P	_
160-50	30853-30854	,	_
160-51	30855-30861	Elekes	_
160-52	30862-30863	Z	_
160-53	30863-30864	,	_
160-54	30865-30871	Feijao	_
160-55	30872-30873	F	_
160-56	30873-30874	,	_
160-57	30875-30880	Frick	_
160-58	30881-30882	U	_
160-59	30882-30883	,	_
160-60	30884-30888	Gual	_
160-61	30889-30890	A	_
160-62	30890-30891	,	_
160-63	30892-30896	Gmel	_
160-64	30897-30898	G	_
160-65	30898-30899	,	_
160-66	30900-30902	Jr	_
160-67	30902-30903	.	_
160-68	30903-30904	,	_
160-69	30905-30910	Kraus	_
160-70	30911-30912	L	_
160-71	30913-30915	et	_
160-72	30916-30918	al	_
160-73	30918-30919	.	_
160-74	30919-30920	:	_
160-75	30921-30931	Prevalence	_
160-76	30932-30934	of	_
160-77	30935-30938	and	_
160-78	30939-30948	potential	_
160-79	30949-30960	influencing	_
160-80	30961-30968	factors	_
160-81	30969-30972	for	_
160-82	30973-30980	alcohol	_
160-83	30981-30991	dependence	_
160-84	30992-30994	in	_
160-85	30995-31001	Europe	_
160-86	31001-31002	.	_

#Text=Eur Addict Res 2015, 21(1):6–18.
161-1	31003-31006	Eur	_
161-2	31007-31013	Addict	_
161-3	31014-31017	Res	_
161-4	31018-31022	2015	_
161-5	31022-31023	,	_
161-6	31024-31026	21	_
161-7	31026-31027	(	_
161-8	31027-31028	1	_
161-9	31028-31029	)	_
161-10	31029-31030	:	_
161-11	31030-31031	6	_
161-12	31031-31032	–	_
161-13	31032-31034	18	_
161-14	31034-31035	.	_

#Text=Explaining abstinence rates following treatment for alcohol abuse: a quantitative synthesis of patient, research design and treatment effects
#Text=How effective is alcoholism treatment in the United States?
162-1	31036-31046	Explaining	_
162-2	31047-31057	abstinence	_
162-3	31058-31063	rates	_
162-4	31064-31073	following	_
162-5	31074-31083	treatment	_
162-6	31084-31087	for	_
162-7	31088-31095	alcohol	_
162-8	31096-31101	abuse	_
162-9	31101-31102	:	_
162-10	31103-31104	a	_
162-11	31105-31117	quantitative	_
162-12	31118-31127	synthesis	_
162-13	31128-31130	of	_
162-14	31131-31138	patient	_
162-15	31138-31139	,	_
162-16	31140-31148	research	_
162-17	31149-31155	design	_
162-18	31156-31159	and	_
162-19	31160-31169	treatment	_
162-20	31170-31177	effects	_
162-21	31178-31181	How	_
162-22	31182-31191	effective	_
162-23	31192-31194	is	_
162-24	31195-31205	alcoholism	_
162-25	31206-31215	treatment	_
162-26	31216-31218	in	_
162-27	31219-31222	the	_
162-28	31223-31229	United	_
162-29	31230-31236	States	_
162-30	31236-31237	?	_

#Text=Transcranial magnetic stimulation of deep brain regions: evidence for efficacy of the H-coil
#Text=Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial
#Text=George MS, Wassermann EM.
163-1	31238-31250	Transcranial	_
163-2	31251-31259	magnetic	_
163-3	31260-31271	stimulation	_
163-4	31272-31274	of	_
163-5	31275-31279	deep	_
163-6	31280-31285	brain	_
163-7	31286-31293	regions	_
163-8	31293-31294	:	_
163-9	31295-31303	evidence	_
163-10	31304-31307	for	_
163-11	31308-31316	efficacy	_
163-12	31317-31319	of	_
163-13	31320-31323	the	_
163-14	31324-31330	H-coil	_
163-15	31331-31339	Efficacy	_
163-16	31340-31343	and	_
163-17	31344-31350	safety	_
163-18	31351-31353	of	_
163-19	31354-31358	deep	_
163-20	31359-31371	transcranial	_
163-21	31372-31380	magnetic	_
163-22	31381-31392	stimulation	_
163-23	31393-31396	for	_
163-24	31397-31402	major	_
163-25	31403-31413	depression	_
163-26	31413-31414	:	_
163-27	31415-31416	a	_
163-28	31417-31428	prospective	_
163-29	31429-31440	multicenter	_
163-30	31441-31451	randomized	_
163-31	31452-31462	controlled	_
163-32	31463-31468	trial	_
163-33	31469-31475	George	_
163-34	31476-31478	MS	_
163-35	31478-31479	,	_
163-36	31480-31490	Wassermann	_
163-37	31491-31493	EM	_
163-38	31493-31494	.	_

#Text=Rapid-rate transcranial magnetic stimulation and ECT.
164-1	31495-31505	Rapid-rate	_
164-2	31506-31518	transcranial	_
164-3	31519-31527	magnetic	_
164-4	31528-31539	stimulation	_
164-5	31540-31543	and	_
164-6	31544-31547	ECT	_
164-7	31547-31548	.	_

#Text=Convuls Ther. 1994;10(4):251–4; Discussion 255-8.
165-1	31549-31556	Convuls	_
165-2	31557-31561	Ther	_
165-3	31561-31562	.	_
165-4	31563-31567	1994	_
165-5	31567-31568	;	_
165-6	31568-31570	10	_
165-7	31570-31571	(	_
165-8	31571-31572	4	_
165-9	31572-31573	)	_
165-10	31573-31574	:	_
165-11	31574-31577	251	_
165-12	31577-31578	–	_
165-13	31578-31579	4	_
165-14	31579-31580	;	_
165-15	31581-31591	Discussion	_
165-16	31592-31595	255	_
165-17	31595-31596	-	_
165-18	31596-31597	8	_
165-19	31597-31598	.	_

#Text=Deep TMS on alcoholics: effects on cortisolemia and dopamine pathway modulation.
166-1	31599-31603	Deep	_
166-2	31604-31607	TMS	_
166-3	31608-31610	on	_
166-4	31611-31621	alcoholics	_
166-5	31621-31622	:	_
166-6	31623-31630	effects	_
166-7	31631-31633	on	_
166-8	31634-31646	cortisolemia	_
166-9	31647-31650	and	_
166-10	31651-31659	dopamine	_
166-11	31660-31667	pathway	_
166-12	31668-31678	modulation	_
166-13	31678-31679	.	_

#Text=A pilot study
#Text=Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation
#Text=Prefrontal cortex modulation using transcranial DC stimulation reduces alcohol craving: a double-blind, sham-controlled study
#Text=Transcranial direct current stimulation: state of the art 2008
#Text=Behavioral effects of transcranial direct current stimulation (tDCS) induced dorsolateral prefrontal cortex plasticity in alcohol dependence
#Text=Nucleus Accumbens deep brain stimulation for alcohol addiction - safety and clinical long-term results of a pilot trial
#Text=DEEP BRAIN STIMULATION
#Text=Real-time functional magnetic resonance imaging
#Text=Physiological self-regulation of regional brain activity using real-time functional magnetic resonance imaging (fMRI): methodology and exemplary data
#Text=Real-time functional magnetic resonance imaging neurofeedback can reduce striatal cue-reactivity to alcohol stimuli
#Text=Meta-analysis of cue-reactivity in addiction research
#Text=What does cue-reactivity have to offer clinical research?
167-1	31680-31681	A	_
167-2	31682-31687	pilot	_
167-3	31688-31693	study	_
167-4	31694-31706	Excitability	_
167-5	31707-31714	changes	_
167-6	31715-31722	induced	_
167-7	31723-31725	in	_
167-8	31726-31729	the	_
167-9	31730-31735	human	_
167-10	31736-31741	motor	_
167-11	31742-31748	cortex	_
167-12	31749-31751	by	_
167-13	31752-31756	weak	_
167-14	31757-31769	transcranial	_
167-15	31770-31776	direct	_
167-16	31777-31784	current	_
167-17	31785-31796	stimulation	_
167-18	31797-31807	Prefrontal	_
167-19	31808-31814	cortex	_
167-20	31815-31825	modulation	_
167-21	31826-31831	using	_
167-22	31832-31844	transcranial	_
167-23	31845-31847	DC	_
167-24	31848-31859	stimulation	_
167-25	31860-31867	reduces	_
167-26	31868-31875	alcohol	_
167-27	31876-31883	craving	_
167-28	31883-31884	:	_
167-29	31885-31886	a	_
167-30	31887-31899	double-blind	_
167-31	31899-31900	,	_
167-32	31901-31916	sham-controlled	_
167-33	31917-31922	study	_
167-34	31923-31935	Transcranial	_
167-35	31936-31942	direct	_
167-36	31943-31950	current	_
167-37	31951-31962	stimulation	_
167-38	31962-31963	:	_
167-39	31964-31969	state	_
167-40	31970-31972	of	_
167-41	31973-31976	the	_
167-42	31977-31980	art	_
167-43	31981-31985	2008	_
167-44	31986-31996	Behavioral	_
167-45	31997-32004	effects	_
167-46	32005-32007	of	_
167-47	32008-32020	transcranial	_
167-48	32021-32027	direct	_
167-49	32028-32035	current	_
167-50	32036-32047	stimulation	_
167-51	32048-32049	(	_
167-52	32049-32053	tDCS	_
167-53	32053-32054	)	_
167-54	32055-32062	induced	_
167-55	32063-32075	dorsolateral	_
167-56	32076-32086	prefrontal	_
167-57	32087-32093	cortex	_
167-58	32094-32104	plasticity	_
167-59	32105-32107	in	_
167-60	32108-32115	alcohol	_
167-61	32116-32126	dependence	_
167-62	32127-32134	Nucleus	_
167-63	32135-32144	Accumbens	_
167-64	32145-32149	deep	_
167-65	32150-32155	brain	_
167-66	32156-32167	stimulation	_
167-67	32168-32171	for	_
167-68	32172-32179	alcohol	_
167-69	32180-32189	addiction	_
167-70	32190-32191	-	_
167-71	32192-32198	safety	_
167-72	32199-32202	and	_
167-73	32203-32211	clinical	_
167-74	32212-32221	long-term	_
167-75	32222-32229	results	_
167-76	32230-32232	of	_
167-77	32233-32234	a	_
167-78	32235-32240	pilot	_
167-79	32241-32246	trial	_
167-80	32247-32251	DEEP	_
167-81	32252-32257	BRAIN	_
167-82	32258-32269	STIMULATION	_
167-83	32270-32279	Real-time	_
167-84	32280-32290	functional	_
167-85	32291-32299	magnetic	_
167-86	32300-32309	resonance	_
167-87	32310-32317	imaging	_
167-88	32318-32331	Physiological	_
167-89	32332-32347	self-regulation	_
167-90	32348-32350	of	_
167-91	32351-32359	regional	_
167-92	32360-32365	brain	_
167-93	32366-32374	activity	_
167-94	32375-32380	using	_
167-95	32381-32390	real-time	_
167-96	32391-32401	functional	_
167-97	32402-32410	magnetic	_
167-98	32411-32420	resonance	_
167-99	32421-32428	imaging	_
167-100	32429-32430	(	_
167-101	32430-32434	fMRI	_
167-102	32434-32435	)	_
167-103	32435-32436	:	_
167-104	32437-32448	methodology	_
167-105	32449-32452	and	_
167-106	32453-32462	exemplary	_
167-107	32463-32467	data	_
167-108	32468-32477	Real-time	_
167-109	32478-32488	functional	_
167-110	32489-32497	magnetic	_
167-111	32498-32507	resonance	_
167-112	32508-32515	imaging	_
167-113	32516-32529	neurofeedback	_
167-114	32530-32533	can	_
167-115	32534-32540	reduce	_
167-116	32541-32549	striatal	_
167-117	32550-32564	cue-reactivity	_
167-118	32565-32567	to	_
167-119	32568-32575	alcohol	_
167-120	32576-32583	stimuli	_
167-121	32584-32597	Meta-analysis	_
167-122	32598-32600	of	_
167-123	32601-32615	cue-reactivity	_
167-124	32616-32618	in	_
167-125	32619-32628	addiction	_
167-126	32629-32637	research	_
167-127	32638-32642	What	_
167-128	32643-32647	does	_
167-129	32648-32662	cue-reactivity	_
167-130	32663-32667	have	_
167-131	32668-32670	to	_
167-132	32671-32676	offer	_
167-133	32677-32685	clinical	_
167-134	32686-32694	research	_
167-135	32694-32695	?	_

#Text=Identifying the neural circuitry of alcohol craving and relapse vulnerability
#Text=Largely overlapping neuronal substrates of reactivity to drug, gambling, food and sexual cues: a comprehensive meta-analysis
#Text=Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics
#Text=Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review
#Text=Cognitive Neuroscience Approaches To understanding behavior change in alcohol use disorder treatments
#Text=Striatal activation and frontostriatal connectivity during non-drug reward anticipation in alcohol dependence
#Text=Becker A, Gerchen MF, Kirsch M, Hoffmann S, Kiefer F, Kirsch P.
168-1	32696-32707	Identifying	_
168-2	32708-32711	the	_
168-3	32712-32718	neural	_
168-4	32719-32728	circuitry	_
168-5	32729-32731	of	_
168-6	32732-32739	alcohol	_
168-7	32740-32747	craving	_
168-8	32748-32751	and	_
168-9	32752-32759	relapse	_
168-10	32760-32773	vulnerability	_
168-11	32774-32781	Largely	_
168-12	32782-32793	overlapping	_
168-13	32794-32802	neuronal	_
168-14	32803-32813	substrates	_
168-15	32814-32816	of	_
168-16	32817-32827	reactivity	_
168-17	32828-32830	to	_
168-18	32831-32835	drug	_
168-19	32835-32836	,	_
168-20	32837-32845	gambling	_
168-21	32845-32846	,	_
168-22	32847-32851	food	_
168-23	32852-32855	and	_
168-24	32856-32862	sexual	_
168-25	32863-32867	cues	_
168-26	32867-32868	:	_
168-27	32869-32870	a	_
168-28	32871-32884	comprehensive	_
168-29	32885-32898	meta-analysis	_
168-30	32899-32910	Cue-induced	_
168-31	32911-32921	activation	_
168-32	32922-32924	of	_
168-33	32925-32928	the	_
168-34	32929-32937	striatum	_
168-35	32938-32941	and	_
168-36	32942-32948	medial	_
168-37	32949-32959	prefrontal	_
168-38	32960-32966	cortex	_
168-39	32967-32969	is	_
168-40	32970-32980	associated	_
168-41	32981-32985	with	_
168-42	32986-32996	subsequent	_
168-43	32997-33004	relapse	_
168-44	33005-33007	in	_
168-45	33008-33017	abstinent	_
168-46	33018-33028	alcoholics	_
168-47	33029-33039	Functional	_
168-48	33040-33052	neuroimaging	_
168-49	33053-33060	studies	_
168-50	33061-33063	of	_
168-51	33064-33071	alcohol	_
168-52	33072-33075	cue	_
168-53	33076-33086	reactivity	_
168-54	33086-33087	:	_
168-55	33088-33089	a	_
168-56	33090-33102	quantitative	_
168-57	33103-33116	meta-analysis	_
168-58	33117-33120	and	_
168-59	33121-33131	systematic	_
168-60	33132-33138	review	_
168-61	33139-33148	Cognitive	_
168-62	33149-33161	Neuroscience	_
168-63	33162-33172	Approaches	_
168-64	33173-33175	To	_
168-65	33176-33189	understanding	_
168-66	33190-33198	behavior	_
168-67	33199-33205	change	_
168-68	33206-33208	in	_
168-69	33209-33216	alcohol	_
168-70	33217-33220	use	_
168-71	33221-33229	disorder	_
168-72	33230-33240	treatments	_
168-73	33241-33249	Striatal	_
168-74	33250-33260	activation	_
168-75	33261-33264	and	_
168-76	33265-33279	frontostriatal	_
168-77	33280-33292	connectivity	_
168-78	33293-33299	during	_
168-79	33300-33308	non-drug	_
168-80	33309-33315	reward	_
168-81	33316-33328	anticipation	_
168-82	33329-33331	in	_
168-83	33332-33339	alcohol	_
168-84	33340-33350	dependence	_
168-85	33351-33357	Becker	_
168-86	33358-33359	A	_
168-87	33359-33360	,	_
168-88	33361-33368	Gerchen	_
168-89	33369-33371	MF	_
168-90	33371-33372	,	_
168-91	33373-33379	Kirsch	_
168-92	33380-33381	M	_
168-93	33381-33382	,	_
168-94	33383-33391	Hoffmann	_
168-95	33392-33393	S	_
168-96	33393-33394	,	_
168-97	33395-33401	Kiefer	_
168-98	33402-33403	F	_
168-99	33403-33404	,	_
168-100	33405-33411	Kirsch	_
168-101	33412-33413	P	_
168-102	33413-33414	.	_

#Text=Striatal reward sensitivity predicts therapy-related neural changes in alcohol addiction.
169-1	33415-33423	Striatal	_
169-2	33424-33430	reward	_
169-3	33431-33442	sensitivity	_
169-4	33443-33451	predicts	_
169-5	33452-33467	therapy-related	_
169-6	33468-33474	neural	_
169-7	33475-33482	changes	_
169-8	33483-33485	in	_
169-9	33486-33493	alcohol	_
169-10	33494-33503	addiction	_
169-11	33503-33504	.	_

#Text=Eur Arch Psychiatry Clin Neurosci. 2017;
#Text=Abstinence self-efficacy and abstinence 1 year after substance use disorder treatment
#Text=Real-time self-regulation of emotion networks in patients with depression
#Text=Real-time fMRI neurofeedback training of amygdala activity in patients with major depressive disorder
#Text=Effects of salience-network-node neurofeedback training on affective biases in major depressive disorder
#Text=Correlation between amygdala BOLD activity and frontal EEG asymmetry during real-time fMRI neurofeedback training in patients with depression
#Text=Randomized clinical trial of real-time fMRI amygdala neurofeedback for major depressive disorder: effects on symptoms and autobiographical memory recall
#Text=Real-time functional magnetic resonance imaging amygdala neurofeedback changes positive information processing in major depressive disorder
#Text=Ruiz S, Birbaumer N, Sitaram R.
170-1	33505-33508	Eur	_
170-2	33509-33513	Arch	_
170-3	33514-33524	Psychiatry	_
170-4	33525-33529	Clin	_
170-5	33530-33538	Neurosci	_
170-6	33538-33539	.	_
170-7	33540-33544	2017	_
170-8	33544-33545	;	_
170-9	33546-33556	Abstinence	_
170-10	33557-33570	self-efficacy	_
170-11	33571-33574	and	_
170-12	33575-33585	abstinence	_
170-13	33586-33587	1	_
170-14	33588-33592	year	_
170-15	33593-33598	after	_
170-16	33599-33608	substance	_
170-17	33609-33612	use	_
170-18	33613-33621	disorder	_
170-19	33622-33631	treatment	_
170-20	33632-33641	Real-time	_
170-21	33642-33657	self-regulation	_
170-22	33658-33660	of	_
170-23	33661-33668	emotion	_
170-24	33669-33677	networks	_
170-25	33678-33680	in	_
170-26	33681-33689	patients	_
170-27	33690-33694	with	_
170-28	33695-33705	depression	_
170-29	33706-33715	Real-time	_
170-30	33716-33720	fMRI	_
170-31	33721-33734	neurofeedback	_
170-32	33735-33743	training	_
170-33	33744-33746	of	_
170-34	33747-33755	amygdala	_
170-35	33756-33764	activity	_
170-36	33765-33767	in	_
170-37	33768-33776	patients	_
170-38	33777-33781	with	_
170-39	33782-33787	major	_
170-40	33788-33798	depressive	_
170-41	33799-33807	disorder	_
170-42	33808-33815	Effects	_
170-43	33816-33818	of	_
170-44	33819-33840	salience-network-node	_
170-45	33841-33854	neurofeedback	_
170-46	33855-33863	training	_
170-47	33864-33866	on	_
170-48	33867-33876	affective	_
170-49	33877-33883	biases	_
170-50	33884-33886	in	_
170-51	33887-33892	major	_
170-52	33893-33903	depressive	_
170-53	33904-33912	disorder	_
170-54	33913-33924	Correlation	_
170-55	33925-33932	between	_
170-56	33933-33941	amygdala	_
170-57	33942-33946	BOLD	_
170-58	33947-33955	activity	_
170-59	33956-33959	and	_
170-60	33960-33967	frontal	_
170-61	33968-33971	EEG	_
170-62	33972-33981	asymmetry	_
170-63	33982-33988	during	_
170-64	33989-33998	real-time	_
170-65	33999-34003	fMRI	_
170-66	34004-34017	neurofeedback	_
170-67	34018-34026	training	_
170-68	34027-34029	in	_
170-69	34030-34038	patients	_
170-70	34039-34043	with	_
170-71	34044-34054	depression	_
170-72	34055-34065	Randomized	_
170-73	34066-34074	clinical	_
170-74	34075-34080	trial	_
170-75	34081-34083	of	_
170-76	34084-34093	real-time	_
170-77	34094-34098	fMRI	_
170-78	34099-34107	amygdala	_
170-79	34108-34121	neurofeedback	_
170-80	34122-34125	for	_
170-81	34126-34131	major	_
170-82	34132-34142	depressive	_
170-83	34143-34151	disorder	_
170-84	34151-34152	:	_
170-85	34153-34160	effects	_
170-86	34161-34163	on	_
170-87	34164-34172	symptoms	_
170-88	34173-34176	and	_
170-89	34177-34193	autobiographical	_
170-90	34194-34200	memory	_
170-91	34201-34207	recall	_
170-92	34208-34217	Real-time	_
170-93	34218-34228	functional	_
170-94	34229-34237	magnetic	_
170-95	34238-34247	resonance	_
170-96	34248-34255	imaging	_
170-97	34256-34264	amygdala	_
170-98	34265-34278	neurofeedback	_
170-99	34279-34286	changes	_
170-100	34287-34295	positive	_
170-101	34296-34307	information	_
170-102	34308-34318	processing	_
170-103	34319-34321	in	_
170-104	34322-34327	major	_
170-105	34328-34338	depressive	_
170-106	34339-34347	disorder	_
170-107	34348-34352	Ruiz	_
170-108	34353-34354	S	_
170-109	34354-34355	,	_
170-110	34356-34365	Birbaumer	_
170-111	34366-34367	N	_
170-112	34367-34368	,	_
170-113	34369-34376	Sitaram	_
170-114	34377-34378	R	_
170-115	34378-34379	.	_

#Text=Abnormal neural connectivity in schizophrenia and fMRI-brain-computer Interface as a potential therapeutic approach.
171-1	34380-34388	Abnormal	_
171-2	34389-34395	neural	_
171-3	34396-34408	connectivity	_
171-4	34409-34411	in	_
171-5	34412-34425	schizophrenia	_
171-6	34426-34429	and	_
171-7	34430-34449	fMRI-brain-computer	_
171-8	34450-34459	Interface	_
171-9	34460-34462	as	_
171-10	34463-34464	a	_
171-11	34465-34474	potential	_
171-12	34475-34486	therapeutic	_
171-13	34487-34495	approach	_
171-14	34495-34496	.	_

#Text=Front Psychiatry. 2013;4:7.
172-1	34497-34502	Front	_
172-2	34503-34513	Psychiatry	_
172-3	34513-34514	.	_
172-4	34515-34519	2013	_
172-5	34519-34520	;	_
172-6	34520-34521	4	_
172-7	34521-34522	:	_
172-8	34522-34523	7	_
172-9	34523-34524	.	_

#Text=Cordes JS, Mathiak KA, Dyck M, Alawi EM, Gaber TJ, Zepf FD, Klasen M, Zvyagintsev M, Gur RC, Mathiak K.
173-1	34525-34531	Cordes	_
173-2	34532-34534	JS	_
173-3	34534-34535	,	_
173-4	34536-34543	Mathiak	_
173-5	34544-34546	KA	_
173-6	34546-34547	,	_
173-7	34548-34552	Dyck	_
173-8	34553-34554	M	_
173-9	34554-34555	,	_
173-10	34556-34561	Alawi	_
173-11	34562-34564	EM	_
173-12	34564-34565	,	_
173-13	34566-34571	Gaber	_
173-14	34572-34574	TJ	_
173-15	34574-34575	,	_
173-16	34576-34580	Zepf	_
173-17	34581-34583	FD	_
173-18	34583-34584	,	_
173-19	34585-34591	Klasen	_
173-20	34592-34593	M	_
173-21	34593-34594	,	_
173-22	34595-34606	Zvyagintsev	_
173-23	34607-34608	M	_
173-24	34608-34609	,	_
173-25	34610-34613	Gur	_
173-26	34614-34616	RC	_
173-27	34616-34617	,	_
173-28	34618-34625	Mathiak	_
173-29	34626-34627	K	_
173-30	34627-34628	.	_

#Text=Cognitive and neural strategies during control of the anterior cingulate cortex by fMRI neurofeedback in patients with schizophrenia.
174-1	34629-34638	Cognitive	_
174-2	34639-34642	and	_
174-3	34643-34649	neural	_
174-4	34650-34660	strategies	_
174-5	34661-34667	during	_
174-6	34668-34675	control	_
174-7	34676-34678	of	_
174-8	34679-34682	the	_
174-9	34683-34691	anterior	_
174-10	34692-34701	cingulate	_
174-11	34702-34708	cortex	_
174-12	34709-34711	by	_
174-13	34712-34716	fMRI	_
174-14	34717-34730	neurofeedback	_
174-15	34731-34733	in	_
174-16	34734-34742	patients	_
174-17	34743-34747	with	_
174-18	34748-34761	schizophrenia	_
174-19	34761-34762	.	_

#Text=Front Behav Neurosci. 2015;9:169.
175-1	34763-34768	Front	_
175-2	34769-34774	Behav	_
175-3	34775-34783	Neurosci	_
175-4	34783-34784	.	_
175-5	34785-34789	2015	_
175-6	34789-34790	;	_
175-7	34790-34791	9	_
175-8	34791-34792	:	_
175-9	34792-34795	169	_
175-10	34795-34796	.	_

#Text=Dyck MS, Mathiak KA, Bergert S, Sarkheil P, Koush Y, Alawi EM, Zvyagintsev M, Gaebler AJ, Shergill SS, Mathiak K.
176-1	34797-34801	Dyck	_
176-2	34802-34804	MS	_
176-3	34804-34805	,	_
176-4	34806-34813	Mathiak	_
176-5	34814-34816	KA	_
176-6	34816-34817	,	_
176-7	34818-34825	Bergert	_
176-8	34826-34827	S	_
176-9	34827-34828	,	_
176-10	34829-34837	Sarkheil	_
176-11	34838-34839	P	_
176-12	34839-34840	,	_
176-13	34841-34846	Koush	_
176-14	34847-34848	Y	_
176-15	34848-34849	,	_
176-16	34850-34855	Alawi	_
176-17	34856-34858	EM	_
176-18	34858-34859	,	_
176-19	34860-34871	Zvyagintsev	_
176-20	34872-34873	M	_
176-21	34873-34874	,	_
176-22	34875-34882	Gaebler	_
176-23	34883-34885	AJ	_
176-24	34885-34886	,	_
176-25	34887-34895	Shergill	_
176-26	34896-34898	SS	_
176-27	34898-34899	,	_
176-28	34900-34907	Mathiak	_
176-29	34908-34909	K	_
176-30	34909-34910	.	_

#Text=Targeting treatment-resistant auditory verbal hallucinations in schizophrenia with fMRI-based neurofeedback – exploring different cases of schizophrenia.
177-1	34911-34920	Targeting	_
177-2	34921-34940	treatment-resistant	_
177-3	34941-34949	auditory	_
177-4	34950-34956	verbal	_
177-5	34957-34971	hallucinations	_
177-6	34972-34974	in	_
177-7	34975-34988	schizophrenia	_
177-8	34989-34993	with	_
177-9	34994-35004	fMRI-based	_
177-10	35005-35018	neurofeedback	_
177-11	35019-35020	–	_
177-12	35021-35030	exploring	_
177-13	35031-35040	different	_
177-14	35041-35046	cases	_
177-15	35047-35049	of	_
177-16	35050-35063	schizophrenia	_
177-17	35063-35064	.	_

#Text=Front Psychiatry. 2016;7:37.
178-1	35065-35070	Front	_
178-2	35071-35081	Psychiatry	_
178-3	35081-35082	.	_
178-4	35083-35087	2016	_
178-5	35087-35088	;	_
178-6	35088-35089	7	_
178-7	35089-35090	:	_
178-8	35090-35092	37	_
178-9	35092-35093	.	_

#Text=Real-time fMRI neurofeedback in adolescents with attention deficit hyperactivity disorder
#Text=fMRI neurofeedback training for increasing anterior cingulate cortex activation in adult attention deficit hyperactivity disorder.
179-1	35094-35103	Real-time	_
179-2	35104-35108	fMRI	_
179-3	35109-35122	neurofeedback	_
179-4	35123-35125	in	_
179-5	35126-35137	adolescents	_
179-6	35138-35142	with	_
179-7	35143-35152	attention	_
179-8	35153-35160	deficit	_
179-9	35161-35174	hyperactivity	_
179-10	35175-35183	disorder	_
179-11	35184-35188	fMRI	_
179-12	35189-35202	neurofeedback	_
179-13	35203-35211	training	_
179-14	35212-35215	for	_
179-15	35216-35226	increasing	_
179-16	35227-35235	anterior	_
179-17	35236-35245	cingulate	_
179-18	35246-35252	cortex	_
179-19	35253-35263	activation	_
179-20	35264-35266	in	_
179-21	35267-35272	adult	_
179-22	35273-35282	attention	_
179-23	35283-35290	deficit	_
179-24	35291-35304	hyperactivity	_
179-25	35305-35313	disorder	_
179-26	35313-35314	.	_

#Text=An exploratory randomized, single-blinded study
#Text=Zilverstand A, Sorger B, Sarkheil P, Goebel R. fMRI neurofeedback facilitates anxiety regulation in females with spider phobia.
180-1	35315-35317	An	_
180-2	35318-35329	exploratory	_
180-3	35330-35340	randomized	_
180-4	35340-35341	,	_
180-5	35342-35356	single-blinded	_
180-6	35357-35362	study	_
180-7	35363-35374	Zilverstand	_
180-8	35375-35376	A	_
180-9	35376-35377	,	_
180-10	35378-35384	Sorger	_
180-11	35385-35386	B	_
180-12	35386-35387	,	_
180-13	35388-35396	Sarkheil	_
180-14	35397-35398	P	_
180-15	35398-35399	,	_
180-16	35400-35406	Goebel	_
180-17	35407-35408	R	_
180-18	35408-35409	.	_
180-19	35410-35414	fMRI	_
180-20	35415-35428	neurofeedback	_
180-21	35429-35440	facilitates	_
180-22	35441-35448	anxiety	_
180-23	35449-35459	regulation	_
180-24	35460-35462	in	_
180-25	35463-35470	females	_
180-26	35471-35475	with	_
180-27	35476-35482	spider	_
180-28	35483-35489	phobia	_
180-29	35489-35490	.	_

#Text=Front Behav Neurosci. 2015;9:148.
181-1	35491-35496	Front	_
181-2	35497-35502	Behav	_
181-3	35503-35511	Neurosci	_
181-4	35511-35512	.	_
181-5	35513-35517	2015	_
181-6	35517-35518	;	_
181-7	35518-35519	9	_
181-8	35519-35520	:	_
181-9	35520-35523	148	_
181-10	35523-35524	.	_

#Text=Caria A, de Falco S.
182-1	35525-35530	Caria	_
182-2	35531-35532	A	_
182-3	35532-35533	,	_
182-4	35534-35536	de	_
182-5	35537-35542	Falco	_
182-6	35543-35544	S	_
182-7	35544-35545	.	_

#Text=Anterior insular cortex regulation in autism spectrum disorders.
183-1	35546-35554	Anterior	_
183-2	35555-35562	insular	_
183-3	35563-35569	cortex	_
183-4	35570-35580	regulation	_
183-5	35581-35583	in	_
183-6	35584-35590	autism	_
183-7	35591-35599	spectrum	_
183-8	35600-35609	disorders	_
183-9	35609-35610	.	_

#Text=Front Behav Neurosci. 2015;9:38.
184-1	35611-35616	Front	_
184-2	35617-35622	Behav	_
184-3	35623-35631	Neurosci	_
184-4	35631-35632	.	_
184-5	35633-35637	2015	_
184-6	35637-35638	;	_
184-7	35638-35639	9	_
184-8	35639-35640	:	_
184-9	35640-35642	38	_
184-10	35642-35643	.	_

#Text=The neurobiology of emotion regulation in posttraumatic stress disorder: amygdala downregulation via real-time fMRI neurofeedback
#Text=Alterations of amygdala-prefrontal connectivity with real-time fMRI neurofeedback in BPD patients
#Text=Real-time fMRI in the treatment of nicotine dependence: a conceptual review and pilot studies
#Text=Sustained reduction of nicotine craving with real-time neurofeedback: exploring the role of severity of dependence
#Text=Reduction of cue-induced craving through realtime neurofeedback in nicotine users: the role of region of interest selection and multiple visits
#Text=Volitional reduction of anterior cingulate cortex activity produces decreased cue craving in smoking cessation: a preliminary real-time fMRI study
#Text=Individualized real-time fMRI neurofeedback to attenuate craving in nicotine-dependent smokers
#Text=The inclusion of functional connectivity information into fMRI-based neurofeedback improves its efficacy in the reduction of cigarette cravings
#Text=Modulation of craving related brain responses using real-time fMRI in patients with alcohol use disorder
#Text=Münster RD: Wittchen, H.U., Zaudig, M. & Fydrich, T.
185-1	35644-35647	The	_
185-2	35648-35660	neurobiology	_
185-3	35661-35663	of	_
185-4	35664-35671	emotion	_
185-5	35672-35682	regulation	_
185-6	35683-35685	in	_
185-7	35686-35699	posttraumatic	_
185-8	35700-35706	stress	_
185-9	35707-35715	disorder	_
185-10	35715-35716	:	_
185-11	35717-35725	amygdala	_
185-12	35726-35740	downregulation	_
185-13	35741-35744	via	_
185-14	35745-35754	real-time	_
185-15	35755-35759	fMRI	_
185-16	35760-35773	neurofeedback	_
185-17	35774-35785	Alterations	_
185-18	35786-35788	of	_
185-19	35789-35808	amygdala-prefrontal	_
185-20	35809-35821	connectivity	_
185-21	35822-35826	with	_
185-22	35827-35836	real-time	_
185-23	35837-35841	fMRI	_
185-24	35842-35855	neurofeedback	_
185-25	35856-35858	in	_
185-26	35859-35862	BPD	_
185-27	35863-35871	patients	_
185-28	35872-35881	Real-time	_
185-29	35882-35886	fMRI	_
185-30	35887-35889	in	_
185-31	35890-35893	the	_
185-32	35894-35903	treatment	_
185-33	35904-35906	of	_
185-34	35907-35915	nicotine	_
185-35	35916-35926	dependence	_
185-36	35926-35927	:	_
185-37	35928-35929	a	_
185-38	35930-35940	conceptual	_
185-39	35941-35947	review	_
185-40	35948-35951	and	_
185-41	35952-35957	pilot	_
185-42	35958-35965	studies	_
185-43	35966-35975	Sustained	_
185-44	35976-35985	reduction	_
185-45	35986-35988	of	_
185-46	35989-35997	nicotine	_
185-47	35998-36005	craving	_
185-48	36006-36010	with	_
185-49	36011-36020	real-time	_
185-50	36021-36034	neurofeedback	_
185-51	36034-36035	:	_
185-52	36036-36045	exploring	_
185-53	36046-36049	the	_
185-54	36050-36054	role	_
185-55	36055-36057	of	_
185-56	36058-36066	severity	_
185-57	36067-36069	of	_
185-58	36070-36080	dependence	_
185-59	36081-36090	Reduction	_
185-60	36091-36093	of	_
185-61	36094-36105	cue-induced	_
185-62	36106-36113	craving	_
185-63	36114-36121	through	_
185-64	36122-36130	realtime	_
185-65	36131-36144	neurofeedback	_
185-66	36145-36147	in	_
185-67	36148-36156	nicotine	_
185-68	36157-36162	users	_
185-69	36162-36163	:	_
185-70	36164-36167	the	_
185-71	36168-36172	role	_
185-72	36173-36175	of	_
185-73	36176-36182	region	_
185-74	36183-36185	of	_
185-75	36186-36194	interest	_
185-76	36195-36204	selection	_
185-77	36205-36208	and	_
185-78	36209-36217	multiple	_
185-79	36218-36224	visits	_
185-80	36225-36235	Volitional	_
185-81	36236-36245	reduction	_
185-82	36246-36248	of	_
185-83	36249-36257	anterior	_
185-84	36258-36267	cingulate	_
185-85	36268-36274	cortex	_
185-86	36275-36283	activity	_
185-87	36284-36292	produces	_
185-88	36293-36302	decreased	_
185-89	36303-36306	cue	_
185-90	36307-36314	craving	_
185-91	36315-36317	in	_
185-92	36318-36325	smoking	_
185-93	36326-36335	cessation	_
185-94	36335-36336	:	_
185-95	36337-36338	a	_
185-96	36339-36350	preliminary	_
185-97	36351-36360	real-time	_
185-98	36361-36365	fMRI	_
185-99	36366-36371	study	_
185-100	36372-36386	Individualized	_
185-101	36387-36396	real-time	_
185-102	36397-36401	fMRI	_
185-103	36402-36415	neurofeedback	_
185-104	36416-36418	to	_
185-105	36419-36428	attenuate	_
185-106	36429-36436	craving	_
185-107	36437-36439	in	_
185-108	36440-36458	nicotine-dependent	_
185-109	36459-36466	smokers	_
185-110	36467-36470	The	_
185-111	36471-36480	inclusion	_
185-112	36481-36483	of	_
185-113	36484-36494	functional	_
185-114	36495-36507	connectivity	_
185-115	36508-36519	information	_
185-116	36520-36524	into	_
185-117	36525-36535	fMRI-based	_
185-118	36536-36549	neurofeedback	_
185-119	36550-36558	improves	_
185-120	36559-36562	its	_
185-121	36563-36571	efficacy	_
185-122	36572-36574	in	_
185-123	36575-36578	the	_
185-124	36579-36588	reduction	_
185-125	36589-36591	of	_
185-126	36592-36601	cigarette	_
185-127	36602-36610	cravings	_
185-128	36611-36621	Modulation	_
185-129	36622-36624	of	_
185-130	36625-36632	craving	_
185-131	36633-36640	related	_
185-132	36641-36646	brain	_
185-133	36647-36656	responses	_
185-134	36657-36662	using	_
185-135	36663-36672	real-time	_
185-136	36673-36677	fMRI	_
185-137	36678-36680	in	_
185-138	36681-36689	patients	_
185-139	36690-36694	with	_
185-140	36695-36702	alcohol	_
185-141	36703-36706	use	_
185-142	36707-36715	disorder	_
185-143	36716-36723	Münster	_
185-144	36724-36726	RD	_
185-145	36726-36727	:	_
185-146	36728-36736	Wittchen	_
185-147	36736-36737	,	_
185-148	36738-36741	H.U	_
185-149	36741-36742	.	_
185-150	36742-36743	,	_
185-151	36744-36750	Zaudig	_
185-152	36750-36751	,	_
185-153	36752-36753	M	_
185-154	36753-36754	.	_
185-155	36755-36756	&	_
185-156	36757-36764	Fydrich	_
185-157	36764-36765	,	_
185-158	36766-36767	T	_
185-159	36767-36768	.	_

#Text=SKID Strukturiertes Klinisches Interview für DSM-IV.
186-1	36769-36773	SKID	_
186-2	36774-36788	Strukturiertes	_
186-3	36789-36799	Klinisches	_
186-4	36800-36809	Interview	_
186-5	36810-36813	für	_
186-6	36814-36820	DSM-IV	_
186-7	36820-36821	.	_

#Text=Achse I und II.
187-1	36822-36827	Achse	_
187-2	36828-36829	I	_
187-3	36830-36833	und	_
187-4	36834-36836	II	_
187-5	36836-36837	.	_

#Text=Göttingen: Hogrefe, DM 158,-.
188-1	36838-36847	Göttingen	_
188-2	36847-36848	:	_
188-3	36849-36856	Hogrefe	_
188-4	36856-36857	,	_
188-5	36858-36860	DM	_
188-6	36861-36864	158	_
188-7	36864-36865	,	_
188-8	36865-36866	-	_
188-9	36866-36867	.	_

#Text=Hiller, W., Zaudig, M. & Mombour, W. (1997).
189-1	36868-36874	Hiller	_
189-2	36874-36875	,	_
189-3	36876-36877	W	_
189-4	36877-36878	.	_
189-5	36878-36879	,	_
189-6	36880-36886	Zaudig	_
189-7	36886-36887	,	_
189-8	36888-36889	M	_
189-9	36889-36890	.	_
189-10	36891-36892	&	_
189-11	36893-36900	Mombour	_
189-12	36900-36901	,	_
189-13	36902-36903	W	_
189-14	36903-36904	.	_
189-15	36905-36906	(	_
189-16	36906-36910	1997	_
189-17	36910-36911	)	_
189-18	36911-36912	.	_

#Text=IDCL Internationale Diagnosen Checklisten für DSM-IV und ICD-10.
190-1	36913-36917	IDCL	_
190-2	36918-36932	Internationale	_
190-3	36933-36942	Diagnosen	_
190-4	36943-36954	Checklisten	_
190-5	36955-36958	für	_
190-6	36959-36965	DSM-IV	_
190-7	36966-36969	und	_
190-8	36970-36973	ICD	_
190-9	36973-36974	-	_
190-10	36974-36976	10	_
190-11	36976-36977	.	_

#Text=Göttingen: Hogrefe, DM 198,- bzw.
191-1	36978-36987	Göttingen	_
191-2	36987-36988	:	_
191-3	36989-36996	Hogrefe	_
191-4	36996-36997	,	_
191-5	36998-37000	DM	_
191-6	37001-37004	198	_
191-7	37004-37005	,	_
191-8	37005-37006	-	_
191-9	37007-37010	bzw	_
191-10	37010-37011	.	_

#Text=DM 239.
192-1	37012-37014	DM	_
192-2	37015-37018	239	_
192-3	37018-37019	.	_

#Text=Zeitschrift für Klinische Psychologie und Psychotherapie 1999, 28(1):68–70.
193-1	37020-37031	Zeitschrift	_
193-2	37032-37035	für	_
193-3	37036-37045	Klinische	_
193-4	37046-37057	Psychologie	_
193-5	37058-37061	und	_
193-6	37062-37076	Psychotherapie	_
193-7	37077-37081	1999	_
193-8	37081-37082	,	_
193-9	37083-37085	28	_
193-10	37085-37086	(	_
193-11	37086-37087	1	_
193-12	37087-37088	)	_
193-13	37088-37089	:	_
193-14	37089-37091	68	_
193-15	37091-37092	–	_
193-16	37092-37094	70	_
193-17	37094-37095	.	_

#Text=Unique brain areas associated with abstinence control are damaged in multiply detoxified alcoholics
#Text=Analyzing task-dependent brain network changes by whole-brain psychophysiological interactions: a comparison to conventional analysis
#Text=Statistical power analyses using G*power 3.1: tests for correlation and regression analyses
#Text=
#Text=Neurofeedback training for alcohol dependence versus treatment as usual: study protocol for a randomized controlled trial
#Text=Effects of d-cycloserine on extinction of mesolimbic cue reactivity in alcoholism: a randomized placebo-controlled trial
#Text=Initial, habitual and compulsive alcohol use is characterized by a shift of cue processing from ventral to dorsal striatum
#Text=Real-time fMRI neurofeedback: progress and challenges
194-1	37096-37102	Unique	_
194-2	37103-37108	brain	_
194-3	37109-37114	areas	_
194-4	37115-37125	associated	_
194-5	37126-37130	with	_
194-6	37131-37141	abstinence	_
194-7	37142-37149	control	_
194-8	37150-37153	are	_
194-9	37154-37161	damaged	_
194-10	37162-37164	in	_
194-11	37165-37173	multiply	_
194-12	37174-37184	detoxified	_
194-13	37185-37195	alcoholics	_
194-14	37196-37205	Analyzing	_
194-15	37206-37220	task-dependent	_
194-16	37221-37226	brain	_
194-17	37227-37234	network	_
194-18	37235-37242	changes	_
194-19	37243-37245	by	_
194-20	37246-37257	whole-brain	_
194-21	37258-37277	psychophysiological	_
194-22	37278-37290	interactions	_
194-23	37290-37291	:	_
194-24	37292-37293	a	_
194-25	37294-37304	comparison	_
194-26	37305-37307	to	_
194-27	37308-37320	conventional	_
194-28	37321-37329	analysis	_
194-29	37330-37341	Statistical	_
194-30	37342-37347	power	_
194-31	37348-37356	analyses	_
194-32	37357-37362	using	_
194-33	37363-37364	G	_
194-34	37364-37365	*	_
194-35	37365-37370	power	_
194-36	37371-37374	3.1	_
194-37	37374-37375	:	_
194-38	37376-37381	tests	_
194-39	37382-37385	for	_
194-40	37386-37397	correlation	_
194-41	37398-37401	and	_
194-42	37402-37412	regression	_
194-43	37413-37421	analyses	_
194-44	37423-37436	Neurofeedback	_
194-45	37437-37445	training	_
194-46	37446-37449	for	_
194-47	37450-37457	alcohol	_
194-48	37458-37468	dependence	_
194-49	37469-37475	versus	_
194-50	37476-37485	treatment	_
194-51	37486-37488	as	_
194-52	37489-37494	usual	_
194-53	37494-37495	:	_
194-54	37496-37501	study	_
194-55	37502-37510	protocol	_
194-56	37511-37514	for	_
194-57	37515-37516	a	_
194-58	37517-37527	randomized	_
194-59	37528-37538	controlled	_
194-60	37539-37544	trial	_
194-61	37545-37552	Effects	_
194-62	37553-37555	of	_
194-63	37556-37569	d-cycloserine	_
194-64	37570-37572	on	_
194-65	37573-37583	extinction	_
194-66	37584-37586	of	_
194-67	37587-37597	mesolimbic	_
194-68	37598-37601	cue	_
194-69	37602-37612	reactivity	_
194-70	37613-37615	in	_
194-71	37616-37626	alcoholism	_
194-72	37626-37627	:	_
194-73	37628-37629	a	_
194-74	37630-37640	randomized	_
194-75	37641-37659	placebo-controlled	_
194-76	37660-37665	trial	_
194-77	37666-37673	Initial	_
194-78	37673-37674	,	_
194-79	37675-37683	habitual	_
194-80	37684-37687	and	_
194-81	37688-37698	compulsive	_
194-82	37699-37706	alcohol	_
194-83	37707-37710	use	_
194-84	37711-37713	is	_
194-85	37714-37727	characterized	_
194-86	37728-37730	by	_
194-87	37731-37732	a	_
194-88	37733-37738	shift	_
194-89	37739-37741	of	_
194-90	37742-37745	cue	_
194-91	37746-37756	processing	_
194-92	37757-37761	from	_
194-93	37762-37769	ventral	_
194-94	37770-37772	to	_
194-95	37773-37779	dorsal	_
194-96	37780-37788	striatum	_
194-97	37789-37798	Real-time	_
194-98	37799-37803	fMRI	_
194-99	37804-37817	neurofeedback	_
194-100	37817-37818	:	_
194-101	37819-37827	progress	_
194-102	37828-37831	and	_
194-103	37832-37842	challenges	_
